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Abstract
High frequencies of loss of heterozygosity have been observed at the q31 region of 
chromosome 7 in a variety of tumour types, suggesting that a multi-tissue tumour 
suppressor gene maps to this region. Introduction of an intact copy of human 
chromosome 7 into non-tumourigenic cell lines that have lost 7q31 markers and belong 
to immortality complementation group D causes a proportion of hybrids to senesce. 
This indicates that the group D senescence gene maps to chromosome 7. Moreover, this 
gene may be the target of losses observed in tumours.
To further investigate these effects I have used the microcell mediated 
monochromosome transfer technique to introduce chromosome 7 into the ovarian 
tumour cell line OVCAR5 and the breast tumour cell line MDA-MB-231. I had 
previously shown that both these cell lines are hemizygous for chromosome 7q and 
belong to senescence complementation group D as determined by mortalin staining and 
cell-cell fusion analysis. Following microcell transfer approximately 30% of hybrids of 
each cell type underwent a rapid growth arrest. Growth-arrested hybrids stained positive 
for senescence-associated endogenous p-galactosidase activity and showed reversion of 
the mortality marker mortalin to its mortal distribution. In total 79 immortal hybrids, 
which have presumably deleted or otherwise inactivated the senescence gene on the 
introduced chromosome, were also generated. PCR-based microsatellite deletion 
analysis demonstrated that more than half of these had lost markers from the introduced 
chromosome, but no single region of loss was identified.
To investigate whether the 7q senescence and tumour suppressor gene are one 
and the same, I compared the growth in soft agar and the tumourigenicity in nude mice 
of three immortal OVCAR5/Chromosome 7 hybrids—specifically hybrids for which no 
microsatellite losses had been found—to that of the parent cell line. A reduced 
tumourigenicity of these hybrids would suggest that the senescence-inducing and 
tumour suppressive effects of the chromosome are separable. Although two of the 
hybrids did indeed exhibit reduced colony formation in soft agar and delayed tumour 
formation in nude mice, interpretation of these results was clouded by the high level of 
clonal variation found within the cell line as a whole.
To circumvent this problem I investigated the soft agar growth and 
tumourigenicity of a panel of OVCAR5/Chromosome 7 hybrids that I had derived from 
the same single OVCAR5 cell clone. Five of the six hybrids generated showed a
xv
marked reduction in colony formation in soft agar compared to the parent cell clone. 
Three of these hybrids were then tested for tumourigenicity in nude mice: two displayed 
a significant delay in tumour formation. These results suggest that there is a gene on 
chromosome 7, independent of the senescence gene, that can suppress the 
tumourigenicity of the OVCAR5 cell line. The challenge now is to identify these genes 
and to assess their relative contributions to tumour suppression and tumourigenicity.
xvi
CHAPTER 1 
INTRODUCTION
1
1. Introduction
1.1 Cancer as a genetic disease: oncogenes and tumour suppressor genes
Cancer is a genetic disease, arising from the progressive accumulation of mutations that 
promote the clonal selection of cells with increasingly deregulated growth. Most of 
these alterations are somatically acquired, but some are inherited. During the last two 
decades many of the genetic targets of the mutations have been identified. However, 
except for one or two notable examples little is known about the precise combination of 
genetic alterations required to produce a particular type of tumour and of what 
determines the tissue specificity of these changes. Moreover, the cancer phenotype is a 
result of complex gene interactions, not only involving the known cancer gene products 
but also a multitude of other proteins. A great many ‘modifier’ and low penetrance 
cancer susceptibility genes are still to be discovered—the individual impact of any one 
of these genes is likely to be small compared to that of the known cancer genes, but 
collectively their variant alleles may hugely influence an individual’s cancer risk. 
Additionally, all these interactions are subject to modification by poorly understood 
environmental factors. The disentangling of all such interrelations clearly poses a tough 
challenge to cancer biologists.
Cancer genes fall into two broad classes: proto-oncogenes, which are positive 
regulators of cell proliferation, survival, invasion and metastasis, and tumour suppressor 
genes, which are negative regulators. The coordinated regulation of these diametrically 
opposed gene classes is responsible for maintaining tissue homeostasis; cancer reflects a 
fundamental breakdown in this control. The types of alteration that occur in proto­
oncogenes and tumour suppressor genes display intrinsic differences. Point mutations 
in proto-oncogenes are usually missense and tend to activate—or give new functions 
to—the gene product. Alternatively proto-oncogenes can be subject to amplification or 
to translocations that put them under the control of active promoter sequences or that 
generate a fusion product with new or constitutive function. Tumour suppressor genes, 
on the other hand, are subject to loss of function alterations, most commonly through 
deletions or through point mutations that truncate the protein product or alter a crucial 
functional domain. These differences partially account for the dominant transforming 
ability of oncogenes and the recessiveness (at the cellular level) of tumour suppressors.
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1.1.1 Oncogenes
The identification of oncogenes began with studies of acutely transforming retroviruses. 
Although not oncogenic in humans, these can rapidly induce tumours in animals and 
transform cells in vitro. The discovery that v-src, the transforming gene of the Rous 
sarcoma virus, has a counterpart in the cellular gene c-src was groundbreaking in this 
field (Stehelin et al., 1976). Since then, it has transpired that nearly all retroviral 
oncogenes are transduced cellular proto-oncogenes whose expression and activity is 
increased as a consequence of the transduction process. Many DNA viruses of the 
adenovirus, herpesvirus, poxvirus and papovavirus families also encode oncoproteins; 
however, the transforming genes rarely have proto-oncogene homologues within the 
normal genome. Chronic transforming retroviruses (such as mouse mammary tumour 
virus and avian leukosis virus) also possess no cellular sequences. These viruses induce 
neoplastic transformation after a latency period of months or years, via the integration of 
proviral DNA in such a way as to activate specific host target genes: cellular genes are 
either brought under the control of the viral LTR or are fused to viral sequences with the 
consequent production of novel proteins (Hayward et al., 1981). This knowledge led to 
the prospective use of insertional mutagenesis as a means of identifying novel proto­
oncogenes that are consistent targets for proviral insertion (Nusse and Varmus, 1982). It 
was suggested that spontaneous alteration of any of these genes might account for 
tumours—including most human tumours—whose initiation is virus-independent; the 
finding that around one in five tumours possesses genomic sequences with intrinsic 
transforming ability gave weight to this (Shih et al., 1981). Indeed, tumour gene transfer 
experiments identified oncogenes already known to be the cellular counterparts of 
various retroviral oncogenes, in addition to several novel genes (many of which 
belonged to the src and ras superfamilies). The presence of activating alterations in 
many of these cellular genes was subsequently demonstrated (Santos et al., 1982; Tabin 
et al., 1982; Taparowsky et al., 1982). Other oncogenes were identified directly through 
their association with translocations, which caused activation either by the generation of 
new fusion products or by bringing the proto-oncogene under the transcriptional control 
of nearby enhancer elements (Adams et al., 1983; Gale and Canaani 1984). Probes and 
primers derived from the oncogenes identified in these various ways were then used to 
isolate further, homologous, genes by cross-hybridisation or PCR. Table 1.1 
summarises some of the oncogenes identified by these various methods.
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The precise location of oncogenic mutations often gave the first indication of the 
important functional domains of the protein (McKay et a l, 1986). Genetic, biochemical 
and cellular studies in both humans and model organisms have further illuminated the 
functions of these genes. The majority of proto-oncogenes are now known to be 
components of signal transduction pathways, which are responsible for translating 
extracellular signals into nuclear changes in gene expression. Activation of proto­
oncogenes (and inactivation of tumour suppressor genes) results in the deregulation of 
these pathways, such that aspects of cellular behaviour—for example proliferation and 
survival—become autonomous. Proto-oncogenes have been discovered at most stages 
of the signal transduction pathways, acting as (among others) ligands, receptors, 
membrane-associated tyrosine kinases, lipid kinases, cytoplasmic regulators, G proteins, 
kinases, transcription factors and transcriptional co-activators—Table 1.2 classifies 
oncoproteins according to these biochemical roles in signal transduction. A small 
subset of proto-oncogenes are more directly involved in cellular proliferation and 
survival, and function as components of the cell cycle or anti-apoptotic machinery. 
CCND1 and CDK4, encoding cyclin D1 and cyclin dependent kinase 4 (CDK4) 
respectively, have both been found to be activated in tumours (Hall and Peters, 1996). 
The anti-apoptotic gene Bcl-2 is another target for activation, and was first identified at 
the breakpoint of translocations in follicular lymphomas (Bakhshi et al., 1985; 
Tsujimoto et al., 1985). An important consequence of oncogenic activation, therefore, 
is to uncouple cell proliferation and survival from regulation by extrinsic factors; this 
can be achieved either by constitutive activation of mitogenic signalling pathways or 
through direct stimulation of cell cycle progression or cellular survival.
Certain oncogenes are important in the advanced stages of tumourigenesis. A 
variety of proto-oncogenes—often also components of signal transduction pathways— 
are involved in the regulation of the actin cytoskeleton, of cell adhesion, and of the 
extracellular matrix. Deregulation of these facets via oncogene activation promotes the 
cell migration and substrate independence required for tumour cell invasion and 
metastasis. Other oncogenes are thought to have a role in the process of angiogenesis, 
the induction of new blood vessel growth from existing vessels; this process is probably 
essential if solid tumours are to enlarge beyond around one millimetre square.
Proto-oncogene activation probably contributes to the development of all 
sporadic cancers. Activating germline mutations in proto-oncogenes are likely to be 
lethal, but mutations in a limited number of proto-oncogenes are heritable and give rise
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to familial cancer syndromes. Germ-line mutations in MET, RET and CDK4, for 
example, are respectively responsible for hereditary papillary renal cancer, multiple 
endocrine neoplasia type 2 (MEN2), and some cases of familial melanoma (Mulligan et 
al., 1993; Zuo et al., 1996; Schmidt et al., 1997). However, the majority of cancer 
syndromes are caused by germline mutations in recessive-acting tumour suppressor 
genes, where loss of the remaining wild-type allele is the initiating transforming event 
(see Section 1.1.2.1). Even here, progression to full tumourigenicity requires further 
mutations in additional, probably multiple, proto-oncogenes and tumour suppressors.
1.1.2 Tumour suppressor genes
1.1.2.1 Origins of the tumour suppressor gene concept: the study of hereditary 
cancer syndromes
That cancer might arise from the effects of negative as well as positive regulators of cell 
growth was first suggested early this century (Boveri, 1914). The modern day concept 
of tumour suppressor genes, however, stems from two more recent lines of enquiry. 
First, somatic cell fusion studies demonstrated that hybrid cells formed by fusing 
tumourigenic with non-tumourigenic cells could give rise to tumours in suitable hosts, 
but only following the ejection of particular chromosomes (Reviewed in Harris, 1988). 
This provided the first real evidence that tumourigenicity is suppressed by specific 
genetic sequences, and that neoplastic transformation results (at least partly) from the 
loss of function of normal alleles. Analysis of the chromosome loss incurred in 
tumourigenic variants of suppressed hybrids allowed putative tumour suppressor genes 
to be mapped to specific chromosomes (Stoler & Bouck, 1985).
Studies of hereditary cancer syndromes further ensconced the concept of genes 
that negatively regulate tumour development, and led to the first cloning of a tumour 
suppressor gene. Although cancer that is unmistakably hereditary accounts for only 1% 
of all cancer cases, the genes that are altered are frequently mutated in sporadic tumours 
too. The childhood ocular tumour retinoblastoma is unusual in that around 40% of 
cases are inherited. Like most hereditary cancer syndromes, the inheritance pattern is 
autosomal dominant. The ground-breaking achievement of Alfred Knudson was to 
account for this inheritance in terms of recessive, loss-of-function mutations in a 
putative tumour suppressor gene (Knudson, 1971). He suggested that members of 
families exhibiting a predisposition to retinoblastoma transmit an initial mutation in 
their germline; the acquisition of a further, somatic mutation that inactivates the
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remaining allele constitutes the initiating, rate-limiting step in development of the 
tumour. In cases of retinoblastoma where there is no family history (that typically occur 
in slightly older children), Knudson postulated that two independent somatic mutations 
needed to occur in a single retinoblast. This ‘two-hit’ hypothesis was based purely on 
epidemiological data. However, the finding that a proportion of individuals who inherit 
retinoblastoma possess a deletion in all their cells at chromosome 13ql4 provided clear 
experimental evidence of the inherited alteration—the ‘first hit’ (Yunis & Ramsay, 
1978). Subsequently, the demonstration of ‘loss of heterozygosity’ (LOH) of 
polymorphic markers at 13ql4 in both familial and sporadic tumours gave evidence for 
the second hit, arising via chromosome loss, deletion, mitotic recombination or gene 
conversion (Cavenee et al., 1983; Knudson, 1978). The fact that this second hit occurs 
in almost all carriers of the germline mutation accounts for retinoblastoma’s apparent 
dominant inheritance. A particular probe mapping to chromosome 13ql4 identified a 
homozygous deletion in two tumours (Friend et al., 1986). This sequence was used in a 
‘chromosome walk’ to identify sequences that were expressed in normal retinoblasts but 
not in retinoblastomas, and thus paved the way for isolation of the RBI gene.
Following the demonstration of internal deletions within the RBI gene and of the 
ability of normal RBI cDNA to revert the tumourigenic properties of mutant tumour 
cells in culture, RBI was universally acknowledged as a true tumour suppressor gene 
(Friend et al., 1986; Huang et al., 1988). Several different types of genetic lesion have 
been shown to inactivate the RBI locus, including large and small scale deletions, 
splicing mutations and point mutations (Bookstein et al., 1990a; Horowitz et al., 1989; 
Kaye et al., 1990). RBI is now known to encode a ubiquitously expressed, 105kDa 
nuclear phosphoprotein called pRB (Lee et al., 1987), which appears to function as a 
negative regulator of cell cycle progression (see Section 1.1.2.3). The importance of 
this role is reflected in the fact that RBI mutations have also been found in a wide 
variety of sporadic tumours. These include sarcomas, small cell carcinomas of the lung, 
bladder carcinomas and breast carcinomas (Horowitz et al., 1990; Lee et al., 1988). 
Interestingly, the proteins pl07 and pl30 are structurally and functionally similar to 
pRB (Reviewed in Mulligan & Jacks, 1998). The involvement of these proteins in 
tumour suppression, however, remains uncertain.
More than 20 different hereditary cancer syndromes have now been attributed to 
germline mutations in specific tumour suppressor genes (Table 1.3). These tumour 
suppressors usually follow the ‘two hit’ paradigm, with inactivation of the second copy
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of the gene being the initiating, rate-limiting event in tumourigenesis. The acquisition 
of additional mutations in oncogenes and tumour suppressors is then required for 
conversion to full malignancy. Like R B I , many of the tumour suppressor genes 
unearthed through the study of hereditary cancer syndromes are also now known to be 
inactivated in sporadic tumours. Again in line with Knudson’s prediction, this usually 
requires the acquisition of two somatic mutations, the second mutation arising in a 
descendant of the cell that incurred the first. Such a sequence of mutational events is 
likely to occur only rarely, thus accounting for the fact that sporadic tumours tend to 
occur singly and relatively late in life. Patients with an inherited cancer syndrome, on 
the other hand, often present with multiple tumours at a young age.
1.1.2.2 Departure of tumour suppressor genes from the classic retinoblastoma model
Tumour suppressor genes do not always follow the classic Knudson paradigm, and can 
differ from the retinoblastoma model in several ways. In some cases, inactivation of one 
allele only appears sufficient for tumour initiation. The WT1 gene has been implicated 
in the growth abnormality syndromes WAGR and DDS, of which the paediatric 
nephroblastoma Wilm’s tumour is one manifestation, as well as in isolated inherited, 
and some sporadic, Wilm’s tumour cases (Little & Wells, 1997; Pelletier et al., 1991). 
WAGR syndrome patients usually display large, constitutional deletions spanning the 
WT1 gene and the nearby PAX6 gene. Not all tumours from these patients, however, 
show a somatic mutation in the remaining WT1 allele (Little & Wells, 1997). In 
addition, the non-tumour manifestations of the growth abnormality syndromes 
mentioned above are associated with germline WT1 mutation (or deletion) only. The 
TP53 gene may also be haploinsufficient for tumour suppression in some instances, 
studies of murine p53 heterozygotes indicating that tumourigenesis does not always 
require loss of the second allele—again, gene dosage appears important (Venkatachalam 
et al., 1998). Mice heterozyous for the murine tumour suppressor gene p 2 'fCipl are also 
predisposed to cancer, the wild type allele being neither mutated nor silenced in tumours 
(Fero et al., 1998). As a CDK inhibitor p27&pl is a candidate human tumour suppressor 
(Coats et al., 1996); indeed, many tumours display low levels of the protein (Porter et 
al., 1997; Yasui et al., 1999; Yatabe et al., 1998), and hemizygous alterations of the 
chromosomal region to which it maps have been observed (Spirin et al., 1996; 
Stegmaier et al., 1996; Takeuchi et al., 1996).
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Heritable retinoblastoma is a phenotypically simple disease. Some heritable 
cancer syndromes, however, are characterised by extensive phenotypic variation in 
terms of penetrance, severity of symptoms, tumour type and age of onset, von Hippel- 
Lindau (VHL) disease, which predisposes to kidney, brain and eye neoplasms, and 
familial adenomatous polyposis (FAP), which predisposes to colon cancer, both display 
such variation. These syndromes are associated with germline mutations in the genes 
VHL and APC  respectively. In each of these genes, certain mutations are known to give 
rise to particular phenotypes (Reviewed in Kaelin & Maher, 1998; Kinzler & 
Vogelstein, 1996); this ‘allelic heterogeneity’ accounts for some—but not all—of the 
variability in symptoms (although clear molecular explanations for the genotype- 
phenotype relationships are lacking). Extensive phenotypic variation also exists within 
the multiple endocrine neoplasia syndrome MEN1. However, in this case there are no 
clear correlations between specific mutations within the MEN1 gene (the functions of 
which little is known) and the clinical manifestations of the disorder (Reviewed in 
Thakker, 1998). This phenotypic variation—and much of that of the VHL and FAP 
syndromes—is presumably attributable to variant alleles of modifier genes and to 
environmental factors. Such variables are likely to be equally important in determining 
susceptibility to (and clinical outcome of) sporadic tumours.
The correlation of particular mutations with variations in phenotype implies that 
alterations of tumour suppressor genes more subtle than simple, complete loss of 
function mutations can contribute to cancer susceptibility. As further evidence of this, 
polymorphisms within the TP53 coding sequence may confer differential susceptibility 
to oncogenesis (Buller et al., 1997; Wang-Gohrke et al., 1998). Moreover, a germline 
‘mutation’ of APC  found in Ashkenazi Jews does not alter the function of the encoded 
protein, but generates a hypermutable tract in the coding sequence such that somatic 
mutations near it arise at increased frequency (Laken et al., 1997). These subtle 
variations in known cancer genes may account for some familial cancer clusterings that 
do not show simple Mendelian inheritance. A variety of undiscovered low penetrance 
susceptibility and modifier genes are also likely to contribute to such aggregations.
RBI appears to be inactivated in almost all retinoblastomas, be they sporadic or 
familial (Horowitz et al., 1990). Many tumour suppressor genes isolated through study 
of a hereditary cancer syndrome, however, are inactivated in only a subset of sporadic 
tumours of the same type. Only around 10% of sporadic Wilm’s tumours, for example, 
show mutation or deletion of WT1 (Little & Wells, 1997). Indeed, a second WT locus
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has been identified on chromosome llp l5  that is implicated in some sporadic Wilm’s 
tumours and in the growth abnormality syndrome BWS, and five other loci are also 
thought to harbour genes involved in the biology of this tumour (Reviewed in Coppes & 
Egeler, 1999). Germline mutations in BRCA1 and BRCA2 predispose to female breast 
and ovarian cancer and to male & female breast cancer respectively, but mutations in 
these genes are very rarely observed in sporadic breast and ovarian tumours (Futreal et 
al., 1994; Lancaster et al., 1996). It is in fact now widely accepted that inherited and 
sporadic breast tumours develop through very different mutational pathways (see 
Section 1.1.2.3).
Perhaps more fundamentally, the dogma that tumour suppressors act to suppress 
proliferation or promote apoptosis can also be questioned in some instances. For 
example, while some studies support the hypothesis that WT1 plays a tumour 
suppressing, anti-proliferative role, other analyses suggest that the wild-type protein can 
promote proliferation and suppress apoptosis. (Yamagami et al., 1998). Moreover, the 
presence of wild-type WT1 in acute myeloid leukaemia has been proposed by some as 
an indicator of poor prognosis and drug resistance (Bergmann et al., 1997; King- 
Underwood & Pritchard-Jones, 1998). The prototypical tumour suppressor pRB has 
also been demonstrated to suppress apoptosis in some circumstances (Morgenbesser et 
al., 1994; Whitaker & Hansen, 1997). Interestingly, there is evidence to suggest that 
some TP53 mutations in tumours are in fact gain-of-function mutations, that endow the 
protein with new properties. One such activating mutation may promote genetic 
instability by disrupting spindle checkpoint control, thus promoting—rather than 
inhibiting—tumour progression (Gualberto et al., 1998). The existence of such 
mutations might partly account for the fact that different classes of TP53 mutations have 
different effects on resistance of tumour cells to chemotherapy (Blandino, Levine & 
Oren, 1999).
The Knudson paradigm has provided a useful framework upon which much of 
our current understanding of tumour suppressor genes rests. Not surprisingly, however, 
it has proved too simplistic in some instances. As alluded to in Section 1.1.2.4, novel 
approaches to the isolation of cancer genes will almost certainly result in the 
identification of an increasing number of genes whose inactivation does not fulfil 
classical tumour suppressor gene criteria.
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1.1.2.3 Gatekeepers and Caretakers
Some rare syndromes of which an increased cancer risk is one manifestation differ from 
the retinoblastoma model in that they have a recessive mode of inheritance. These 
syndromes include ataxia telangiectasia (susceptibility to lymphoma and breast cancer), 
Bloom’s syndrome (susceptibility to many solid tumours), xeroderma pigmentosum 
(susceptibility to skin cancer caused by heightened sensitivity to UV-irradiation) and 
Werner’s syndrome (susceptibility to multiple tumour types). Although these 
syndromes predispose to different types of tumour, they all result from germ-line 
mutations in genes responsible for maintaining genomic integrity. Xeroderma 
pigmentosum sufferers inherit a mutation in one of the nucleotide excision repair (NER) 
genes (Hoeijmakers, 1993), Bloom’s and Werner’s sufferers in the DNA helicases BLM 
and WRN respectively (Ellis et al., 1995; Yu et al., 1996), and ataxia telangiectasia 
sufferers in the DNA damage response gene ATM (Savitsky et al., 1995). These 
defects, although not directly responsible for tumour development, increase the chances 
of mutations arising in those genes that are.
In view of these findings, Kinzler and Vogelstein proposed that tumour 
suppressor genes should be classified as either ‘gatekeepers’ or ‘caretakers’ (Kinzler & 
Vogelstein, 1997). Gatekeepers directly inhibit cell proliferation or promote cell death, 
and their inactivation provides cells with a direct growth advantage. Each cell type 
appears to have only one or a few gatekeepers, with inactivation of a particular 
gatekeeper leading to very specific types of tumour. Inactivation of RBI, APC and NF1, 
for example, constitutes the initiating, rate limiting step in development of 
retinoblastomas, colon tumours and Schwann tumours respectively. Although 
mutations in other cancer genes clearly play a role in the progression of these tumours, 
such mutations do not appear to be able to efficiently initiate the neoplastic process 
(Garber et al., 1991; Jen et al., 1994). Caretaker genes are involved in maintaining 
genetic stability and preventing mutation. Unlike gatekeepers, inactivation of a 
caretaker gene does not directly promote tumour initiation. Instead, their disruption 
gives rise to a ‘mutator phenotype’, where the observed mutation frequency of all 
genes—including cancer gatekeepers—is increased. The fact that tumour initiation 
depends upon the acquisition of further mutations is thought to partly account for the 
non-dominant pattern of inheritance of the cancer syndromes referred to above.
Undisputed gatekeepers include the prototypical tumour suppressor pRB, which 
acts to inhibit progression through the cell cycle. pRB is hypophosphorylated during GO
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and early G l, but from mid to late G1 becomes increasingly phosphorylated by cyclin 
dependent kinases (CDKs) (Lundberg & Weinberg, 1998). Hypophosphorylated pRB 
binds to the transcription factor E2F, forming a complex that actively represses the 
transcription of genes required for S phase entry; recruitment of either a histone 
deacetylase or a CtlP/CtBP co-repressor complex appears to mediate this repression 
(Luo, Postigo & Dean, 1998; Meloni, Smith & Nevins, 1999). Hyperphosphorylation of 
pRB disrupts the pRB/E2F repression complex, allowing transcription of S phase genes 
and G l to S phase progression (Harbour et al., 1999). Thus pRB plays a central role in 
cell-cycle regulation. In view of this, it is perplexing that germline RBI mutations 
predispose carriers to only retinoblastoma and osteosarcoma; the reasons for the tissue- 
specificity of pRB’s gatekeeping functions have yet to be elucidated, but redundancy of 
function in non-affected tissues may offer a partial explanation. The significance in 
cancer development of the pRB/E2F cell cycle control pathway is further emphasised by 
the frequent inactivation in tumours of the tumour suppressor p l6 INK4a (Reviewed in 
Pollock, Pearson & Hayward, 1996). The p lb0^ 43 protein binds to and inhibits the 
cyclin D dependent kinases CDK4 and CDK6, thus negatively regulating pRB 
phosphorylation (Sherr & Roberts, 1995). In addition to its involvement in sporadic 
tumours, germline mutations in p l6 INK4A are associated with familial melanoma and 
familial pancreatic adenocarcinoma (Hussussian et al., 1994; Whelan, Bartsch & 
Goodfellow, 1995).
Abnormalities of the p53 tumour suppressor constitute one of the most common 
cancer defects. Germline mutation of TP53 is associated with Li Fraumeni syndrome, 
an autosomal dominant predisposition to cancers of the breast, brain, bone, adrenal 
cortex, soft tissues and haematopoietic system (Malkin et al., 1990). Mutation or 
deletion of TP53 is also displayed by a huge array of sporadic tumours (Hainaut et al., 
1998). The p53 protein is a modular transcription factor that integrates signals arising 
from a wide array of cellular stresses (such as DNA damage, hypoxia, hyperoxia and 
heat shock) and elicits an appropriate response via activation or repression of specific 
downstream effector genes (Reviewed in Prives & Hall, 1999). The p53-mediated 
response to stress is usually one of apoptosis, G l or G2 arrest or induction of 
differentiation, the precise outcome being highly dependent upon poorly understood 
factors specific to the cell or tissue type. p53 activity is subject to many levels of 
regulation, mediated by protein-protein interactions, post-translational modification and 
(probably) subcellular localisation (Reviewed in Prives & Hall, 1999). The best
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characterised p53-activating cellular stress is DNA damage, and in the absence of a p53- 
mediated response genetic lesions induced by DNA damaging agents more readily lead 
to neoplastic transformation (Kemp, Wheldon & Balmain, 1994). Many of the diverse 
array of cellular functions that p53 has been implicated in thus concern the maintenance 
of genomic integrity; the fact that loss of p53 leads to increased genomic instability 
argues in favour of a caretaker role for this protein. However, overexpression of p53 
suppresses transformation (Finlay, Hinds & Levine, 1989), and its loss can clearly 
endow cells with a direct proliferative and survival advantage. These features indicate 
that the inactivation of p53 could well constitute the initiating step of tumourigenesis. 
Two mammalian homologues of p53, p73 and p63 (originally named KET) have been 
identified in recent years which also appear to function as transcription factors (Kaghad 
et al., 1997; Schmale & Bamberger, 1997). There is currently no conclusive evidence 
that either homologue functions as a tumour suppressor (Kovalev et al., 1998), and it is 
unclear whether the three gene products activate the same, overlapping, or different 
target genes. Two further, as yet largely uncharacterised, proteins also show strong 
similarity to p53 (Bian & Sun, 1997; Zeng, Levine & Lu, 1998).
p53 has also been implicated in oncogene-induced apoptosis and cell cycle arrest 
(see Section 1.2.5), responses that may serve as a tumour suppressive adaptation to 
inappropriate proliferative signals. It is unclear whether loss of this function or of the 
DNA damage response pathway is of most importance to tumourigenesis. The p53 
response to oncogene expression is mediated by pl4ARF (Sections 1.2.1 and 1.2.5), 
which may also represent a bona fide tumour suppressor gene. A role of p l4ARF in 
tumour suppression has been hard to demonstrate conclusively, since its coding 
sequence overlaps that of p lb 1^ 43 (Mao et al., 1995); the deletions of the locus that are 
very commonly found in cancer affect both genes. The fact that few point mutations 
within the locus appear to specifically affect p l4ARF, while many have been shown to 
specifically affect p l6 INK4a, argues against a tumour suppressor function for p l4ARF 
(Munro et al., 1999; Sharpless & DePinho, 1999). However, mice null for p l9ARF (the 
murine homologue of p i4ARF) that retain functional p lb 1^ 43 are highly tumour prone 
(Kamijo et al., 1997). This, together with the very high frequency of homozygous 
deletion of the INK4A/ARF locus in sporadic tumours, suggests that p l4ARF loss may yet 
be considered to play an important role in tumour progression in humans.
Another presumed gatekeeper is the product of the APC gene. In addition to the 
association of germline APC  mutations with FAP (sufferers of which develop hundreds
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of intestinal polyps, a very small number of which will progress to malignancy), somatic 
APC mutations are present in the majority of sporadic intestinal adenomas and 
carcinomas (Powell et al., 1992). The APC protein functions as a negative regulator of 
P-catenin, which was originally identified as a cadherin binding protein. APC targets 
free P-catenin (that which is not sequestered by E-cadherin) for degradation, via 
complex-formation with glycogen synthase kinase 3 (GSK3, a component of the WNT 
signalling pathway) and Axin; free p-catenin is phosphorylated by GSK3 and 
subsequently degraded by the ubiquitin-proteasome pathway (Munemitsu et al., 1995; 
Nakamura et al., 1998; Rubinfeld et al., 1996). P-catenin is stabilised in response to 
either WNT signalling (via inhibition of GSK3) or APC inactivation; in addition, 
activating mutations of P-catenin have been observed in a subset of tumours that lack 
APC mutations (Kolligs et al., 1999; Morin et al., 1997). Accumulation of P-catenin 
allows it to complex with the Tcf-4 transcription factor and induce the expression of 
Tcf-4 regulated genes. APC thus regulates cellular levels of P-catenin and consequently 
the formation of active p-catenin/Tcf-4 transcription complexes. The identity of the p- 
catenin/Tcf-4 target genes is an area of intense investigation. Recent studies have 
demonstrated Tcf-4/p-catenin-mediated upregulation of the proto-oncogene c-MYC 
following loss of APC function, thus providing a functional connection between APC 
inactivation and the hyperproliferation of colon endothelial cells (He et al., 1998; 
Pignatelli, 1999). It is also possible that the Tcf-4/p-catenin complex represses 
expression of E-cadherin (Huber, Bierkamp & Kemler, 1996), whose cell-cell adhesion 
function is known to be lost in most epithelial cancers (Birchmeier & Behrens, 1994). 
(Loss of sequestration of P-catenin by E-cadherin may lead in turn to accumulation of 
free p-catenin and Tcf-4 activation (Fagotto et al., 1996).) Significantly, loss of cell-cell 
adhesion characterises the progression of benign lesions to invasive, metastatic tumours. 
Deletion or mutation of the E-cadherin gene has been observed in several tumours 
(Guilford et al., 1998; Huber et al., 1996); it may therefore itself represent a bone fide 
tumour suppressor gene. Negative regulation of the p-catenin/Tcf-4 pathway is unlikely 
to be the only means by which APC exerts its tumour suppressive effects. In particular, 
the observation that APC  germline mutations are frequent in FAP patients while p- 
catenin germline mutations are rare suggests that p-catenin mutation cannot substitute 
for APC mutation in the initiation of FAP (Cao et al., 1999). APC is known to 
upregulate the differentiation-inducing CDX2 gene in a manner that is not directly
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mediated by P-catenin/Tcf-4; in rare cases of colorectal cancer where the APC/p-catenin 
pathway is intact, mutation of CDX2 or of other APC regulated genes may constitute the 
initiating event (da Costa et al., 1999). An APC homologue known as APC2 has 
recently been identified; APC2 can also regulate the formation of active P-catenin/Tcf 
complexes (Nakagawa et al., 1998; van Es et al., 1999). Any role of APC2 in cancer, 
however, has yet to be elucidated.
Other tumour suppressor gene products also appear to be involved in specific 
signalling pathways. Germline mutations in the NF1 gene are associated with the 
neurofibromatosis type 1 syndrome (Cawthon et al., 1990; Viskochil et al., 1990). 
Neurofibromin, the NF1 gene product, contains a GTPase-activating protein (GAP)- 
related domain and is a major negative regulator of the Ras signal transduction pathway; 
its loss leads to increased levels of activated Ras and constitutive downstream mitogenic 
signalling (Feldkamp, Gutmann & Guha, 1998). The tumour suppressor PTEN is 
another negative regulator of signal transduction. The PTEN gene is deleted or mutated 
in a wide variety of sporadic tumours (Steck et al., 1997), and has also been implicated 
in the Cowden tumour susceptibility syndrome (Liaw et al., 1997). PTEN functions as a 
phosphatase, modulating signal transduction pathways that involve lipid second 
messengers. Specifically, PTEN is thought to dephosphorylate insulin-induced 
phosphatidylinositol (3,4, 5) trisphosphate (Maehama & Dixon, 1999), and may thereby 
inhibit activation of the AKT protein kinase and the subsequent generation of AKT- 
induced cell survival signals (Coffer, Jin & Woodgett, 1998). The PTCH tumour 
suppressor also modulates a signal transduction pathway, but is unusual in that it 
encodes a transmembrane protein. PTCH is known to suppress the sonic hedgehog 
signalling pathway, but the target genes activated in its absence in tumours are mainly 
unknown (Ingham, 1998). Germline mutation of PTCH is associated with Gorlin’s 
syndrome, which predisposes to basal cell carcinomas, medullablastomas or 
meningiomas, while somatic PTCH mutations are found in some sporadic basal cell 
carcinomas (Gailani et al., 1996; Johnson et al., 1996). Rather than negatively 
regulating a mitogenic or anti-apoptotic signalling pathway, the DPC4/Smad4 tumour 
suppressor (a homologue of the Drosophila mothers against dpp (MAD) protein) is a 
positive mediator of anti-proliferative TGFjJ signalling; it probably effects the TGF|3 
response by inducing the transcription of TGFjl responsive genes (Duff & Clarke,
1998). Smad4 has also been linked to the SAPK/JNK cascade, thus implicating Smad4 
in the control of both cell cycle arrest and apoptosis (Atfi et al., 1997). Loss of Smad4
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is strongly associated with both pancreatic and colorectal malignancy (Hahn et al., 1996; 
Takagi et al., 1996). Interestingly, the SMAD2 gene, which maps adjacent to SMAD4 at 
chromosome 18q21, has also been implicated in tumour suppression and may be 
involved in the control of cellular invasion (Prunier et al., 1999).
The Wilm’s tumour suppressor gene WT1 encodes four protein isoforms that 
appear to act as zinc finger-containing transcription factors involved in both 
transactivation and repression (Haber et al., 1991; Madden et al., 1991). Many 
transcriptional targets have been proposed, but none have been conclusively verified in 
vivo (Reviewed in Little, Holmes & Walsh, 1999). Recent data suggest that WT1 may 
also regulate gene expression through interactions with RNA, probably via a role in 
gene splicing (Davies et al., 1998). In addition, WT1 binds to a variety of proteins, 
including p53. Again, the physiological relevance of many of these interactions remains 
unclear (Little et al., 1999).
The VHL tumour suppressor appears to have multiple, tissue-specific functions, 
with different germline mutations predisposing to different tumour types. One of the 
roles of the cytoplasmic protein involves inhibition of the vascular endothelial growth 
factor VEGF (Iliopoulos et al., 1996). VHL loss leads to inappropriate accumulation of 
VEGF mRNA even under normoxic conditions, possibly via constitutive activation of 
the oxygen-regulated transcription factor HIF1 (Maxwell et al., 1999); inactivation of 
VHL could thus be critical to the process of angiogenesis. The protein forms a complex 
with elongins B and C and the cullin protein family member Cul2 (Duan et al., 1995; 
Pause et al., 1997). The homology of elongin C and Cul2 with the yeast proteins Skpl 
and Cdc53 suggests that the pVHL/elongins/Cul2 complex could also be involved in 
targeting cell cycle control proteins for ubiquitination and degradation (Pause et al.,
1999).
Caretaker genes include the seven NER xeroderma pigmentosum 
complementation group genes XPA-XPG. Inactivation of the NER gene products 
impairs repair of UV-induced cyclobutane pyrimidine dimers and pyrimidine- 
pyrimidone (6-4) photoproducts, thus increasing the likelihood of mutation at the next 
DNA replication cycle. XPA and XPE are responsible for recognising DNA lesions, 
XPB and XPD are DNA helicases required for unwinding the DNA duplex at regions of 
damage, XPF and XPG are endonucleases responsible for excising the lesions, while 
XPC is a single-stranded DNA binding protein.
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The BLM and WRN helicases, implicated in Bloom’s syndrome and Werner’s 
syndrome respectively, also function as caretakers. Again, genomic instability is a 
feature of these disorders, manifested in Bloom’s syndrome as an increased frequency of 
chromosome breakage and chromatid exchange between homologous chromosomes and 
sister chromatids. In Werner’s syndrome, chromosomal instability is manifested by 
inversion, translocation, and deletion. The rate of spontaneous mutation is increased in 
both syndromes; this is despite apparent normal functioning of DNA repair pathways 
(Warren et al., 1981; Fukuchi et al., 1989).
The product of the ATM  gene, implicated in ataxia telangiectasia (AT), is 
probably another caretaker. Cells from AT individuals display an elevated level of 
spontaneous chromosomal breaks, are extremely sensitive to ionizing radiation and 
appear defective in a number of DNA-damage cell cycle checkpoints (Friedberg et al.,
1995). These features of AT imply a role for ATM in the repair or processing of DNA 
double-strand breaks. Certain human and mouse cells with ATM  defects fail to 
upregulate p53 on induction of DNA damage, suggesting that ATM lies upstream of p53 
in the p53 DNA damage-recognition pathway (Kastan et al., 1992; Xu et al., 1996; 
Westphal et al., 1997). Indeed, it is now know that ATM functions as a kinase and is 
capable of phosphorylating p53 in response to DNA damage (Banin et al., 1998; 
Canman et al., 1998). ATM belongs to the same family as DNA-dependent protein 
kinase DNA-PK, which is implicated in non-homologous end-joining of double-strand 
DNA breaks and which also acts upstream of p53 in the DNA damage response pathway 
(Woo et al., 1998). ATM is also related to the MEC1 and TEL1 proteins of S. 
cerevisiae, Rad3 of S. pombe, and MEI-41 of D. melanogaster; these are all involved in 
DNA-damage sensitive checkpoint controls and cause repair deficient phenotypes when 
mutated.
Mismatch repair (MMR) genes also fall under the caretaker category. Germline 
mutations in the MMR genes MLH1, PMS1, PMS2 and, particularly, MSH2, are 
associated with the dominant inherited syndrome of nonpolyposis colorectal cancer 
(HNPCC); in contrast to FAP, HNPCC sufferers typically develop only one or two 
intestinal polyps, each of which rapidly progresses to malignancy. Not surprisingly, 
HNPCC tumour cells have an increased spontaneous mutation rate and show 
microsatellite length heterogeneity. The latter is also observed in some sporadic 
colorectal tumours and in certain other sporadic tumour types; such tumours are often 
associated with somatic mutation of MSH2 (Bubb et al., 1996; Risinger et al., 1995).
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The gatekeeper/caretaker classification of other tumour suppressor genes is less 
clear-cut, partly because the functions of many tumour suppressor genes are not yet well 
defined, and partly because the same gene may be able to act as both gatekeeper and 
caretaker depending on the circumstances. BRCA1 and BRCA2, for example, both 
possess a transactivation domain that is compromised by mutations found in BRCA1 and 
BRCA2 families (Chapman & Verma, 1996; Milner et al., 1997). BRCA1, moreover, 
can inhibit cell proliferation via induction of p21WAF1 (Somasundaram et al., 1997), and 
expression of both BRCA1 and BRCA2 correlates with cell cycle progression (Ruffner 
& Verma, 1997; Vaughn et al., 1996). These are features that would be expected of a 
gatekeeper. However, BRCA1 and BRCA2 can both bind (directly or indirectly) to the 
RecA homologue RAD51, which is involved in homologous recombination and DNA 
damage repair (Scully et al., 1997; Sharan et al., 1997). Furthermore, mice embryos that 
are null for Brcal or Brca2 display increased sensitivity to radiation (Sharan et al., 1997; 
Shen et al., 1998). These findings suggest that both BRCA1 and BRCA2 are involved 
in RAD51-mediated repair and recombination and may thus function as caretakers. 
Indeed, the generation of a conditional Brcal knockout in mouse mammary epithelial 
cells has convincingly demonstrated that Brcal disruption causes genetic instability and 
triggers further genomic changes (Xu et al., 1999). Tumours arose only after a long 
latency period and displayed frequent chromosomal alterations, many of which involved 
the TP53 gene. Significantly, introduction of a loss-of-function TP53 allele into the 
Brcal conditional mutant was found to accelerate tumour formation. Loss of the p53 
checkpoint function may thus represent one genetic change required for Brcal-mediated 
tumourigenesis. Given that accumulation of p53 has been found to activate a cell cycle 
checkpoint and inhibit the malignancy of Brca2 defective tumours, the same may also 
be true of Brca2-mediated tumourigenesis (Connor et al., 1997).
A caretaker function for these genes could explain a puzzling finding, namely 
the lack of somatic BRCA1 and BRCA2 mutations found in sporadic breast cancers. 
Kinzler and Vogelstein (1997) argue that mutations in caretaker genes would not 
necessarily be expected to occur in sporadic cancers, since tumour initiation would 
require the accumulation of four independent mutations—inactivation of two caretaker 
alleles and two gatekeeper alleles—in a single cell. Progression to full malignancy 
would require even more mutational events. In all likelihood, a cell would undergo 
terminal differentiation, replicative senescence or apoptosis before the necessary number 
of mutations had been acquired. If this scenario holds true then familial and sporadic
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breast tumours must arise through distinct mutational pathways, and inherent differences 
should exist between the aetiology of the two tumour types. A number of observations 
indicate that the genetic makeup of familial and sporadic breast tumours does indeed 
differ. Most fundamentally, breast tumours of patients with a germline BRCA1 or 
BRCA2 mutation display a greater number of genetic defects than sporadic breast 
tumours (Tirkkonen et al., 1997). As in the mouse Brcal model, these defects include 
an increase in TP53 alterations (Crook et al., 1997; Eiriksdottir et al., 1998). In 
summary, these findings are fully consistent with a caretaker role of BRCA1 and 
BRCA2.
Tumour suppressor genes thus constitute critical points in a variety of complex 
cellular pathways. These pathways control proliferation, differentiation, apoptosis, 
response to DNA damage or mutation, angiogenesis and cell-cell adhesion. As 
discussed later tumour suppressor genes are also involved in replicative senescence, the 
process that limits the proliferative lifespan of normal somatic cells but which is 
abrogated in most malignancies. Another cellular property that is altered in tumours is 
that of gap junctional intercellular communication; genes with a role in this aspect of 
cell behaviour, most notably the connexins, may also function as tumour suppressors 
(Reviewed in Yamasaki et al., 1999). Many tumour suppressor genes, for example 
SMAD4, WT1 and BRCA1, encode proteins that have essential roles in development. 
Indeed, it is becoming increasingly apparent that these developmental roles may account 
for the involvement of such genes in neoplasia.
The role of tumour suppressor genes in protecting against cancer is underscored 
by the finding that several DNA tumour viruses, including the oncogenic human 
papillomaviruses, encode oncoproteins that bind to and inhibit the normal activity of 
tumour suppressor gene products. Adenovirus E1A proteins, polyoma T antigen and 
HPV E7 can all bind to and inhibit the action of pRB, while adenovirus E1B and HPV 
E6 inhibit p53. The SV40 large T antigen can inhibit both pRB and p53 via distinct 
binding sites. Many other cellular proteins are detected in complexes with these and 
other DNA viral antigens; it is probable that these proteins include currently unknown 
tumour suppressors.
1.1.2.4 The identification of tumour suppressor genes
The isolation of recessive-acting tumour suppressor genes—whose existence becomes 
apparent only after their inactivation—has proved much more difficult than that of
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dominant-transforming oncogenes. Functional screens greatly facilitated the isolation of 
novel oncogenes. Screening sequences for suppression of the transformed phenotype, 
however, has proved more difficult, not least because tumour cells usually possess 
multiple genetic defects and are extremely well adapted to evading growth inhibition. 
Moreover, tumour suppressor genes that function as caretakers and give rise to a 
mutator phenotype would not even be predicted to inhibit tumourigenicity: the genetic 
defects that directly confer enhanced growth and survival would have already occurred, 
and would not be reversed by subsequent restoration of genomic stability.
As discussed below, functional screens can prove useful in the isolation of novel 
genes that have direct growth inhibitory functions. However, most tumour suppressors 
have been identified by ‘reverse genetics’, or positional cloning. The list of cancer 
genes isolated by this approach includes APC, ATM , BLM , BRCA1, BRCA2, DCC, 
DPC4, FHIT, LKB1, NF1, NF2, MEN1, MMAC1, RBI, TSC1, TSC2, VHL, WRN and 
WT1. In the mapping of genes associated with hereditary cancer syndromes, linkage 
analysis frequently identified the relevant chromosomal region. In future, the resolution 
of linkage analyses may be greatly improved by the advent of DNA chip technology, 
which can be used to identify and monitor thousands of genome-wide single nucleotide 
polymorphisms (SNPs) (Reviewed in Gerhold, Rushmore & Caskey, 1999). 
Cytogenetic clues can then help refine a region identified by linkage studies (and in 
fortuitous cases such as the mapping of RBI to chromosome 13ql4 can define a region 
independently of linkage); gross chromosomal deletions in normal cells are rare, but if 
detected in just one family can be of great assistance. Candidate genes can then be 
identified from within the area of interest. Any known tumour suppressor genes 
residing within the region are obvious subjects for germline-mutation screening; this 
approach linked TP53 to Li Fraumeni syndrome and CDKN2A to familial melanoma. 
Completion of the human genome project and of a genome-wide transcript map will 
greatly facilitate the identification of novel candidates (Schuler et al., 1996).
However, the identification of genes that confer inherited susceptibility to cancer 
is likely to remain a formidable task. This is partly because of a lack of families suitable 
for genetic studies. Linkage studies have the greatest chance of success in families 
containing multiple affected and unaffected individuals in two or more generations, but 
such families are hard to find. This is partly because of difficulties in distinguishing a 
real familial cancer syndrome from chance familial aggregations of sporadic tumours, 
particularly when a syndrome predisposes to common forms of the disease. Incomplete
1 9
penetrance can pose a further complication, as can the development of sporadic cancers 
in family members who do not carry the mutant allele. Moreover, germline mutations in 
several different inherited cancer genes (usually those whose products lie on the same 
functional pathway) can give rise to indistinguishable clinical symptoms. Even leaving 
these difficulties aside, traditional linkage analyses are unlikely to remain the principal 
means of mapping inherited cancer genes. This type of study is very effective at 
mapping rare alleles that cause Mendelian, highly penetrant syndromes. However, only 
1% of cancers are associated with such syndromes, although more than 15% of all 
cancer may have a major inherited component. Indeed, the isolation of highly penetrant 
cancer susceptibility genes has now largely been completed, and attention is shifting 
towards the identification of low penetrance susceptibility genes. New methods of 
epidemiological analysis will be needed to detect non-Mendelian familial clusterings, 
and alternative mapping strategies—such as sib-pair gene sequence segregation 
analysis—will doubtless be required to locate the genes responsible.
The study of chromosomal abnormalities is central to the mapping of tumour 
suppressor genes involved in both sporadic and familial tumours. Consistent with 
Knudson’s ‘two-hit’ hypothesis, chromosomal regions at which high frequencies of 
LOH are found in tumours often harbour a tumour suppressor gene (Ponder, 1988). 
LOH at several chromosomal locations has now been described for most tumour types. 
Once a region of LOH has been defined and cloned, tumour-specific alterations and 
candidate genes within it can be identified. LOH mapping has thus helped isolate genes 
involved in both sporadic and familial tumours including TP53, DCC, NF2 and MEN1. 
The utility of LOH mapping, however, is limited by its insensitivity, with losses often 
spanning very large areas. The presence in tumours of homozygous deletions can be 
much more informative. Moreover, subtractive hybridisation techniques such as 
representational difference analysis (RDA) can be used to hunt for these deletions even 
when no positional information is available (Lisitsyn & Wigler, 1995). This technology 
helped in the cloning of BRCA2 at 13ql2 and of PTEN at 10q22-23 (Li et al., 1997; 
Wooster et al., 1995). RDA and LOH mapping would be expected to identify not only 
genes whose inactivation constitutes the initial, rate-limiting step of tumourigenesis, but 
also genes involved in tumour progression.
Studies of genomic loss have thus been the foundation of most efforts to isolate 
tumour suppressor genes. However, it is becoming increasingly apparent that alteration 
to DNA sequence is not the only means by which tumour suppressor genes can be
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inactivated. Epigenetics—the mitotic (or meiotic) inheritance of information on the 
basis of gene expression levels rather than gene sequence—almost certainly also plays a 
part in tumour development. The methylation of cytosine residues in promoter CpG 
islands is a powerful mechanism for suppression of gene activity, resulting from an 
inhibition of transcription initiation caused by reduced binding of sequence-specific 
transcription factors and (possibly) recruitment of methylation-dependent transcriptional 
repressors (Asiedu et al., 1994; Clark, Harrison & Molloy, 1997; Prendergast & Ziff,
1991). The promoters of a number of known tumour suppressor genes contain CpG 
islands and show evidence of methylation silencing. The best documented of these is 
p l6 INK4A, but RB I , VHL and APC are additional examples (Hiltunen et al., 1997; 
Myohanen, Baylin & Herman, 1998; Ohtani-Fujita et al., 1997; Prowse et al., 1997). 
Moreover, there is now good evidence from tumour studies that methylation of these 
promoters can constitute one—and sometimes both—of the Knudson hits (Reviewed in 
Jones & Laird, 1999). Over 80% of hits to the mismatch repair gene MLH1 appear to be 
achieved by promoter methylation; significantly, treatment of cells derived from 
tumours that display a methylated MLH1 promoter with the DNA methyltransferase 
inhibitor 5-aza-deoxycytosine leads to re-accumulation of the MLH1 protein and 
restoration of mismatch repair activity (Herman et al., 1998). Many tumour suppressors 
are preferentially inactivated by a particular pathway: for example, point mutation is the 
most common means of p53 inactivation while homozygous gene deletion is the main 
means of p lb ™ ^  inactivation. Jones and Laird (1999) argue that a group of tumour 
suppressor genes may exist unrecognised whose primary means of inactivation is 
through DNA hypermethylation.
A number of new techniques have been developed to scan the genome for 
changes in methylation, and are beginning to isolate a range of new genes relevant to 
cancer. The methods include restriction landmark genome scanning (Hatada, Sugama & 
Mukai, 1993), methylation-sensitive arbitrarily primed PCR (Gonzalgo et al., 1997) and 
methylated CpG islands amplification (Toyota et al., 1999); RDA can also be used to 
detect methylation differences (Ushijima et al., 1997). Other new methodologies have 
greatly improved the accuracy of measuring methylation levels at known CpG islands 
(Reviewed in Jones & Laird, 1999), and may thus confirm the involvement in cancer of 
suspected genes in which no tumour-specific mutations or deletions have been found.
Other strategies for isolating tumour suppressors involved in sporadic cancers 
aim not to identify genetic or epigenetic genomic alterations, but to detect differences in
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expression directly—thus exploiting the fact that the expression of tumour suppressor 
genes is usually decreased in tumours. Differential hybridisation in its simplest form 
has been in use for several years, and helped isolate the metastasis suppressor Nm23 
(Rosengard et al., 1989). Now, complex, fluorescently labelled cDNA populations 
derived from tumour and normal cells can be hybridised to DNA chips that bear tens of 
thousands of gene tags, and differentially expressed genes identified with fairly high 
sensitivity (Reviewed in Gerhold et al., 1999). Completion of the human genome 
project will give rise to gene expression arrays that represent the whole genome. 
Subtractive hybridisation, differential display and, more recently, the technique of serial 
analysis of gene expression (SAGE) are also identifying many new potential tumour 
suppressors. This technology, of course, will identify many sequences whose 
downregulation is not the disease triggering event but is rather a consequence of 
previous oncogene or tumour suppressor gene mutation. Increased knowledge of signal 
transduction pathways should help us make sense of the huge amounts of data generated 
by these methods, as well as exposing new candidate tumour suppressors based on 
biochemical information alone.
Functional approaches are unearthing further candidate tumour suppressors. 
These approaches may prove particularly useful in isolating genes whose inactivation is 
important to the later stages of tumourigenesis (those involved in invasion, metastasis, 
and angiogenesis) about which little is currently known. Large fragments of genomic 
material can be introduced into cells and the effects on the transformed phenotype 
analysed; microcell mediated monochromosome transfer, for example, is being 
extensively used to introduce entire human chromosomes into tumour cells. Simple in 
vitro and in vivo assays can then be used to determine any effect of the chromosome on 
invasive or metastatic ability (Nihei et al., 1999). Effects on additional transformed 
phenotypes, such as unlimited replicative capacity, anchorage independent growth in 
soft agar or primary tumour formation in nude mice can also be analysed (Gustafson et 
al., 1996; Ogata et al., 1995). The subsequent identification of the gene’s sub- 
chromosomal location is not always easy, but deletion analysis of the donor 
chromosome in revertant hybrids can prove informative (England et al., 1996). Once a 
region has been defined, increasingly smaller fragments of the chromosome can be 
introduced using radiation hybrids, BACs, PACs, P is and cosmids.
Novel functional techniques will increasingly be used to isolate candidate 
tumour suppressor genes for which no positional information is available. One such
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approach relies upon the production of genomic suppressor elements (GSEs), gene 
fragments that give rise to antisense molecules or dominant negative peptides which can 
inhibit the action of the gene from which they are derived (Holzmayer, Pestov & 
Roninson, 1992). PCR-amplified cDNA fragments derived from normal cells are 
inserted into viral vectors such that they can be expressed in sense or antisense 
orientiation, and are used to infect untransformed cells via a virus-packaging cell line. 
Any insert expressed in the antisense orientation that, for example, extends replicative 
lifespan, confers resistance to apoptosis or permits anchorage independent growth in 
soft agar, can be PCR-cloned using primers specific to the vector sequences. The 
candidate tumour suppressor gene p33ING1 was isolated by this approach; in this instance 
the GSE library used was the product of a subtractive hybridisation between non- 
tumourigenic and tumourigenic breast cell line cDNA, and was thus presumably already 
enriched for tumour suppressor sequences (Garkavtsev et al., 1996).
Animal models are another useful tool in the isolation of tumour suppressor 
genes, exploiting the fact that cancer genes have been widely conserved through 
evolution. The amenability of Drosophila melanogaster for use in comprehensive 
mutagenesis screens makes the fruit fly a particularly valuable resource. Recent studies 
demonstrate that the same gene can indeed function as a tumour suppressor in both 
vertebrates and invertebrates. The Lats gene was identified in a Drosophila mutagenic 
screen, its inactivation causing aberrant proliferation and altered differentiation (Xu et 
al., 1995). The human homologue LATS1 has now been cloned, and the product shown 
to bind CDC2 in a cell cycle dependent manner (Tao et al., 1999). Moreover, mice 
deficient in Latsl are prone to tumours (St. John et al., 1999). Whether or not LATS1 is 
declared a true human tumour suppressor, it is clear that the use of non-mammalian 
model organisms is a valid approach in the hunt for novel human cancer genes. Murine 
models of inherited cancer are likely to prove particularly useful in the identification of 
low penetrance susceptibility genes and modifier genes; for example, allelic variants of 
the phospolipase A2-encoding Mom-1 gene have been shown to account for variation in 
the number of intestinal polyps that arise in inbred mice strains carrying identical 
germline APC mutations (Dietrich et al., 1993).
Collectively these approaches are already providing a huge pool of candidate 
tumour suppressor genes, increasing the need for clear definition of the essential 
characteristics of a tumour suppressor. Haber and Harlow (1997) argue that merely 
being down-regulated in cancer is not enough: to qualify as a bona fide tumour
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suppressor, a gene must sustain loss of function mutations during cancer development. 
They say this still allows for epigenetic mechanisms of inactivation but does not 
discriminate on the basis of function, thus including, for example, mismatch repair 
genes whose re-introduction into cancer cells has no direct effect on cellular 
proliferation. The advent of SNP DNA chips may greatly facilitate the screening of 
candidate tumour suppressor genes for loss of function mutations in tumours.
As highlighted by the lack of understanding of the workings of many known 
tumour suppressors, elucidating the function of a given tumour suppressor gene— 
particularly when not cloned via a functional assay—can be extremely difficult. Re­
introducing the gene into tumour cells does not always give much of a hint as to even its 
broad mechanism of action. Ectopic expression of R B I , for example, suppresses both 
growth rate and tumourigenicity in some cell lines but tumourigenicity only in others 
(Bookstein et al., 1990b; Huang et al., 1988). Moreover many tumour suppressors, such 
as VHL, BRCA1 and MEN1, have little homology with known proteins. Some tumour 
suppressor genes encode proteins that have several functional domains and a few, such 
as WT1, have many splice variants. Analysis of mutational hotspots can prove useful in 
indicating the relative importance of functional domains, but does not always. Much of 
our information about the function of novel tumour suppressors, therefore, has been 
gained through use of animal models. The generation of knockout mice via introduction 
of specific mutations into chosen genes by gene targeting has proved especially useful, 
particularly given the extreme rarity of human homozygote nulls. Mouse knockouts of 
most known tumour suppressor genes die in utero, indicating that the genes have 
essential developmental, as well as tumour suppressive, functions. Analysis of the 
abnormal embryos can indicate what these functions are, as demonstrated by the WT1 
knockout mouse whose renal and gonadal development is completely obliterated 
(Kreidberg et al., 1993). Chimeras can be generated that allow survival of null cells to a 
later developmental stage and, as in the Brcal study discussed earlier, conditional 
targeting can be used to introduce a chosen mutation into a particular tissue and at a 
particular stage of development. The use of heterozygotes, on the other hand, allows 
study of cancer susceptibility.
The identification of novel tumour suppressor genes and the elucidation of their 
function will doubtless provide new therapeutic targets. Some therapies will aim to 
restore specific genes; in this respect the possibility of reversing the epigenetic 
inactivation of tumour suppressor genes whose promoter has been methylated is
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particularly encouraging. Our increasing understanding of the biochemical pathways in 
which tumour suppressor genes function will illuminate further molecular targets for 
therapeutic intervention.
1.1.2.5 Evidence for a tumour suppressor gene on human chromosome 7
A wealth of cytogenetic and molecular data point to the existence of a multi-tissue 
tumour suppressor gene on chromosome 7. Karyotypic alterations of chromosome 7 are 
common in many tumour types (Reviewed in Zenklusen & Conti, 1996). Monosomy 7, 
for example, is often observed in lymphoid, myeloid and other non-epithelial disorders, 
while trisomy 7—cases of which often also contain interstitial deletions of the 
chromosome—is frequently found in epithelial tumours. Significantly, the chromosome 
loss associated with monosomy 7 appears to occur at an early developmental stage. 
Specific deletion of the long arm of chromosome 7 is common in squamous cell 
carcinomas of the head and neck (where the deletion appears to be the primary event) 
and has also been observed in prostate cancers and malignant melanomas. Interstitial 
losses of chromosome 7 give an indication of the subchromosomal location of the gene; 
deletion of the 7q31 to q32 region is common in malignant andrological neoplasias and 
has also been observed in breast and ovarian carcinomas and myeloid disorders.
High frequency LOH of a particular genomic marker is similarly indicative of 
the existence in that region of a tumour suppressor gene. Since the introduction of (C- 
A)n microsatellite repeat analysis as a means of investigating LOH, several studies have 
demonstrated a high incidence of allelic imbalance on 7q. LOH at this region is found 
in a wide range of tumour types, including carcinomas of the breast (Bieche et al., 1997; 
Zenklusen et al., 1994a), colon (Zenklusen et al., 1995a), kidney (Shridhar et al., 1997), 
ovary (Kerr et al., 1996; Koike et al., 1997; Zenklusen et al., 1995b), pancreas (Achille 
et al., 1996), prostate (Zenklusen et al., 1994c), stomach (Kuniyasu et al., 1994), mouth 
(Wang et al., 1998b) and head & neck (Loughran et al., 1996; Zenklusen et al., 1995a). 
The highest reported incidence of LOH—in a panel of breast tumours at the 7q31.1 
marker D7S522—was 83% (Zenklusen et al., 1994a). Collectively the allele loss 
centred on 7q31.1 to q31.2, thus implicating this region as harbouring a tumour 
suppressor gene whose inactivation is important to the development of several tumour 
types. Studies in our laboratory support this conclusion, Adam Hurlstone finding 40% 
LOH—again centring on 7q31—in a series of breast carcinomas (unpublished data). 
Collectively, the studies indicate that 7q31 alteration is an early rather than late event in
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the development of many tumours. Significantly, LOH at this region in breast tumours 
has been associated with a higher risk of relapse and decreased survival rates (Bieche et 
al., 1992). High frequencies of LOH have also been found on the syntenic region of 
mouse chromosome 6 (band 6A1) in chemically induced skin carcinomas and 
hepatomas (Kemp, Fee & Balmain, 1993; Zenklusen et al., 1996). Again, LOH 
appeared to be important in the initiation rather than progression of these tumours. 
These studies indicate that the chromosome 7 gene—like all tumour suppressors cloned 
to date—is evolutionarily conserved.
Functional evidence for the existence of a tumour suppressor gene on 
chromosome 7 has also been obtained. When microcell mediated monochromosome 
transfer was used to introduce human chromosome 7 into a murine squamous cell 
carcinoma cell line, five of seven hybrids generated were significantly suppressed for 
tumour formation in nude mice (Zenklusen et al., 1994b). The suppressed hybrids only 
regained their tumourigenicity after expelling the donor chromosome. Significantly, one 
of the two clones whose tumourigenicity was not suppressed contained a deletion on the 
donor chromosome spanning 7q31.1 to q31.3. The suppression/non-suppression of 
tumourigenicity did not correlate with variations in in vitro surface growth rates, 
indicating that the gene does not function by slowing progression through the cell cycle. 
Chromosome 7 has also been found to suppress the tumourigenicity of a human 
choriocarcinoma cell line (Miyamoto et al., 1991). However, introduction of human 
chromosome 7 into a rat prostate cell line was found to cause suppression of metastatic 
ability rather than of tumourigenicity (Nihei et al., 1999). Microsatellite analysis of the 
hybrids generated indicated that the gene responsible was not located at 7q31.1; this, 
together with the fact that LOH at 7q is usually an early event in tumour progression, 
suggests that the metastasis suppressor is not the same as the gene defined by the studies 
described above.
Much of the evidence for a chromosome 7 tumour suppressor gene therefore 
implicates the 7q31.1 to 31.2 region. However, it is probable that other regions of 
chromosome 7 also contain tumour suppressor genes of relevance to certain neoplasias. 
For example, breakpoints of the q22 and q31-32 regions of chromosome 7 are both 
common in myeloid disorders (Tosi et al., 1999), while LOH studies indicate that the 
q22 region is also a common target of loss in uterine leiomyomas and breast carcinomas 
(van der Heijden et al., 1998; Zeng et al., 1999). Advanced ovarian carcinomas, 
conversely, display high frequencies of LOH at 7q31.3 (Edelson et al., 1997). Despite
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the probability of the existence of multiple tumour suppressor genes on chromosome 7, 
the q31.1 to 31.2 region stands out as being of particular relevance to a very wide range 
of tumour types.
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1.2 Replicative Senescence
Replicative senescence—the phenomenon that limits the replicative lifespan of most 
normal cells—may act in vivo to curb the proliferation of cells carrying growth- 
promoting mutations. It has therefore been proposed as one mechanism of tumour 
suppression (see Section 1.2.6). Indeed, many malignant tumours contain immortal 
cells that have apparently overcome the proliferative barrier that senescence imposes. 
Cessation of cell division at senescence is accompanied by alterations in cellular 
physiology, morphology and gene expression—changes that may endow replicative 
senescence with an additional role in human ageing (Reviewed in Faragher & Kipling,
1998).
The limited proliferative lifespan of normal cells was first described for human 
fibroblasts in culture. Although they remained viable, the cells were observed to enter a 
non-dividing state after between 50 and 70 population doublings (Hayflick, 1965). 
Senescence—also known as M l—has since been observed in a wide variety of primary 
cell cultures of both mesenchymal and epithelial origin, always occurring after a 
specific, cell type-dependent, number of cell divisions. An accumulating body of 
evidence indicates that replicative senescence also occurs in vivo. The replicative 
lifespan of fibroblasts in culture, for example, is inversely correlated to the age of the 
donor (Martin, Sprague & Epstein, 1970), a finding that has since been extended to 
keratinocytes (Gilchrest, 1979), lens epithelial cells (Lipman & Taylor, 1987) and T 
cells (Perillo et al., 1989). As further correlative evidence, fibroblasts isolated from 
sufferers of premature ageing conditions such as Werner’s syndrome undergo 
senescence earlier than do their normal counterparts (Brown, 1990). The most 
convincing evidence for in vivo senescence, however, comes from a study of skin: 
analysis of the senescence-associated endogenous p-galactosidase marker has identified 
an age-dependent increase in its expression in dermal fibroblasts and epidermal 
keratinocytes (Dimri et al., 1995).
Because senescence is related to the number of elapsed population doublings 
rather than chronological time, cells must possess a means to count the number of 
divisions they have undergone. One such ‘mitotic clock’ is the progressive erosion of 
telomeres that occurs with each cell cycle (Olovnikov, 1973). The shortening of 
telomeres to a critical length may trigger senescence via a DNA damage response 
pathway. Ultimately, immortalisation requires the activation of mechanisms that halt
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telomere erosion. Sections 1.2.3 and 1.2.5 give a more in depth discussion of these 
topics.
1.2.1 The effector molecules of senescence (Ml)
Fusion of normal and immortal (tumour-derived) cells usually produces hybrids that 
have a limited lifespan (Pereira-Smith & Smith, 1983). This indicates that the mortal 
phenotype is dominant and that immortality is the result of recessive defects in 
senescence-inducing genes. One such gene is the TP53 tumour suppressor. Inactivating 
TP53 mutations or the use of antibodies against the protein product extend the 
proliferative lifespan of fibroblasts (Bond, Wyllie & Wynford-Thomas, 1994; Gire & 
Wynford-Thomas, 1998). Fibroblasts isolated from sufferers of Li Fraumeni syndrome, 
which is caused by a germline mutation in TP53, also display an extended lifespan after 
spontaneous loss of the remaining allele (Bischoff et al., 1990). Similarly, abrogation of 
p53 function by expression of the HPV16 protein E6 has been shown to increase the 
lifespan of breast epithelial cells (Shay et al., 1993). Consistent with these findings, the 
transactivating ability of p53 increases during senescence (Bond et al., 1996) despite no 
simultaneous increase in protein levels (Afshari et al., 1993). This activation is believed 
to occur as a response to a DNA damage signal induced by telomeric erosion (Section 
1.2.5). The direct cause of p53 activation is still uncertain, but upregulation of 
transcriptional cofactors such as pSS^01 may be partly responsible (Garkavtsev et al., 
1998; Garkavtsev & Riabowol, 1997).
Other senescence effector molecules are upregulated at the protein level. The 
CDK inhibitor p21WAF1, for example, is upregulated in senescent fibroblasts and 
keratinocytes (Noda et al., 1994; Sayama et al., 1999). p21WAF1-mediated inhibition of 
cyclin E/CDK2 helps retain pRB in its hypophosphorylated state and thus prevent 
expression of genes required for entry into S phase (Dimri, Hara & Campisi, 1994; 
Dulic et al., 1993). In early senescence, p21WAF1 may additionally play a role in the 
inactivation of the DNA replication factor PCNA (Stein et al., 1999). Disruption of 
p21WAF1 allows fibroblasts to temporarily bypass senescence, confirming that p21WAF1 is 
an essential component of the senescence machinery (Brown, Wei & Sedivy, 1997). 
Moreover, its ectopic expression induces senescence in bladder carcinoma cells (Fang et 
al., 1999). It is now known that p21WAF1 is a downstream effector of p53, inactivation of 
which abolishes p21WAF1 expression and induces escape from senescence (Gire & 
Wynford-Thomas, 1998). However, p21WAF1 is not the only downstream senescence
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effector of p53, as a partial loss of p53 expression (insufficient to turn off p21WAF1) still 
prevents the onset of senescence (Bond et al., 1995; Tahara et al., 1995). Moreover, it is 
likely that p21WAF1 can be induced during senescence in a p53-independent manner 
(Tahara et al., 1995).
Another CDK inhibitor that is upregulated in senescence and that maintains pRB 
in its growth-suppressive, hypophosphorylated state is the tumour suppressor p l6 INK4a 
(Alcorta et al., 1996; Hara et al., 1996). In contrast to p21WAF1, whose expression in 
fibroblasts increases sharply just before senescence but then declines, p l6 INK4a 
accumulates gradually to a sustained, greatly elevated level in the later stages of 
senescence. While p21WAF1 may be responsible for the induction of senescence, 
p ^ iN K 4 a  m a y  ^  e s s e n t j a i  f o r  j t s  maintenance (Stein et al., 1999). The upstream effector 
of p l6INK4a is still unknown; its expression is clearly p53 independent. However, it has 
recently been shown that treating fibroblasts with agents that induce double strand 
breaks results in both p l6 INK4a enrichment and premature senescence (Robles & Adami,
1998). It is plausible, therefore, that p lb 1^ 43 is also induced in response to a DNA 
damage signal from eroded telomeres. Another recent study indicates that p lb 1^ 43 (and 
p l4ARF) is under the transcriptional control of the Polycomb-group protein Bmil, which 
represses transcription by packaging DNA into higher order chromatin (Jacobs et al.,
1999). Fibroblasts from mice that lack bmil express very high levels of p l6INK4a and 
undergo premature senescence, suggesting that downregulation of this gene could play a 
crucial role in the induction of p l6INK4a in normal senescence. It has been difficult to 
demonstrate conclusively that p lb11^ 43 is essential for senescence. As discussed in 
Section 1.1.2.3 this is partly because deletion of the INK4a locus affects the overlapping 
gene encoding p l4ARF, which has also been implicated in cell cycle arrest (Agarwal et 
al., 1995; Liggett et al., 1996). However, p l6 INK4a expression is clearly very frequently 
lost by mutation, deletion or promoter silencing in both immortal tumour cell lines and 
in vitro immortalised, non-tumourigenic cell lines (Okamoto et al., 1994; Vogt et al.,
1998). Furthermore, loss of the protein by methylation of its promoter is associated 
with the increased lifespan of a subset of normal human breast epithelial cells (Brenner, 
Stampfer & Aldaz, 1998). Treatment of these cells with the methylation inhibitor 5-aza- 
2-deoxycytidine restores pl6 expression and induces premature senescence. Re­
expression of p l6 INK4a in this manner can also induce senescence in an oral squamous 
cell carcinoma cell line and in immortalised human fibroblasts (Timmermann, Hinds & 
Munger, 1998; Vogt et al., 1998). Further evidence is now emerging for the specific
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involvement in human replicative senescence of p l6IN1C4a rather than p l4ARF. In a recent 
study of keratinocytes, no p l4ARF protein was detected in senescent cells and no p l6INK4a 
-independent deletions or mutations of p l4 ARF observed in neoplastic cells (Munro et al.,
1999). p l4ARF exerts its growth inhibitory effects through the inhibition of mdm2- 
induced degradation of p53 (Stott et a l, 1998). The fact, then, that p53 levels do not 
increase during senescence also argues against a role of p i4 " ^  in replicative senescence 
in humans, and suggests that p l6 INK4a is indeed the target of losses at the INK4a locus in 
immortal cell lines. (However, as discussed in Section 1.2.5 p l4ARF probably is 
involved in the premature senescence induced by oncogenes.) The role of p l6 INK4a in 
pRB-mediated replicative senescence is further emphasised by the fact that loss of 
function of p i6]NK4!l or pRB, but not of both together, occurs in most immortal cell lines 
(Whitaker et al., 1995). Inactivation of pRB, as predicted, also extends the replicative 
capacity of fibroblasts (Shay et al., 1993); furthermore, its re-expression in tumour cells 
induces senescence (Xu et al., 1997).
p21WAF1 and p l6 INK4a-mediated inhibition of CDKs thus results in retention of 
the pRB/E2F transcriptional repressor complex, lack of expression of genes required for 
entry into S phase, and G l arrest (Figure 1.1). Senescent cells are characterised by their 
insensitivity to mitogen stimulation. While this may be explained in part by the direct 
inhibition of CDKs and pRB/E2F-mediated transcriptional repression, it is apparent that 
key S phase entry genes regulated by other means also fail to be induced by the signal 
transduction machinery. Such genes include that encoding the transcription factor c-fos 
(Seshadri & Campisi, 1990), whose activity is essential for DNA replication (Riabowol, 
Schiff & Gilman, 1992), and the ‘immediate-early’ response gene Egr-1 (Meyyappan, 
Wheaton & Riabowol, 1999). Suppression of these genes appears to result from 
alterations to—but not a complete breakdown of—the early signal transduction 
pathway, specifically from a decrease in activity of the serum response factor that 
regulates their transcription (Meyyappan et al., 1999). The block to cell cycle 
progression in senescence is thus a fairly complex phenomenon, that involves the 
coordinated upregulation of growth inhibitory factors together with the repression of key 
growth-activating genes.
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1.2.2 Intermediate lifespan barriers and the regulation of senescence: differences 
between cell types
The escape from senescence induced by inactivation of any one of the components of 
the p53/p21 or pl6/pRB pathway is only temporary. For example, expression of a 
mutant p53 or of HPV16 E6 confers on fibroblasts a lifespan extension of around 20 
population doublings, after which the cells enter a senescence-like growth arrest known 
as M lb (Bond et al., 1999). Fibroblasts cultured from Li-Fraumeni syndrome patients 
enter a similar state of arrest after the lifespan extension conferred by spontaneous loss 
of the wild-type p53 allele (Rogan et al., 1995). During this growth arrest p l6 INK4a 
accumulates to a level greater than that observed in M l, suggesting that cells 
compensate for loss of the p53 pathway through upregulation of the pRB pathway. The 
targeting of pRB with antisense oligomers or HPVI6 E7 also demonstrates the existence 
of a second barrier to proliferation, cells undergoing growth arrest after approximately 
the same number of additional population doublings as conferred by loss of p53 (Bond 
et al., 1999; Hara et al., 1991).
Accumulating evidence indicates that there are major cell type-specific 
differences in the regulation of senescence. Most fundamentally the Hayflick limit, the 
number of divisions that cells undergo before they senesce, varies widely. Differences 
in the functional significance of the p53 and pl6/pRB effector pathways also exist. The 
lifespan of the majority of normal breast epithelial cells, for example, can be extended 
by expression of E7 but not of E6. This indicates that these cells senesce through a p53- 
independent pathway (Foster & Galloway, 1996). This is in contrast to fibroblasts in 
which the p53 and pl6/pRB pathways are both essential components of the M l 
machinery. Interestingly, breast epithelial cells that have bypassed senescence through 
expression of E7  do eventually enter a senescence-like state that is now p53-dependent 
(Foster et al., 1998). The delay in p53-mediated arrest is such, however, that it may not 
represent a barrier to cancer progression. Other examples of p53-independent 
senescence have been documented in subsets of keratinocytes and uroepithelial cells 
(Kang, Guo & Park, 1998; Puthenveettil, Frederickson & Reznikoff, 1996). In contrast, 
the lifespan of a population of long-lived normal breast epithelial cells can be further 
extended by the expression of E6 but not of E7  (Shay et al., 1993). It is now known that 
this apparent p53-dependent senescence is actually a consequence of previous 
inactivation of the pl6/pRB pathway (Foster et al., 1998). These cells appear to 
consistently suppress this ‘back-up’ pathway early in their life history, and may exist in
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vivo as an oestrogen receptor negative stem cell pool that form a sub-set of particularly 
aggressive breast tumours (Wynford-Thomas, 1999). Thyroid epithelial cells also differ 
from the fibroblast model of senescence, and can apparently undergo a senescence-like 
growth arrest in the absence of both p53 and pRB (Bond et al., 1996).
Not surprisingly, species-dependent variations in the regulation of senescence 
also exist. Mouse and human cells, the cell types in which most senescence research has 
been carried out, appear to differ in both the way that senescence is triggered and in the 
actual effector pathways. While the primary ‘mitotic clock’ in human cells is believed 
to be progressive erosion of telomeres, the telomere dynamics of rodent cells are such 
that this clock can be of little functional significance (see Section 1.2.5). As discussed 
above, there is little direct evidence in human cells for the involvement in replicative 
senescence of p l4ARF, despite its role in the inhibition of mdm2-induced degradation of 
p53 and the fact that its ectopic expression induces growth arrest. However, this is not 
the case for the murine homologue p l9ARF, which accumulates greatly as rodent 
fibroblasts approach senescence (Zindy et al., 1998). A mouse knockout of p i 9 ^  in 
which the coding sequence of p lb 1^ 4* is unaffected has now been generated (Kamijo et 
al., 1997). Significantly, embryonic fibroblasts derived from these mice do not undergo 
senescence. This is reflected by the fact that establishment of mouse embryonic 
fibroblast cultures is usually accompanied by loss of function of just p i9 " ^  or p53. 
These differences in the trigger of senescence and in the effector mechanisms may be 
functionally related: while in humans senescence may be largely triggered by telomeric 
attrition and subsequent, p l4ARF-independent activation of p53, a different trigger in 
mice could result in the p l9ARF-mediated p53 response. Consistent with this, there is no 
evidence for the involvement of p l9ARF in DNA damage signalling to the cell cycle 
machinery (Stott et al., 1998). Species-dependent differences in the effector pathways 
of senescence also account for variations in the stringency of senescence. While 
inactivation of the pl9/p53 pathway is enough for murine cells to escape senescence, 
human cells invariably need to disrupt—at a minimum (see Section 1.2.4)—both the 
p53/p21 and pl6/pRB pathways. Perhaps in consequence, human cells very rarely 
spontaneously immortalise in culture whereas rodent cells do so much more easily. The 
existence of ‘back-up’ senescence pathways in human cells is probably a reflection of 
the importance of cancer avoidance mechanisms in long-lived animals.
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1.2.3 Crisis (M2) and immortalisation
Evasion of the proliferative barriers imposed by both M l and M lb is still not sufficient 
for cellular immortality. Abrogation of both p53 and pRB function by expression of the 
SV40 large T antigen (or of HPV16 E6 and E7) extends the lifespan of human 
fibroblasts beyond Mlb; however, the cells eventually hit a block known as crisis (M2) 
(Wright, Pereira-Smith & Shay, 1989). This barrier is characterised by extreme 
genomic instability, and is manifested by a marked increase in cell death rather than a 
decrease in proliferation per se. During the period of extended lifespan conferred by 
large T antigen, the telomeres continue to shorten (Counter et al., 1992). Indeed, crisis 
probably represents the state at which the extent of telomeric erosion is incompatible 
with cell viability, following the loss of telomere binding proteins such as TRF2 that 
protect chromosomes from end-fusion and non-dysjunction (van Steensel, 
Smogorzewska & de Lange, 1998). Very rare clones emerge from crisis that are capable 
of indefinite division (Wright et al., 1989). Significantly, this gain of immortality is 
invariably correlated with stabilisation of telomeres. Telomere stabilisation most 
commonly occurs through upregulation of the multimeric ribonucleoprotein telomerase, 
which adds new telomeric repeats to chromosome ends (Counter et al., 1992). The 
suggestion that tumour cells too may become immortal through re-activation of 
telomerase was supported by the discovery that nearly 85% of malignant human 
tumours express telomerase (while most normal somatic cells contain very low levels or 
none at all) (Shay & Bacchetti, 1997). The cloning of the catalytic subunit of telomerase 
(hTERT) allowed the causal link between telomerase expression and immortality to be 
tested directly. Indeed, overexpression of the subunit in normal human fibroblasts and 
retinal pigment epithelial cells fully reconstituted telomerase activity and resulted in 
telomere elongation and an apparent indefinite expansion of proliferative lifespan 
(Bodnar et al., 1998); the pRB and p53 pathways in these cells appear to be intact (Jiang 
et al., 1999; Morales et al., 1999). Moreover, inhibition of telomerase by antisense 
oligomers had previously been shown to cause telomere shortening and the restoration 
of a finite lifespan (Feng et al., 1995). However, in at least some cell types expression 
of telomerase is not sufficient for immortality. Introduction of certain chromosomes by 
microcell transfer can induce senescence in target tumour cell lines despite the 
continued expression of telomerase components (Tanaka et al., 1999). In addition, 
immortalisation of keratinocytes and breast epithelial cells appears to require 
inactivation of the pl6/pRB pathway in addition to hTERT expression (Kiyono et al.,
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1998); however, it is possible that this requirement was simply a consequence of 
inadequate in vitro growth conditions. The mechanisms by which tumour cells 
upregulate telomerase have not been fully elucidated. However, ectopic expression of c- 
myc and of the gene encoding the helix-loop-helix protein Id-1 have both been shown to 
increase hTERT expression and extend lifespan (Alani et al., 1999; Wang et al., 1998a). 
Repression or inactivation of telomerase inhibitors is also likely to play a major role; 
indeed, microcell transfer experiments have indicated the existence of a repressor of 
hTERT on a region of chromosome 3 that is commonly altered in tumours and immortal 
cell lines (Horikawa, Oshimura & Barrett, 1998). Regulation of the RNA component of 
telomerase may also be functionally significant: the gene encoding it is over-represented 
and amplified in many tumours and cell lines (Soder et al., 1997). The high frequency 
with which telomerase is expressed in tumour cells makes it an extremely attractive 
therapeutic target. Recent studies demonstrate that chemical inhibitors of telomerase 
and dominant-negative mutants of hTERT induce telomere shortening and cell death in 
human tumour cell lines (Naasani et al., 1999; Hahn et al., 1999; Zhang et al., 1999). 
However, some caution is required—in certain genetic backgrounds and at certain stages 
of tumour development the inhibition of telomerase might promote, rather than inhibit, 
tumour growth (Chin et al., 1999).
Not all immortal cells stabilise their telomeres through expression of telomerase: 
a quarter of in vitro immortalised cell lines and a small number of tumours appear to use 
instead a poorly defined mechanism known as alternative lengthening of telomeres 
(ALT) (Bryan et al., 1997; Bryan et al., 1995). This mechanism is probably 
recombination-based. Cells that use ALT contain novel promyelocytic leukaemia 
(PML) bodies which, in addition to telomeric DNA and telomere binding proteins, 
contain the DNA recombination factors RAD51 and RAD52 (Yeager et al., 1999). 
Activation of the ALT pathway appears to involve the loss of ALT repressors that are 
present in normal cells (Perrem et al., 1999). Interestingly, cells of mesenchymal origin 
seem to utilise ALT more commonly than epithelial cells. This may reflect inherent 
differences in the ability of these cell types to upregulate telomerase. Figure 1.2 
illustrates the two-stage (M1/M2) model of cellular immortalisation.
1.2.4 Multiple pathways to senescence
As discussed above, inactivation of both the p53/p21 and pl6/pRB pathways precedes 
the immortalisation of many cell types. Suppression of systems that repress the
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maintenance of telomeres is also essential for immortality. However, there is evidence 
that many cell types employ additional senescence pathways, and that these must also be 
inactivated in order to become immortal.
Microcell mediated monochromosome transfer experiments have demonstrated 
that at least ten human chromosomes can restore the senescence programme in 
particular immortal cell types (Reviewed in Oshimura & Barrett, 1997). Furthermore, 
somatic cell fusion experiments have identified four distinct immortality 
complementation groups, A to D (Pereira-Smith & Smith, 1988). Over thirty immortal 
cell lines have been inter-fused and assigned to one of these groups on the basis of the 
mortality or immortality of their hybrids. Cell lines that formed immortal hybrids were 
presumed to have inactivated the same senescence gene (and were hence assigned to the 
same complementation group), while those that formed mortal hybrids had inactivated 
different genes (and were assigned to different complementation groups). The cell lines 
that complemented each other, namely whose hybrids senesced, were frequently 
dysfunctional for p53 and pRB; this indicated that at least four more genes were targets 
for inactivation during immortalisation (Whitaker et al., 1995). A variety of immortal 
fibroblast, endothelial and tumour cell lines were included in the original study, the 
results indicating that complementation group assignment did not correlate to cell type, 
tumour type, embryonal layer of origin, or expression of particular activated oncogenes. 
However, the majority of cell lines assigned to group A had been immortalised by the 
SV40 virus, indicating a subsequent mutational bias in these cells. Moreover, a 
subsequent study assigned each of seven lymphoid cell lines to complementation group 
D, indicating that T and B cells undergo a common mechanism of immortalisation 
(Goletz, Robetorye & Pereira-Smith, 1994).
Human chromosomes 4, 1 and 7 have been found to induce senescence 
specifically in cell lines belonging to immortality complementation groups B, C and D 
respectively, thus mapping three of the complementation group genes to specific 
chromosomes (Hensler et al., 1994; Ning et al., 1991; Ogata et al., 1995). The 
chromosome of the complementation group A gene is not yet known. Significantly, the 
chromosomal regions that the B and D group genes appear to map to are frequent targets 
of alteration in tumours or tumour cell lines (Loughran et al., 1997; Zenklusen & Conti,
1996). In one study, immortal keratinocytes were found to display LOH at either 4q32- 
34 (the putative group B locus) or 7q31 (the putative group D locus) but not at lq25 (the 
putative group C locus) (Loughran et al., 1997). The mutually exclusive nature of this
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LOH suggests that the complementation group B and D genes encode proteins on the 
same pathway to senescence. None of the complementation group genes have yet been 
cloned and little is known about their precise role in senescence. The observation that 
the group D gene is lost in some telomerase negative cell lines suggests that the 
complementation group pathway does not function by suppressing telomerase 
(Loughran et al., 1997). However, there’s evidence nevertheless that the group D gene 
is involved in the suppression of telomere maintenance, presumably via repression of 
the ALT mechanism (Nakabayashi et al., 1997)—the group D gene may thus be 
involved in crisis, M2, rather than the true senescence program of M l. The fact that p53 
and pRB are inactivated in many cell lines that belong to a specific complementation 
group also argues that the complementation group gene products do not reside on the 
p53 or pRB senescence pathway (alternatively, of course, inactivation of p53 or pRB 
may confer selective advantages in addition to the extension of replicative lifespan). 
Significantly, the chromosomes carrying the complementation group genes can induce 
senescence in the absence of p53 or pRB (Ning et al., 1991). It is intriguing that the 
distribution of the heat shock protein mortalin correlates with complementation group 
assignment (see Chapter 3). Mortalin has itself been implicated in the processes of 
replicative senescence and immortalisation but, at least in immortal keratinocyte cell 
lines, does not appear to be a common target for inactivation during immortalisation 
(Loughran et al., 1997).
Other chromosomes capable of inducing senescence do not correlate with 
complementation groups A-D. Indeed, the fact that there are more chromosomes with 
senescence-inducing capability than there are immortality complementation groups is 
somewhat paradoxical; there may be other complementation groups that are yet to be 
defined (Moy et al., 1997). Some chromosomes appear to contain more than one 
senescence gene. Human chromosome 6 appears to harbour at least 3 senescence genes: 
of these, one seems to be inactivated in immortalised human fibroblasts, a second in 
ovarian tumour cell lines and a third in head and neck squamous cell carcinoma cell 
lines (Sanhu et al., 1994; Sandhu et al., 1996; Sara Fitzsimmons, BICR, personal 
communication). Similarly, two senescence loci exist on chromosome 1, one of which 
represents the complementation group B gene (Vojta et al., 1996). In some cell lines 
senescence can be induced by the introduction of at least two different chromosomes 
(Sasaki et al., 1994), implying that the cell line in question has inactivated both the 
relevant genes and hence that the senescence genes on these chromosomes are involved
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in different senescence pathways (each of which must be inactivated if immortality is to 
occur). It is therefore likely that the senescence genes mapped by MMCT have different 
functions. It is probable that some of these genes will participate in the actual 
mechanisms of growth arrest while others will be involved in the regulation of 
senescence. Introduction of chromosome 3 into a particular renal carcinoma cell line 
causes loss of telomerase activity, telomere shortening and restoration of senescence 
(Horikawa et al., 1998); this indicates that at least one of the non-complementation 
group senescence genes mapped to a particular chromosome by MMCT functions by 
suppressing telomerase activity, and is therefore more correctly defined as a crisis gene 
rather than a senescence gene. However, mortal hybrids generated by fusing together 
complementing immortal cell lines sometimes remain telomerase positive (Bryan et al., 
1995), demonstrating that the putative gene products do not all function as telomerase 
suppressors. It is likely that each of the senescence pathways involves multiple genes; 
for example, chromosome 3 cannot induce cellular senescence in all telomerase positive 
cell lines, implying that not all tumour cells are defective for the same gene controlling 
telomerase activity. Cloning and characterisation of the genes involved should greatly 
enhance our understanding of the mechanisms of these pathways.
Chromosome transfer experiments and studies with SV40 large T antigen have 
thus demonstrated in many cell types the existence of multiple, independent pathways of 
cellular senescence, each of which must be disrupted in order to attain immortality. The 
genetic defects leading to keratinocyte immortality have been particularly well 
characterised, with studies suggesting that at least four pathways—those of p53/p21, 
pl6/pRB, telomerase repression, and the complementation group B/D gene products— 
must be inactivated (Loughran et al., 1997). Inactivation of individual pathways, 
although unable to cause immortalisation, is likely to confer an extension in 
proliferative lifespan such as that seen after inactivation of the p53 or pRB pathway. 
This in turn would provide the opportunity for cells to acquire the mutations in 
additional pathways that are required for full immortality. Such a ‘multiple pathways’ 
scenario is entirely consistent with the multi-step nature of chemically induced 
immortalisation and in vivo tumourigenesis (Bols, Naaktgeboren & Simons, 1991).
1.2.5 The triggers of senescence
The progressive erosion of telomeres that occurs with each round of cell division is 
thought to be the primary mechanism by which human cells ‘count’ the number of
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doublings they have been through (Olovnikov, 1973). Telomere length is usually 
estimated from the length of the terminal restriction fragment (TRF), which regardless 
of the initial length usually declines to approximately 6 Kb at senescence (Allsopp et al.,
1992). TRF lengths vary widely within a cell, so it is possible that senescence is 
triggered when one or more of the telomeres reaches a critical length (Allsopp & Harley, 
1995). Indeed, experimental amputation of a yeast telomere has been shown to induce 
proliferative arrest (Sandell & Zakian, 1993). The intrinsic telomere clock is likely to 
be prone to environmental modulation. Hyperoxia, for example, is known to accelerate 
telomeric erosion and to reduce the replicative lifespan of fibroblasts (von Zglinicki et 
al., 1995).
Precisely how critically short telomeres signal to and activate the senescence 
machinery has yet to be fully elucidated. One hypothesis proposes that telomeric 
proteins sequester transcription factors. As the telomeres erode, these factors would be 
released and available to repress growth promoting genes (or activate senescence genes). 
There is no evidence in mammalian cells to support such a hypothesis. However, the 
yeast telomere-associated protein Rapl has been shown to sequester the silencing 
factors SIR3 and SIR4 which are able to act at other sites when not sequestered 
(Marcand et al., 1996). Moreover, mutations of SIR4 can inhibit yeast senescence 
(Kennedy et al., 1995). An alternative hypothesis suggests that the heterochromatic 
structure of sub-telomeric DNA may repress genes involved in senescence. As 
telomeres shorten the extent of the heterochromatin domain may diminish and lead to 
activation of genes formerly residing within it (Wright & Shay, 1992). Again, yeast 
cells provide a precedent for such a scenario, silencing of loci near their telomeres 
having been reproducibly demonstrated (Laurenson & Rine, 1992). However, the extent 
to which senescence of individual human cells resembles that of yeast is unclear.
The hypothesis currently most in favour is that telomeres bind proteins that 
prevent the chromosome end from being recognised as a DNA double strand break; 
when the telomeres reach a critical length these proteins may be released, resulting in 
activation of a DNA damage response pathway. Since normal cells possess no 
mechanism to repair shortened telomeres the growth arrest induced would be 
maintained for as long as the mechanisms that respond to the damage remain intact. In 
support of this proposal, both p53 and its target p21WAF1 are known to be activated by 
DNA double strand breaks (Atadja et al., 1995; Noda et al., 1994). Recent data suggest 
that the same is also true of p lb11^ 43 (Robles & Adami, 1998). Indeed, the sequence of
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events induced in mortal fibroblasts by agents that cause DNA damage—transient 
induction of p53 and p21WAF1 followed by delayed, sustained activation of p l6INK4a—is 
identical to that occurring in fibroblast senescence. Moreover, these agents induce a 
state of growth arrest that has many morphological and biochemical markers of 
senescence. Certain telomere binding proteins have already been identified. The TRF2 
protein, for example, probably plays a key role in protecting chromosome ends from 
DNA damage checkpoints by maintaining the correct ‘duplex loop’ structure of 
telomeric termini (Griffith et al., 1999). Loss of TRF2 as a consequence of telomeric 
erosion may be responsible for induction of the M l DNA damage response pathway as 
well as the formation of end-end chromosome fusions in crisis. In support of this, 
expression of mutant forms of TRF2 induces a senescence-like growth arrest (Griffith et 
al., 1999). Several known genes encode proteins that recognise DNA damage and 
directly or indirectly activate p53. ATM, DNA-PK (see Section 1.1.2.3) and poly(ADP- 
ribose) polymerase (PARP) are three such proteins. Of these PARP may play a 
particularly important role in senescence. Activation of PARP by hyperoxia induces 
premature senescence, and its inactivation by chemical inhibitors extends cellular 
lifespan (Vaziri et al., 1997). PARP physically associates with p53 and may thus be 
directly responsible for the post-translational modification of p53 that appears to occur 
in senescent cells (Vaziri et al., 1997).
A large body of evidence supports the hypotheses that telomeric erosion 
can trigger senescence and that evasion of telomeric shortening is necessary for 
immortalisation (Section 1.2.3). However, telomere erosion is probably not the primary 
trigger of senescence in all cell types. Syrian hamster embryo cells, for example, 
express telomerase and senesce with long telomeres (although in such cases it cannot be 
ruled out that at least one telomere in each cell shortens to the extent that it can trigger 
senescence) (Carman, Afshari & Barrett, 1998). Mice possess extremely long 
telomeres, and the effects on the germline and proliferative tissues of telomerase loss 
become apparent only after several generations (Rudolph et al., 1999). It is therefore 
unlikely that telomere length provides any barrier to tumourigenesis in rodents. 
Telomeric erosion is also unlikely to be the senescence clock in some human cell types, 
for example the sub-populations of keratinocytes and uroepithelial cells that senesce in a 
p53-independent manner. These cells have been shown to be constitutively telomerase 
positive and to senesce without detectable telomere shortening (Belair et al., 1997; Kang 
et al., 1998). Indeed, a growing number of normal human cell subpopulations are now
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believed to express telomerase constitutively. These subpopulations include stem cells, 
for example basal keratinocytes in epidermis, and cells, for example lymphocytes, that 
are required to undergo frequent clonal expansion (Harle-Bachor et al., 1996; Counter et 
al., 1995). More controversially, cell types such as terminal ductal breast epithelium 
may also express telomerase. Other cell types that appear telomerase negative may in 
fact express telomerase when subjected to the appropriate proliferative stimuli (Belair et 
al., 1997).
Given the suggestion that over 90% of cancers arise from cell types that now 
appear to be telomerase positive (Wynford-Thomas, 1999), do tumour cells need to 
escape senescence, and, if they do, could telomere shortening provide the selective 
pressure for senescence evasion? Studies of telomere length in tumours indicate that the 
answer to both questions is yes: the finding that most human cancers have much shorter 
telomeres than the corresponding normal tissue indicates that in most tumours telomere 
shortening has occurred and was followed by telomerase or ALT activation (Hastie et 
al., 1990). It is probable that the activity of telomerase in many cell types is simply not 
great enough to prevent telomeric erosion. This, together with the evidence that many 
cancer cells appear to lose genes encoding repressors of telomerase (Horikawa et al., 
1998), suggest that telomere erosion does usually provoke selection pressure for 
telomerase activation and hence for immortalisation during human tumourigenesis.
Other senescence clocks, however, are probably important in some 
human cell types. One possible clock is the decrease in the level of methylation of 
cytosine bases that occurs with cell division (Matsumura, Malik & Holliday, 1989). 
Like telomeric shortening, the process of demethylation is halted in immortal cells 
(Wilson & Jones, 1983). DNA methylation is associated with repression of 
transcription, and the lack of methylation in aged cells may activate certain senescence- 
inducing genes. This might at least partly explain the induction in senescence of 
p l6 INK4a, whose promoter is known to be silence-able by methylation. Another possible 
‘clock’ is the gradual accumulation of random macromolecular damage that occurs with 
time. Indeed, it is known that a variety of environmental stimuli can induce a premature 
senescence-like state. Some such stimuli, for example oxidation, may induce 
senescence by accelerating telomeric erosion (von Zglinicki et al., 1995); other stimuli, 
however, appear to have no connection with telomeres. Reddel (1998) proposes that 
there are multiple mitotic clocks, each characterised by an accumulation of a particular 
intracellular change. Any of these pathways may cause senescence when a certain
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threshold (a critically short telomere, a critically low level of methylation or a critically 
high level of macromolecular damage) is reached. One of these clocks may 
predominate in a particular cell type because it usually reaches its threshold before the 
others. The existence of multiple clocks may reflect the existence of multiple 
senescence effector pathways, with each pathway being activated by a particular trigger.
Another stimulus that can trigger senescence (at least in vitro) is the expression 
of oncogenes. It has been known for several years that adenovirus 5 E1A and myc 
expression can lead to stabilisation of p53 and apoptosis (Hermeking & Eick, 1994; 
Lowe & Ruley, 1993). More recently, it has been demonstrated that ectopic expression 
of oncogenic ras or raf, or constitutive activation of MEK, can induce senescence in 
primary cells (Lin et al., 1998; Serrano et al., 1997; Zhu et al., 1998). These cellular 
responses to oncogene expression are partly mediated by upregulation of p l9ARF and 
(probably) the human homologue p l4ARF (de Stanchina et al., 1998; Palmero, Pantoja & 
Serrano, 1998; Zindy et al., 1998), whose inhibition of mdm2-induced degradation of 
p53 causes upregulation of the CDK inhibitor p21WAF1 (Kamijo et al., 1998; Stott et al., 
1998). Inactivation of either p53 or p l9ARF is sufficient for murine, but not human, 
fibroblasts to escape ras-induced arrest (Palmero et al., 1998; Serrano et al., 1997). It 
has recently been shown that p l4ARF is transcriptionally activated by unsequestered E2F, 
thus providing the missing molecular link between hyper-proliferative signalling and 
ARF induction and revealing further inter-relations between the p53 and pRB pathways 
(Bates et al., 1998). However, p lb0^ 43 is also induced during ras and raf-induced 
senescence, and in human cells may be the main senescence effector (Serrano et al., 
1997; Zhu et al., 1998). Again, inactivation of p l6INK4a is sufficient for evasion of 
senescence in murine cells but not in human cells (Serrano et al., 1997).
The induction of senescence or apoptosis by oncogenes may represent an in vivo 
safeguard against inappropriate proliferative signals, and thus represent a mechanism of 
tumour suppression. However, the precise relevance of oncogene-induced senescence to 
tumourigenesis remains uncertain. Oncogene expression (rather than telomeric 
shortening) may in some tumours provide the selective pressure for events such as TP53 
or p!6INKa mutation that disable the senescence and apoptotic pathways. Consistent 
with this view, ras mutation does sometimes precede TP53 or INK4A mutation during 
tumourigenesis (Fearon & Vogelstein, 1990). In model systems of skin carcinogenesis, 
however, ras activation is an early event while immortalisation occurs much later 
(Balmain et al., 1984). It is also possible that the cellular response to the artificially
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high levels of ras and raf induced by ectopic expression using heterologous promoters 
has little in vivo relevance.
Whatever the selective pressure driving evasion of M l, telomere length will 
ultimately become the limiting factor. It is thus probable that all tumour cells must 
activate a mechanism of telomere maintenance in order to escape the chronic genomic 
instability and loss of cell viability characteristic of crisis.
1.2.6 Senescence as a mechanism of tumour suppression
There is a significant body of evidence to suggest that tumour cells do indeed face 
selection pressure to overcome the proliferative lifespan barrier imposed by senescence. 
However, this view has been opposed on the basis that a lifespan of 50 population 
doublings (the Hayflick limit of fibroblasts in culture) would still be enough to generate 
an extremely large tumour mass. Aside from ignoring the possibility of premature 
senescence induced by oncogenes, this argument fails to take into account ongoing cell 
death and differentiation (both of which may greatly decrease the number of cells 
generated by a particular number of divisions), and the fact that most tumours are clonal 
in origin. In addition, it is probable that the majority of tumours originate from cell 
types whose Hayflick limit is considerably less than that of fibroblasts. Despite this it is 
unlikely that replicative senescence (as opposed to oncogene-induced senescence) poses 
a barrier in the early growth stages of many tumours, particularly those that develop 
from cells close to the beginning of their proliferative lifespan. However, escape from 
senescence may well be essential for advanced tumour growth, metastasis, recurrence 
and hence lethality. While immortalisation is not a prerequisite for tumourigenicity, 
escape from senescence would clearly permit the extensive cell division required for 
acquisition of the several mutations required for malignant growth. Indeed, the time 
required to accumulate the minimum number of defects needed for malignancy is likely 
to be considerable, and may well bring cells close to (or beyond) the limit of their 
normal proliferative lifespan. The notion that immortality may facilitate tumour 
progression is supported by observations that immortal cells are more susceptible than 
normal cells to spontaneous, oncogene or carcinogen-induced transformation.
There is evidence that senescence, and escape from senescence, do occur in 
tumours. Most fundamentally, not all tumours are capable of unlimited expansion. The 
growth of many benign, early stage tumours is limited, and senescence is a likely 
candidate for the cause of this growth limitation (Wynford-Thomas, 1997). The
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majority of tumours, however, appear to contain cells that are immortal. Furthermore, 
studies of head and neck squamous cell carcinomas indicate that late stage and recurrent 
tumours contain immortal cells more frequently than early stage tumours (Edington et 
al., 1995). This implies that there is selection pressure during tumourigenesis for cells 
with increased replicative potential, and that this pressure arises when tumour cells 
reach the end of their proliferative lifespan. Cells extracted from intermediate-stage 
tumours have lost some but not all of their senescence regulatory controls, and may have 
an extended rather than unlimited lifespan (Loughran et al., 1996).
Genetic evidence also indicates that senescence is a mechanism of tumour 
suppression, with many immortal cell lines exhibiting losses of multiple tumour 
suppressor genes. The existence of multiple mutations may reflect evasion of the 
multiple lifespan barriers that exist in many cell types (Sections 1.2.2, 1.2.3 and 1.2.4). 
Indeed, the extent of genetic defects correlates well with lifespan in culture: in the study 
of head and neck cancers referred to above, immortality correlated with p53 dysfunction 
and high frequencies of allele loss at other loci; allele loss in senescent neoplastic 
cultures, however, was rare (Edington et al., 1995). Wynford Thomas (1998) has 
described further evidence that proliferative lifespan barriers impose selection pressure 
for tumour suppressor gene mutation. He suggests that the pattern of mutations 
observed in different tumour types reflect differential selection pressure for the 
inactivation of particular senescence pathways. Only around 30% of invasive ductal 
breast carcinomas, for example, exhibit TP53 mutation, and this correlates with lack of 
ER expression and poor prognosis. These features suggest that these tumours are 
derived from the long-lived breast cell sub-population referred to in Section 1.2.2. 
These cells (because of previous silencing of p l6 INK4a) exhibit strictly p53-dependent 
regulation of senescence. Most breast tumours, however, retain wild type p53 and have 
a phenotype that correlates with that of the shorter-lived subpopulation of breast cells 
(Section 1.2.2). These shorter-lived cells initially show p53-independent senescence, 
with a p53-dependent barrier only kicking in after a large number of doublings; it is 
possible that a clinically significant tumour can be generated before this barrier is 
reached. The presence or absence of TP53 mutation in a breast tumour could thus be an 
inevitable reflection of the senescence controls that normally operate in the cell of 
origin.
The proliferative barrier of M l may thus have evolved as a mechanism of 
tumour suppression. However, the same is not necessarily true of M2. Crisis might
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simply be the inevitable consequence of unimpeded proliferation in the absence of both 
functional telomeres and p53 (Chin et al., 1999).
1.2.7 Evidence for a senescence gene on human chromosome 7
Microcell mediated monochromosome transfer experiments have mapped the 
complementation group D senescence gene (Section 1.2.4) to chromosome 7. The 
immortal, non-tumourigenic cell lines SUSM1 and KMST6, established from normal 
human diploid fibroblasts by in vitro mutagenesis, have been mapped to immortality 
complementation group D by cell-cell fusion analysis of the immortal phenotype 
(Pereira-Smith & Smith, 1988). Both cell lines have defects at 7q: KMST6 displays 
LOH at 7q31-qter while SUSM1 has a homozygous deletion at 7q31-32. Introduction 
of chromosome 7 into these cell lines induced proliferative arrest within 10 to 30 
population doublings (Ogata et al., 1993). Because the cell lines were fibroblast-derived 
and non-tumourigenic, it was unlikely that the growth arrest induced by the 
chromosome was a consequence of an effect unrelated to senescence such as tumour 
suppression or terminal differentiation. Indeed, the growth arrested hybrid cells were 
enlarged and flattened—a morphology characteristic of senescent cells—and stained 
positive for expression of senescence-associated endogenous P-galactosidase. 
Furthermore, the mortality marker mortalin reverted to the pancytosolic distribution 
associated with cells of limited proliferative potential (Nakabayashi et al., 1997). 
Introduction of chromosomes 1 and 11, which induce a delayed growth arrest in other 
immortal cell lines (Hensler et al., 1994; Koi et al., 1989), had no effect on the 
replicative potential of these cell lines. Similarly, chromosome 7 was found to have no 
effect on the tumour cell lines HT1080, HeLa and TE85, representative of immortality 
complementation groups A, B and C respectively. It has subsequently been 
demonstrated that chromosome 7 also induces senescence in the complementation group 
D hepatoma cell line HepG2 (Ogata et al., 1995), indicating that the senescence- 
inducing effect of the chromosome is irrespective of cell type or tumourigenicity. 
Significantly, the chromosome 7-induced growth arrest of SUSM1 is accompanied by 
telomeric shortening (Nakabayashi et al., 1997). SUSM1 does not express telomerase 
but has unusually long telomeres. These findings suggest that the chromosome 7 
senescence gene may function by suppressing the ALT telomere maintenance 
mechanism.
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1.3 Aims
There is evidence, therefore, for the existence on chromosome 7 of both a senescence 
gene and a multi-tissue tumour suppressor gene. The aim of my project was to 
functionally analyse these genes, using microcell mediated monochromosome transfer to 
introduce the entire chromosome into human tumour cell lines. My initial objective was 
to investigate whether chromosome 7 could induce senescence in breast and ovarian 
tumour cell lines that belong to immortality complementation group D. If it could, I 
hoped to narrow down the region within which the senescence gene is located by 
carrying out PCR-based microsatellite deletion analysis of the donor chromosome of 
immortal hybrids.
We also chose to examine experimentally the suggestion that the chromosome 7 
senescence and multi-tissue tumour suppressor gene are one and the same. I thus 
planned to investigate whether any immortal microcell hybrids generated in the above 
experiments—which had presumably deleted or otherwise inactivated the senescence 
gene on the donor chromosome—showed evidence nevertheless of being suppressed for 
tumourigenicity. Were I to find no evidence for the existence of a separate tumour 
suppressor gene on chromosome 7, the argument that the senescence gene is the target 
of the frequent 7q31 losses found in tumours would be strengthened.
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Table 1.1
T a b le  1 .1
T h e  id e n t if ic a t io n  o f  o n c o g e n e s
See Hesketh, 1997 for the majority of these entries.
The identification of oncogenes
A) Oncogenes first identified in acute transforming retroviruses
ABL, AKT, CBL, CRK, ERB-A, ERB-B, ETS, FES/FPS, FGR, FMS, FOS, JUN, 
KIT, MIL/RAF, MOS, MYB, MYC, H-RAS, K-RAS, REL, ROS, SEA, SIS, SKI, SRC, 
YES
B) Oncogenes activated by retroviral integration
AHI1, BMI1, DSI1, EVI1, FIM1, FIS1, FLU, FLVU, GIN1, INTI/ WNT1, INT2, 
INT3, INT4/ WNT3, LCK, MIS1, MIS2, MIS3, MIS4, MLVI2, MLVI3, PIM1, SPI, 
TIAM1, TPL2, VIN1
C) Oncogenes identified by gene transfer
activated in the tumours from which they were derived:
N-RAS, NEU, MET, TRK
activated during gene transfer:
DBL, FGF5, HST1, LBC, MAS, B-RAF, RET, TRE, VAV
D) Oncogenes identified by their association with chromosomal aberrations
translocation:
ALL1 /MLL/HRX, BCL1/PRAD1/CCND1, BCL2, BCL3, BCR, TALI, TAL2, TAN1 
amplification:
L-MYC, N -MYC, GLI1,AIB1/SCR1
E) Oncogenes identified by cross hybridisation or by PCR with degenerate 
oligonucleotide primers
CCND2, CCND3, CDK4, ELK1, ELK2, EPH, ERB-B2, ERB-B3, ERB-B4, ERG, 
FOSE, FRA1, FRA2, HCK, HST2, JUNB, JUND, LYN, MAX
Table 1.1
T a b le  1 .2
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T a b le  1 .2
T h e  fu n c t io n s  o f  o n c o p r o te in s
Classification of oncoproteins according to their biochemical 
role in signal transduction. This table is not intended to be 
comprehensive. See Hesketh, 1995 and 1997 for the majority 
of entries.
The functions of oncoproteins
A) Ligands
AIGF, HST1, INT2, NOV, SHH, SIS/PDGFB, WNT1, WNT2, WNT3
B) Receptor tyrosine kinases
EPH, ERB-B/EGFR, FMS, KIT, MET, NEU/HER2/ERB-B-2, RET, ROS, SEA, 
TRK
C) Non-catalytic receptors
INT3/NOTCH4, MAS, TAN1/NOTCH1
D) Non-receptor tyrosine kinases
membrane-associated:
FGR, FYN, HCK, LCK, LYN, SRC, TKL, YES
cytoplasmic:
ABL, FPS/FES
E) Lipid kinases
PI3K
F) Cytoplasmic regulators of protein activity
SH2/SH3 containing adaptors:
CRK, NCK, SHC
guanine nucleotide exchange factors:
DBL, ECT2, LBC, TIAM1, VAV
other:
CBL
G) Membrane-associated G proteins
HRAS, KRAS2, NRAS, GSP, GIP2
H) Cytoplasmic protein serine/threonine kinases
AKT, BCR, MEK1/2, MOS, PIM1, RAF/MIL, TPL2
I) DNA-binding nuclear proteins (transcription factors)
ALL1/MLL, ERB-A/THRA, ETS1, ETS2, FOS, JUN, MYB, MYC, REL, TALI, 
SKI
J) Transcription co-activator (acetyl transferase)
AIB1/SCR1
Table 1.2
Table 1.3
Table 1.3 
Genes involved in hereditary predisposition to cancer
BCNS: basal cell nevus syndrome. BZS: Bannayan-Zonana syndrome. 
CD: Cowden disease. HNPCC: hereditary non-polyposis colon cancer. 
HPRC: hereditary papillary renal carcinoma. JPS: juvenile polyposis 
syndrome. LDD: Lhermitte-Duclos disease. MEN: multiple endocrine 
neoplasia. PJS: Peutz-Jeghers syndrome. WAGR: Wilms’ tumour, 
aniridia, genito-urinary malformation and mental retardation.
Genes involved in hereditary predisposition to cancer
Gene Disease/Syndrome Cancer Type Chromosomal
location
APC Familial adenomatous poly­
posis and Gardiner syndrome
Colon 5q21
AR Male breast Xqll-12
ATM Ataxia telangiectasia Multiple Uq21
BLM Bloom’s syndrome Multiple 15q26
BRCA1 Breast and ovary 17q21
BRCA2 Breast 13ql3
CDK4 Melanoma 12ql3
CDKN2A/MTS2 Melanoma 9p21
DPC4 JPS Colon 18q21.1
E-CADHER1N Stomach 16q22
ER Breast 6q23
IGFII Beckwith-Wiedemann
syndrome
Multiple llp l5
hMLHl HNPCC Colon 3p21
HMSH2 HNPCC Colon 2pl6
hPMSl HNPCC Colon 2q31
hPMS2 HNPCC Colon 7p22
p S ^ 2 Beckwith-Wiedemann
syndrome
Multiple llp l5
LKB1 PJS Multiple
hamartomata
19pl3
MEN1 MEN type 1 Multiple endocrine llq l3
MET HPRC Renal 7q31
NF1 Neurofibromatosis type 1/ 
von Recklinghausen’s 
disease
Neural crest 17qll
NF2 Neurofibromatosis type 2 Schwannoma 22ql2
PTCH Gorlin’s syndrome/ BCNS Skin 9q22
PTEN/MMAC1 BZS, CD, JPS, LDD Multiple
hamartomata
10q23
RBI Retinoblastoma 13ql4
RET MEN type 2A and 2B Multiple endocrine lOqll
TSC1 Tuberous sclerosis Multiple 9q34
TSC2 Tuberous sclerosis Multiple 16pl3
TP53 Li-Fraumeni syndrome Multiple 17pl3
VHL von Hippel-Lindau disease Renal 3p25
WRN Werner’s syndrome Multiple 8pll.l-21.1
WT1 Wilms’ tumour/Denys-Drash 
syndrome/WAGR
Renal llp !3
XPA-G Xeroderma pigmentosum Skin
Table 1.3
Figure 1.1
Figure 1.1
Mortality stage 1: Possible telomere to cell cycle signalling mechanisms
Recognition of critically shortened telomeres results in activation of p53 
and upregulation of p l6 INK4a. In turn, p53 induces expression of p21WAF1. 
p l6INK4a- and p21WAF1-mediated inhibition of CDKs prevents the 
phosphorylation of pRB. The pRB/E2F repressor complex is maintained, 
preventing expression of genes required for S phase entry. Arrows 
represent a positive effect, bars represent inhibition.
Mortality stage 1: 
Possible telomere to cell cvcle signalling mechanisms
Telomeres shorten to critical length
PARP/ATM/DNA-PK
p53
▼
p j i W A n  ^ Cyclin D/CDK 4/6
Cyclin E/CDK 2 pRB phosphorlyation
I
Disruption of pRB/E2F repressor complex
I
pRB/E2F independent mechanism S Phase Entry
Figure 1.1
Figure 1.2
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Figure 1.2 
The two-stage model of cellular immortalisation
A) Mortality stage 1 (M l) involves loss of mitogen responsiveness 
and arrest in the G1 phase of the cell cycle. M l is the process 
commonly viewed as in vitro replicative senescence. B) Bypass 
of M l through, for example, expression of SV40 large T 
antigen extends the proliferative lifespan until cells reach a 
second stationary growth phase, mortality stage 2 (M2), 
corresponding to the classical description of postsenescent crisis. 
Inactivation of the M2 mechanism constitutes the final 
immortalising event; this inactivation is a rare event, suggesting a 
mutational origin, and correlates with the emergence of a telomere 
maintenance system. C) Bypass of Ml through, for example, 
expression of HPV E6 or E l confers on fibroblasts a smaller 
extension of proliferative lifespan than does expression of SV40 
large T antigen. Cells reach an intermediate lifespan barrier 
known as Mlb.
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CHAPTER 2 
MATERIALS & METHODS
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2. Materials and Methods
2.1 Materials
2.1.1 Chemicals
Solutions and buffers were prepared using df^O from a Millipore MilliRO 15 System. 
Unless otherwise stated below, all chemicals were obtained from Fisher Scientific, 
Loughborough, UK.
Supplier
Amersham International 
Little Chalfont, UK
Bioline 
London, UK
Boehringer Mannheim UK 
Lewes, UK
Fluka Chemika-Biochemika AG 
Buchs, Switzerland
Gibco BRL Life Technologies 
Paisley, UK
James Burrough 
Witham, UK
Promega Corporation 
Southhampton, UK
Sigma Chemical Company 
Poole, UK
Chemical
Redivue[a32P]dCTP~3000Ci/mmol
X-Gal
Caesium chloride; Hepes 
DMF
Tris
Ethanol
Deoxyribonucleotides
Ethidium bromide; MES; 
TEMED; Tween 80 & 20; 
Triton X-100; EDTA; 
Potassium ferricyanide; 
Potassium ferrocyanide; 
Hydrogen peroxide;
2.1.2 Enzymes
Supplier Enzyme
Bioline Taq DNA polymerase
London, UK
Boehringer Mannheim UK 
Lewes, UK
Proteinase K
Life Technologies 
Paisley, UK
M spl and React 1 buffer
2.1.3 General plasticware
Supplier
Becton Dickinson Labware 
Plymouth, UK
Bibby-Sterilin 
Stone, UK
Elkay
Galway, Eire
Greiner Labortechnik 
Stonehouse, UK
Material
Falcon tubes
5 ml Bijous; 20ml Universals
Microcentrifuge tubes; Pipette tips
Filter pipette tips
2.1.4 Electrophoresis gels
Supplier
Gibco BRL Life Technologies 
Paisley, UK
National Diagnostics 
Hull, UK
Material
Agarose, electrophoresis grade; 
Hae III digested <J>X174 DNA
SequaGel,
19:1 acrylamideibisacrylamide
2.1.5 Paper and X-ray film
Supplier
Eastman Kodak Company 
Rochester, New York, USA
Whatman International 
Maidstone, UK
Material
X-ray film (X-OMAT-AR)
3MM filter paper
2.1.6 Immunocytochemistry antibodies and materials
Supplier Material
Affiniti Research Products Ltd 
Exeter, UK
Anti-Caveolin-1 antibody, 
[C13630] (rabbit polyclonal)
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Autogen Bioclear UK 
Caine, UK
Anti-Mortalin antibody,
[GRP 75 (C-19)] (goat polyclonal)
Sigma Chemical Company 
Poole, UK
FITC-labelled rabbit anti-goat IgG; 
DAB tablets (10 mg); Goat serum; 
Bovine serum albumin
Vector Laboratories 
Peterborough, UK
Vectashield mounting medium; 
Vectastain ABC kit, peroxidase 
rabbit
2.1.7 Microbial host, media and supplies
Supplier Material
Difco, Becton Dickinson Tryptone; Yeast extract
Plymouth, UK
Bibby-Sterilin Petri dishes
Stone, UK
Gibco BRL Life Technologies Competent E. coli DH5a
Paisley, UK
Sigma Chemical Company Ampicillin
Poole, UK
2.1.8 Drug resistance plasmids
pBabe Hygro and psp72 containing a corrected PMC1 neo polA cassette were both 
obtained from Dr E K Parkinson, BICR.
2.1.9 General cell culture media and supplies
Supplier Material
A/S Nunc Cryotubes
Botolph Claydon, UK
Becton Dickinson Labware Falcon tissue culture dishes
Plymouth, UK
Bioclear UK FBS
Devizes, UK
Calbiochem-Novabiochem UK Hygromycin B
Nottingham, UK
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Fisher Scientific UK 
Loughborough, UK
DMSO
Gibco BRL Life Technologies 
Paisley, UK
Sigma Chemical Company 
Poole, UK
L-glutamine; RPMI; 
Neomycin (G-418)
DMEM; Penicillin; 
Sodium bicarbonate; 
Sodium pyruvate; 
Streptomycin;
Worthington Biochemical Corporation 
Reading, UK
Trypsin
2.1.10 Supplies for specialised cell culture techniques
Supplier
Difco, Becton Dickinson 
Plymouth, UK
Costar 
Bucks, UK
Gibco BRL Life Technologies 
Paisley, UK
A/S Nunc
Botolph Claydon, UK
Sigma Chemial Company 
Poole, UK
Material 
Noble agar
5 pm filter membranes
Lipofectamine
Chamber slides;
25 cm2 flasks
Phytohemagglutinin PHA-P; 
Cytochalasin B; Demecolcine; 
PEG-1000
2.1.11 Cell lines
The ovarian carcinoma cell lines listed below were kindly provided by Dr R Brown, 
CRC Beatson Laboratories, Medical Oncology, Glasgow, UK, and the pancreatic 
carcinoma cell lines by Dr N Lemoine, ICRF, London, UK. All other cell lines were 
obtained from Dr E K Parkinson, BICR.
Cell line Tumour of origin
MCF7 breast
MDA-MB-231
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MDA453
ZRF75
HT1080 fibrosarcoma
143BTK osteosarcoma
OVIP ovarian
OVCAR3
OVCAR4
OVCAR5
CHI
C0L0357 pancreatic
SUIT2
TMSG
HeLa cervix
KMST6 fibroblast*
SUSM1
*both are non-tumourigenic, immortalised fibroblast cell lines
The donor cell lines for use in MMCT, A92/Hytkl and A92/Hytkl5, were generated in
Dr R F Newbold’s laboratory, Brunei University, Middlesex, UK.
2.1.12 Websites
Centre d’Etude du Polymorphisme Humain (CEPH) 
http://www.cephb.fr/
Cooperative Human Linkage Centre (CHLC) 
http://lpg.nci.nih.gov/CHLC 
National Center for Biotechnology Information (NCBI) 
http://www.ncbi.nlm.nih.gov 
UK Human Genome Mapping Project Resource Centre 
http://www.hgmp.mrc.ac.uk 
Whitehead Institute/MIT Center for Genome Research 
http://www-genome.wi.mit.edu/
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2.2 Methods
2.2.1 Cell culture techniques
2.2.1.1 Culture of cell lines
Except when stated otherwise, all cell lines and clones were cultured in DMEM 
supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 0.3% sodium bicarbonate and 
1 mM sodium pyruvate. The cell lines MCF7, OVCAR3, OVCAR4 and OVCAR5 were 
cultured in RPMI supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 0.2% sodium 
bicarbonate and 1 mM sodium pyruvate. A92/Hytkl and A92/Hytkl5 donor cells were 
cultured in DMEM supplemented as above and containing 800 units/ml hygromycin B. 
All cell lines were maintained in a humid 37 °C/5% CO2 incubator.
Cryopreserved cell stocks were prepared from early-passage cell lines and clones 
as follows. Cells were maintained in culture until they reached approximately 75% 
confluence. They were then trysinised, neutralised with normal growth medium and 
pelleted. The cell pellet was resuspended in freezing medium (10% DMSO in normal 
growth medium) to a density of 1 x 106 cells/ml, and the suspension transferred into 
cryotubes (1 ml per vial). The cryotubes were wrapped in cotton wool and placed into a 
-70 °C freezer overnight, and the following day were immersed in liquid nitrogen for 
long-term storage. Cryotubes were recovered from liquid nitrogen by rapid immersion 
in a large volume of water at 37 °C. The cell suspension was then made up to a volume 
of 10 ml with normal growth medium and the cells pelleted. Cells were resuspended 
and plated at a density of 0.5-1.0 x 106 cells per 10 cm dish.
2.2.1.2 Transfection
Cells were cultured in 10 cm plates until approximately 80% confluent. 10 pg of 
plasmid DNA was diluted in 400 pi of serum-free medium, and added to a tube 
containing 50 pi of Lipofectamine reagent and 350 pi of serum-free medium. This 
mixture was incubated at room temperature (RT) for 20 min to allow DNA-liposome 
complexes to form; meanwhile, the cells were rinsed once with serum-free medium. 
Following the incubation, 6.4 ml of serum-free medium was added to the complexes and 
the whole mixture gently pipetted onto the cells. A control plate of cells was treated 
with Lipofectamine reagent/serum-free medium only. The plates were incubated 
overnight (approximately 16 hr) at 37 °C before the transfection mixture was removed 
and replaced with complete growth medium. The cells were incubated for a further 24
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hr, and then passaged and plated at a density of 3 x 105 cells per 10 cm dish. Once the 
cells had adhered, hygromycin B or neomycin selection was added as appropriate (Table 
2.1). Selection medium was changed weekly. After approximately four weeks, 
individual transfectant colonies were ring-cloned and expanded as required.
Cell Line Hygromycin B concentration 
(U/ml)
Neomycin concentration 
(mg/ml)
OVCAR5 500 0.4
MDA-MB-231 500 1.4
HeLa 200 0.8
SUSM1 100 0.6
Table 2.1. The minimum concentration of hygromycin B or neomycin required to kill 
all non-transfected cells plated at a density of 3 x 105 cells per 10 cm dish. Selection 
medium is changed weekly. Cell death is complete within 2 weeks.
2.2.1.3 Microcell mediated monochromosome transfer
Donor cells (murine A92 cells containing an Hytk-tagged human chromosome) were 
plated into six Nunc 25 cm2 flasks at a density of 1.25 x 106 cells per flask. After 24 hr 
demecolcine was added to a final concentration of 0.075 pg/ml, and the flasks were 
incubated at 37 °C for a further 48 hr. The medium was then replaced with 30 ml of 10 
pg/ml cytochalasin B in serum-free medium. After a 20 min incubation (37 °C) the 
flasks were placed in a GSA rotor and spun in a pre-heated Sorvall RC 28S centrifuge, 
programmed with the following parameters: 7600 rpm/9500g; 75 min; slow start 
15 min; slow stop 10 min; 37 °C; brake off. Following the run, the pellets (consisting of 
microcells and cell debris) were resuspended in a small amount of supernatent and 
transferred into a single 15 ml sterile Falcon tube. The suspension was centrifuged 
(3470 rpm, RT, 5 min), and the pellet resuspended in 10 ml of serum-free medium. The 
microcell suspension was then passed through three sterile 5 pm filters, and the final 
suspension centrifuged as before. Meanwhile the recipient cells, approximately 80% 
confluent on 10 cm plates, were rinsed twice with serum-free medium. The microcell 
pellet was resuspended in 3 ml of 20 pg/ml phytohemagglutinin PHA-P in serum-free 
medium, and the whole suspension added to a plate of recipient cells. A control plate 
was treated with PHA-P/serum-free medium only. The cells were then incubated at
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37 °C for 1 hr. Following this incubation, the medium was removed and 3 ml of 45% 
PEG-1000 in serum-free medium added gently to the cells. After a 60 s incubation at 
RT, the cells were rinsed five times with serum-free medium (1 x 30 s, 1 x 45 s and 3 x 
60 s rinses), and incubated at 37 °C overnight. The cells were then trypsinised and re­
plated at 3 x 105 cells per 10 cm dish. Hygromycin B selection (500 U/ml for MDA- 
MB-231 and OVCAR5, 200 U/ml for HeLa and SUIT2) was added after 24 hr. The 
selection medium was changed weekly and colony formation monitored. Proliferating 
colonies were ring-cloned and expanded as required, and their DNA extracted. Figure
2.1 shows a schematic of this procedure.
2.2.1.4 Assay for endogenous p-galactosidase activity
Adhered cells were rinsed twice with PBS, and fixed by incubating in 3% (v/v) 
formaldehyde in PBS for 5 min at RT. The cells were then twice rinsed again with PBS. 
5 ml of X-gal staining solution (47 mM MES, 140 mM sodium chloride, 1.9 mM 
magnesium chloride, 4.8 mM potassium ferrocyanide, 4.8 mM potassium ferricyanide 
and 0.95 mg/ml X-Gal) at pH 6 was added to each 10 cm plate. As a control, 
proliferating cells of the same cell type were also treated. The dishes were placed in a 
humid box, and incubated for 16 hr at 37 °C. Following this incubation the cells were 
rinsed with PBS and microscopically examined for blue staining.
2.2.1.5 Cell-cell fusion
Each parent cell population consisted of a pool of eight or more clones transfected with 
a plasmid conferring resistance to either hygromycin B or neomycin. In each 
experiment, a hygromycin B-resistant parent cell population was fused to a neomycin- 
resistant parent cell population.
1 x 105 cells of each parent cell population were seeded into the same 3.5 cm 
plate and incubated for 24 hr. The cells were rinsed twice with serum-free medium and 
fused during a 60 s incubation at RT in 45% PEG-1000 in serum-free medium. As a 
control, each parent cell population alone was also subjected to PEG-1000 treatment. 
Following this incubation the cells were rinsed four times with serum-free medium (1 x 
30 s, 1 x 45 s and 2 x 60 s rinses). Normal growth medium was then added to the cells. 
After a 24 hr incubation, the cells were trypsinised and plated into 10 cm dishes at a 
density of 3 x 105 cells per 10 cm dish, or 1 x 105 per 6 cm dish. The parental control 
cells were mixed together at this stage, by seeding 1.5 x 105 cells of each parent
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population into a 10 cm plate. After 24 hr cells were placed under dual hygromycin B 
and neomycin selection (Table 2.2). The selection medium was changed weekly. 
Hybrid colonies were ring-cloned and expanded as appropriate and passaged for 50 
population doublings or until senescence.
Name of hybrid Medium Hygromycin B 
selection (U/ml)
Neomycin selection 
(mg/ml)
HeLa/HeLa DMEM 200 0.8
HeLa /MDA-MB-231 DMEM 500 1.4
HeLa /OVCAR5 RPMI 500 0.4
MDA-MB-231/MDA-MB-231 DMEM 500 1.4
MDA-MB-231/OVCAR5 RPMI 500 1.4
MDA-MB-231/SUSM1 DMEM 500 1.4
O V CAR5/0 V CAR5 RPMI 500 0.4
OVCAR5/SUSM1 RPMI 500 0.6
SUSM1/SUSM1 DMEM 100 0.6
Table 2.2. Minimum concentrations of hygromycin B and neomycin required to kill all 
non-hybrid cells plated at a density of 3 x 105 cells per 10 cm dish. Selection medium is 
changed weekly. Cell death is complete within 2 weeks.
2.2.1.6 Determination of population doublings
The number of population doublings (PD) that cell-cell hybrid clones had achieved was 
calculated at each passage according to the formula
PD = (log N - log N0) x 3.32
where N0 = initial cell number 
N = final cell number
(Paul et al., 1975)
2.2.1.7 Assay for growth in soft agar
Base agar plates were poured by pipetting 4 ml of base agar medium (0.6% (w/v) noble 
agar in RPMI supplemented with 20% (v/v) FBS, 2 mM L-glutamine and 0.2% (w/v) 
sodium bicarbonate, 37 °C) into 6 cm Sterilin plates. The plates were chilled at 4 °C to 
allow the agar to set. Sub-confluent cells that had been cultured for seven days in the
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absence of drug selection were trypsinised, pelleted, resuspended in RPMI 
(supplemented with 20% (v/v) FBS, 2 mM L-glutamine and 0.2% (w/v) sodium 
bicarbonate) to a density of 5000 cells/ml, and warmed to 37 °C. 4 ml of base agar 
medium at 37 °C was then mixed thoroughly with 4 ml of the cell suspension. 2 ml of 
the final suspension was added to a pre-warmed base plate; at least three replica plates 
were prepared for each cell line. The plates were chilled at 4 °C for 20 min, and then 
incubated at 37 °C in a 10% CO2 humid incubator. Colonies with a diameter of greater 
than 0.1 mm were counted after between two and four weeks with the aid of a dissection 
microscope.
When required, colonies were extracted from the agar using a 200 pi Gilson and 
long pipette tip, again with the aid of a dissection microscope. The colony was 
resuspended in normal growth medium and placed into a well of a 24-well plate. The 
cells were then expanded and their DNA extracted (Section 2.2.4.1).
2.2.2 Mouse tumour studies
2.2.2.1 Preparation and injection of cells
Sub-confluent cells were trypsinised, pelleted and rinsed with PBS. The suspension was 
then re-pelleted and the cells resuspended in ice-cold PBS at a concentration of 
3.333 x 106 cells/ml. 150 pi of the cell suspension was injected subcutaneously into 
athymic nude mice; four or five mice were used for each cell line or clone. The mice 
were monitored weekly for signs of tumour formation, and the diameter of any tumours 
measured using calipers.
2.2.2.2 Extraction of tumour and tail DNA and expansion of tumour cells
The mice were sacrificed and the tumours excised when the diameter of the tumours 
reached approximately 10 mm. Half of each tumour was flash frozen in liquid nitrogen 
and stored at -70 °C.
The remaining half was transferred into an eppendorf containing 1 ml of DNA 
lysis buffer (100 mM Tris.HCl pH 8.5, 5 mM EDTA, 0.2% (w/v) SDS, 200 mM NaCl 
and 100 pg/ml Proteinase K). The eppendorfs were incubated overnight at 55 °C with 
constant agitation and then vortexed. The DNA was then precipitated by addition of an 
equal volume of isopropanol, with gentle mixing until all viscosity was gone. The 
aggregated precipitate was removed by lifting from the solution with a sterile plastic
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inoculation loop. Excess liquid was dabbed off and the DNA rinsed in 70% (v/v) 
ethanol. After being briefly allowed to air-dry, the DNA was dispersed into at least 
0.5 ml of TE (10 mM Tris.HCl and 1 mM EDTA pH 8.0) and maintained at 37 °C with 
agitation until completely dissolved. DNA was prepared from 0.5 cm tail biopsies in a 
similar manner, except that after vortexing the tubes were centrifuged at 12 000 rpm for 
approximately 5 min. The supernatent was then used for isopropanol precipitation as 
before.
When required, cells from the newly excised tumours were expanded in culture. 
A tumour chunk was divided with a scalpel into very small pieces (approximately 1 mm 
square) under sterile conditions. The pieces were spread out on the base of a 10 cm 
tissue culture plate, and gently covered with FBS. Most of the FBS was immediately 
removed, and the dish transferred to a dry 37 °C area for 30 min to allow the tumour 
pieces to adhere to the plate. 4 ml of normal growth medium was then added to the 
cells. After 5 days of incubation at 37 °C in a humid incubator the medium was 
removed and replaced with 10 ml of normal growth medium. The dishes were then 
monitored periodically for signs of cell outgrowth from the tumour pieces. The cells 
were passaged after 3-4 weeks, and maintained in culture until only human cells were 
visible (while the murine cells eventually senesced, the immortal human cells continued 
to proliferate).
2.2.3 Immunocytochemistry
2.2.3.1 Immunofluorescence
Cells were plated into 8-well chamber slides at a density of 2 x 104 cells per well and 
incubated for 24 hr. The cells were then rinsed twice with ice-cold PBS, and fixed by 
incubating for 10 min at RT in 3.7% formalin in KRH buffer (120 mM NaCl, 6 mM 
KC1, 1.2 mM MgCl2, 1 mM CaCb and 25 mM Hepes, pH 7.4). After fixing, the cells 
were rinsed three times with KRH buffer. The cell membranes were then permeablised, 
by incubating in 0.5% triton X-100 in KRH buffer at RT for 5 min. The cells were 
rinsed three times with KRH buffer containing 0.05% (v/v) Tween 80, and were then 
blocked by incubating in blocking buffer (10% FBS in KRH buffer/Tween) for 1 hr. 
After blocking, the cells were incubated for 1 hr at RT in the primary antibody diluted in 
blocking buffer (Table 2.3). No primary antibody was added to control wells. The cells 
were then rinsed in KRH buffer/Tween for three periods of 10 min. Subsequently, the
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cells were incubated in the fluorochrome-conjugated secondary antibody diluted in 
blocking buffer (Table 2.3) for 1 hr at RT in a darkened humid box. The cells were 
again rinsed in KRH buffer/Tween for three periods of 10 min. The plastic chambers 
and sealing gasket were removed from the slides and a drop of Vectashield mounting 
medium applied to each area of cells. A glass coverslip was then placed over the cells 
and sealed in place using clear nail varnish.
2.2.3.2 Visualisation by confocal microscopy
Slides were imaged using a confocal microscope equipped with a krypton/argon ion 
laser (model MRC 600, BioRad, Hercules, CA). 488/568nm line excitation and dual 
channel 522 and 585nm emission filters were used. Image analysis was performed 
using BioRad software.
2.2.3.3 Immunoperoxidase staining
Cells were plated into 8-well chamber slides and grown up as for immunofluorescence. 
The cells were then rinsed twice with ice-cold PBS, and fixed by incubating on ice for 
15 min in ice-cold 1:1 methanol:acetone. After fixing, the slides were air-dried for 20 
min and rinsed twice in PBS for two periods of 10 min. To quench endogenous 
peroxidase activity, the cells were then blocked for 10 min at RT in 3% (v/v) hydrogen 
peroxide in methanol. After again rinsing in PBS for two periods of 10 min the cells 
were blocked again, this time for 20 min at RT in goat serum/blocking buffer (1 drop of 
goat serum per 3.3 ml of 0.1% (w/v) BSA in PBS). The cells were then incubated 
overnight af 4 °C in primary antibody diluted in 0.1% BSA in PBS (Table 2.3). No 
primary antibody was added to control wells. Following this incubation, the cells were 
rinsed in wash buffer (0.15 M sodium chloride and 0.05% (v/v) Tween 20 in PBS) for 
three periods of 5 min, and then incubated for 1 hr at RT in the biotinylated secondary 
antibody provided with the kit (diluted in 0.5% BSA in PBS; Table 2.3). The cells were 
then rinsed as before and incubated for 1 hr at RT in biotinylated peroxidase that had 
been allowed to complex with avidin (ABC complex: 20 pi of kit reagent A, 2 ml of 
0.5% BSA in PBS, and 20 pi of reagent B, incubated at RT for 30 min). Slides were 
rinsed for three periods of 10 min in wash buffer, and incubated in ABC complex at RT 
for 1 hr. After three further 10 min rinses in wash buffer, the cells were incubated for 
7.5 min in the dark in substrate solution (1 DAB tablet and 10 pi of 30% (v/v) hydrogen 
peroxide in 16.7 ml of PBS), before rinsing thoroughly with dH20. Coverslips were
6 4
mounted using mounting solution (50% (v/v) glycerol and 0.025% (w/v) sodium azide 
in PBS), and sealed in place with clear nail varnish. The slides were viewed using a 
Nikon Diaphot phase-contrast microscope.
NB: PBS and wash buffer at pH 7.6.
Antibody Dilution
anti-mortalin (goat polyclonal) 1/500
FITC-labelled anti-goat 1/25
anti-caveolin (rabbit polyclonal) 1/100
biotinylated anti-rabbit 1/200
Table 2.3 Antibody dilutions for immunocytochemistry
2.2.4 Extraction, synthesis and quantitation of DNA
2.2.4.1 Extraction of genomic DNA from human cell lines
Genomic DNA was prepared from mammalian cell lines according to (Laird et al., 
1991). Cells were first harvested by trypsinisation and then pelleted by brief 
centrifugation in a microcentrifuge tube. Cells were resuspended and simultaneously 
lysed in 1 ml of lysis buffer (Section 2.2.2.2), followed by incubation for several hours 
at 37 °C with constant agitation. DNA was precipitated and redissolved as in Section 
2 .2 .2 .2 .
2.2.4.2 Extraction of plasmid DNA from bacteria
Plasmid DNA was isolated from overnight cultures of transformed bacteria by alkaline 
lysis. Cultures were first refrigerated for 20 min before being pelleted by centrifugation, 
and resuspended in the appropriate volume of solution I (100 mM Tris.HCl pH 8.0 and 
100 mM EDTA; Table 2.4). Bacteria were then lysed by addition of solution II (0.2 M 
NaOH and 1% (w/v) SDS; Table 2.4) and gentle mixing by inversion. After a 5 min 
incubation on wet ice, detergent and protein were precipitated by addition of ice-cold 
solution III (3 M KOAc pH 4.8; Table 2.4) and momentary vigorous shaking. After 
incubating on ice for a further 15 min, the flocculate was removed by centrifugation at 
10 000 g. Supernatant containing plasmid DNA was decanted into a fresh 
polypropylene tube. (For small to medium scale preparations of plasmid DNA,
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RNA’ase was added at this stage at a final concentration of 10 |ig/ml and the lysate 
incubated for 15 min at 37 °C.) 1/10 volume of chloroform was then added to the lysate 
to remove residual protein, and the two phases were mixed by shaking and separated by 
centrifugation. The upper aqueous phase was decanted, and the DNA precipitated by 
addition of 0.6 volumes of isopropanol. The DNA was then rinsed with 70% (v/v) 
ethanol, and resuspended in TE (pH 8.0).
50 ml culture 500 ml culture
Solution I 1ml 20 ml
Solution II 2 ml 40 ml
Solution III 1.5 ml 30 ml
Table 2.4. Plasmid prep solution quantities
Plasmid DNA was further purified by equilibrium centrifugation through a 
continuous caesium chloride density gradient prepared by dissolving caesium chloride in 
the DNA solution to a concentration of 1 g/ml and then adding ethidium bromide to a 
final concentration of 740 pg/ml. Centrifugation was performed at 80 000 rpm in 
polycarbonate tubes for 16 hr using a TLA100.3 rotor in a Beckman TL-100 
ultracentrifuge. Following centrifugation, the lowermost (supercoiled) DNA band was 
removed from the gradient using a syringe and an I 8 V2 gauge needle. Ethidium bromide 
was extracted by addition of equal volumes of water-saturated butan-l-ol and the 
volume increased by addition of water. DNA was recovered by addition of 1/10 volume 
of 3 M NaOAc and 2*/2 volumes of ethanol followed by centrifugation at 10 000 g, 
washing in 70% (v/v) ethanol and resuspension in TE (pH 8.0).
2.2.4.3 Synthesis and purification of oligonucleotides
Oligonucleotides were synthesised at the BICR as a core service on an Applied 
Biosystems model 392 or 394 RNA/DNA synthesiser using phosphoramidite chemistry 
according to the manufacturer’s instructions. 5' trityl groups were removed as part of 
the synthesis and the oligonucleotides eluted into a solution of 29% (v/v) ammonia. 
This eluate was then incubated at 55 °C overnight in order to 'de-protect' the 
oligonucleotides. Vials were then chilled on ice and the DNA-ammonia solutions 
transferred to 15 ml Falcon tubes. Oligonucleotides were precipitated by the addition of 
0.1 volumes of 7.5 M ammonium acetate and 3 volumes of ethanol, followed by
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incubation on dry ice for 30 min. The DNA was then pelleted by centrifugation in a 
Sorvall HB-6 rotor at 10 000 g for 15 min. The pellet was washed in 70% (v/v) ethanol, 
air-dried and dissolved in 0.5 ml of dF^O. DNA concentrations were calculated 
(Section 2.2.4.4) and the oligonucleotides stored at -20 °C until required.
2.2.4.4 Quantitation of DNA concentrations
DNA was quantified by spectrophotometric determination of its UV light absorbency. 
5 pi of sample was added to 495 p i of de-ionised water and the absorbency of the 
solution measured at 260 nm and 280 nm in a quartz cuvette, using dH2 0  as a blank. 
The concentration of the solution was calculated using de Beer’s law on the basis that an 
optical density of 1.0 at 260 nm corresponds to a concentration of 50 pg/ml for double­
stranded DNA and 33 pg/ml for single-stranded oligonucleotides. Pure preparations of 
DNA and RNA have a ratio of A260/A280 readings between 1.8 and 2.0.
2.2.5 PCR and analysis of amplification products
2.2.5.1 PCR
The following conditions were used to perform the majority of PCR amplifications. 
Occasional slight alterations to the annealing temperature or concentration of 
magnesium ions were required for optimal results. 1 pi of 0.5 mg/ml template DNA 
was added to 24 pi of PCR mix (1 pM oligonucleotide primers, 1.5 mM MgCU, 50 pM 
dNTPs, 1 x reaction buffer (50 mM KC1 and 10 mM Tris.HCl pH 8.0), and 1 unit Taq 
DNA polymerase). dH20 instead of template was added to control reactions. When 
required, 1 pCi [a32P]dCTP per reaction was included for radiolabelling of 
amplification products. The thermal cycling parameters consisted of 30 rounds of 1 min 
denaturation at 94 °C, 30 s annealing at 55 °C, and 30 s extension at 72 °C, using an 
MJC Research PTC-200 thermal cycler (Genetic Research Instrumentation Ltd, 
Dunmow, Essex, UK).
Primers: see Table A1 (Appendix) for details of primers used to amplify
polymorphic STSs mapping to human chromosome 7
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Primers used to amplify a portion of the hygromycin B resistance cassette 
from pBabe Hygro:
L: CTGGGGCGCCCTCTGGTAAG 
R: GCGTGGATATGTCCTGCGGG 
product size: 209 bp
Primers used to amplify a portion of the neomycin resistance cassette 
from psp72 containing a corrected PMC1 neo polA cassette:
L: ATGCTCTTCGTCCAGATCAT 
R: AAAGTATCCATCATGGCTGAT 
product size: 150 bp
2.2.5.2 Allele loss analysis of microcell hybrid cell clones and tumours
100 ng of template DNA from parental cells and hybrid cell clones or tumours was 
subjected to PCR using the standard reaction conditions (Section 2.2.5.1); amplification 
products were radiolabelled in situ. PCR products were resolved on 6% (w/v) 
polyacrylamide denaturing gels and visualised by autoradiography (Section 2.2.5.3). 
Allele loss was determined by visual examination of autoradiographs. Amplification of 
the restriction fragment length polymorphism GH220/324, which lies within the c-MET 
locus, was performed in the absence of radiolabelling. The PCR product was digested 
with Msp 1 to allow RFLP detection, and resolved on an agarose gel.
2.2.5.3 Denaturing polyacrylamide gel electrophoresis
The radiolabelled PCR products of polymorphic markers were resolved on 6% (w/v) 
polyacrylamide gels under denaturing conditions. A gel solution (6% (w/v) acrylamide, 
0.2% (w/v) bisacrylamide and 8 M urea in 1 x TBE (see below)) was prepared from 
Sequagel stock solutions. The solution was polymerised by the addition of 150 pi of 
20% (w/v) ammonium persulphate and 75 pi of TEMED per 60 ml of gel. This solution 
was then poured between glass plates separated by 0.4 mm spacers and allowed to set at 
room temperature. Gels were pre-run at 100 W for 45 min in 1 x TBE (90 mM Tris- 
borate and 2 mM EDTA pH 8.0) to warm the gels to approximately 50 °C before the 
loading of samples. 4 pi of PCR product was mixed with 6 pi of STOP buffer (95% 
formamide, 20 mM EDTA pH 8.0, 0.05% (w/v) xylene cyanol and 0.05% (w/v)
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bromophenol blue) and denatured by heating at 94 °C for 10 min followed by quenching 
on ice. 4 pi of this mixture was subjected to electrophoresis at 100 W for 2-3 hr 
depending upon the size of the PCR product. The gel was then transferred to a sheet of 
Whatman 3MM paper and dried under vacuum at 80 °C for 45 min. The PCR products 
were detected by autoradiography using X-ray film.
2.2.5.4 Agarose gel electrophoresis of unlabelled PCR products
Unlabelled (cold) PCR products were separated on non-denaturing agarose gels and 
visualised by staining with ethidium bromide and UV transillumination. Gels were 
prepared by dissolving electrophoresis grade agarose in 1 x TAE (40 mM Tris-acetate 
and 2 mM EDTA pH 8). After being heated in a microwave to dissolve the agarose, 
molten gels were cooled to approximately 60 °C and ethidium bromide added to a final 
concentration of 5 pg/ml before being poured into an appropriate gel former. Once 
solid, gels were placed into electrophoresis tanks containing 1 x TAE. Samples were 
mixed with one-fifth volume of gel-loading buffer (40% (w/v) sucrose, 0.05% (w/v) 
bromophenol blue and 0.05% (w/v) xylene cyanol) before being loaded into the wells of 
the gel. Electrophoresis was performed at 5 V/cm. In order to estimate the size of 
fragments resolved by electrophoresis, samples were run alongside aliquots of molecular 
weight marker, normally the Hae III digest of bacteriophage <j)X174 DNA. DNA was 
visualised by UV transillumination and the gel photographed.
2.2.6 Microbiological techniques
2.2.6.1 Transformation of bacteria with plasmid DNA
Competent E. coli (DH5a) were thawed on ice, and aliquots transferred to pre-chilled
1.5 ml screw-cap microcentrifuge tubes. Approximately 10 ng of plasmid DNA was 
added and gently mixed with the cells by stirring with a pipette tip. After incubation on 
ice for 30 min, cells were heat-shocked at 42 °C for 45 s and then placed on ice for a 
further 2 min. 400 pi of SOC medium (2% (w/v) bacto-tryptone, 0.5% (w/v) bacto- 
yeast extract, 20 mM glucose, 10 mM NaCl and 10 mM MgCU) was then added to the 
mixture, and the cells were incubated at 37°C for 1 hr in an orbital shaker at 240 rpm. 
After this time cells were pelleted by pulsing in a microcentrifuge. 450 pi of 
supernatant was discarded and the cells resuspended in the remaining 50 pi. Cells were 
then spread on LB medium plates containing 1.5% (w/v) agar supplemented with the
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appropriate antibiotic. Plates were incubated in an inverted position at 37 °C, and 
colonies transferred into LB medium the following day.
For the preservation of bacterial stocks, a 0.5 ml aliquot of overnight culture in 
LB medium (1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract and 1% (w/v) 
NaCl, pH 7.0) was mixed with an equivalent volume of 50% (w/v) glycerol, chilled on 
ice and then stored at -70° C in plastic cryotubes. Cultures were subsequently re­
established by inoculation of 5 ml of LB medium containing the appropriate antibiotic 
with 20 p,l of the glycerol stock.
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Figure 2.1
Microcell mediated monochromosome transfer procedure
Microcells are prepared from donor rodent cells that contain a single 
Hytk-tagged copy of a particular human chromosome. The microcells 
are then fused to recipient cells using polyethylene glycol. 
Hygromycin B-resistant colonies are examined microscopically for 
growth potential and, when macroscopic, ring-cloned and expanded.
Microcell mediated monochromosome transfer procedure
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3. Results 
Assignment of tumour cell lines to senescence complementation group D: 
identification of recipient cell lines for use in MMCT 
3.1 Purpose
The technique of microcell mediated monochromosome transfer (MMCT) was the 
cornerstone of this study into the role of genes on chromosome 7 in cellular senescence 
and tumour suppression. The first task, therefore, was to select appropriate recipient 
cell lines for use in this assay. Previously, MMCT had been used to introduce 
chromosome 7 into two immortal, but non-tumourigenic, cell lines that belong to
immortality complementation group D and have defects at 7q31. This induced
senescence in a proportion of hybrids, thus mapping the group D gene to this 
chromosome (Ogata et al., 1993). However, we wished to use the technique both to 
determine whether chromosome 7 could reverse the immortal phenotype of
tumourigenic cell lines of the appropriate complementation group, and to investigate the 
tumour suppressive effects of the chromosome: it was therefore necessary to select 
tumourigenic as opposed to purely immortal cell lines.
The only tumour cell lines originally documented as belonging to
complementation group D are A2182 and A1698, derived from lung and bladder 
carcinomas respectively (Pereira-Smith & Smith, 1988). However, since our group is 
primarily interested in breast and ovarian cancer, both of which show very high 
frequencies of LOH at 7q31 (Reviewed in Zenklusen & Conti, 1996), we chose to 
identify for ourselves group D cell lines of these tumour types. Three complementary 
approaches were used to do this. The first approach involved searching for general 
evidence of a gene inactivation event on 7q, while the second two aimed to specifically 
identify tumour cell lines belonging to senescence complementation group D.
3.2 Homozygosity at 7q
Extrapolating from Knudson’s two hit model, loss of all or part of a chromosome arm in 
a tumour or tumour cell line is indicative of loss of a tumour suppressor gene in that 
region. The retained allele is presumed to contain an inactivating mutation (Knudson, 
1971). Replicative senescence is believed to be an important mechanism of tumour 
suppression, and the genes involved—including the complementation group genes—
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may be critical targets for inactivation during tumourigenesis. I therefore analysed 12 
tumour cell lines for evidence of loss of all or part of a copy of the long arm of 
chromosome 7. Three of these cell lines (SUIT2, TMSG and C0L0357) were derived 
from pancreas, four (MDA453, MCF7, MDA-MB-231 and ZR75) from breast, and five 
(OVIP, OVCAR3, OVCAR4, OVCAR5 and CHI) from ovarian tumours. Highly 
polymorphic simple sequence repeats (SSRs), DNA sequences comprising direct 
tandem repeats of two, three or four nucleotides (Sheffield et al., 1995; Weissenbach et 
al., 1992), were used to carry out the study. Variation in the number of repeat units at a 
particular SSR locus translates into length variation; the fact that a particular SSR can 
potentially have many allelomorphic forms accounts for the high frequency of 
heterozygosity among this class of polymorphic marker. Several genetic and physical 
maps that use these markers have been established for the genome, including 
chromosome 7 (Bouffard et al., 1997). These maps, available in electronic form at 
various websites (Section 2.1.12), are proving to be invaluable research resources.
I selected a number of SSR polymorphic markers from the length of 7q and, 
using appropriate primers, PCR-amplified them from DNA extracted from the 12 
tumour cell lines; the products were run out under denaturing conditions on a 
polyacrylamide gel and scored as homozygous or heterozygous. Representative 
autoradiographs are shown in Figure 3.1, and the results are summarised in Table 3.1 
(See Figure 4.8 for an ideogram of 7q giving approximate positions of markers.) In four 
of the cell lines (the breast tumour cell line MDA-MB-231, the ovarian tumour cell line 
OVCAR5 and the pancreatic tumour cell lines COL0357 and TMSG), nearly every 
marker mapping to 7q was found to be homozygous: despite the lack of availability of 
normal paired tissue, it was apparent that one copy of the chromosome arm had been 
lost. Four markers mapping to the p arm were then PCR-amplified from MDA-MB-231 
and OVCAR5, and run out under the same conditions. Most of these markers were 
heterozygous, indicating that the loss was confined to the long arm.
These results are indicative of inactivation of a tumour suppressor gene on 7q in 
four of the 12 cell lines. In three of the four cell lines homozygous for 7q, we observed 
the occasional heterozygous marker amidst the background of homozygosity (D7S821 
in C0L0357, D7S687 in TMSG and D7S633 in MDA-MB-231). This suggests that 
loss of the chromosome arm was followed by endo-reduplication of the remaining copy 
of the arm; subsequent to this duplication a replication slippage event has presumably 
occurred in each of the above cell lines, giving rise to new alleles. This demonstrates
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the advantage of this approach over fluorescent in situ hybridisation (FISH), where 
chromosome loss in these circumstances would be undetectable.
Markers were also PCR-amplified from DNA extracted from the bladder cell 
line A1698, which is known to belong to immortality complementation group D (Pereira 
Smith and Smith, 1988). The cell line was found to be mainly heterozygous for the 
markers analysed (Figure 3.1 for representative autoradiographs). Thus, while we 
hypothesise that cell lines that are homozygous for 7q are likely to belong to 
complementation group D, it does not follow that all group D cell lines are homozygous 
for this region.
3.3 The cellular distribution of mortalin
3.3.1 Cell lines of known senescence complementation group assignment
Mortalin, a member of the HSP70 family, was identified in a protein screen as a 66 kDa 
protein present in the cytosolic fraction of normal mouse embryonic fibroblasts (MEFs), 
but absent from the cytosolic fraction of immortal MEFs (Wadhwa et al., 1993a). The 
protein may have a functional role in senescence: micro-injection of an antibody against 
it can transiently stimulate cell division in senescent MEFs (Wadhwa et al., 1993a), and 
overexpression of cytosolic mortalin in NIH 3T3 cells induces senescence (Wadhwa et 
al., 1993c). Mortalin is present in immortal mice and human cells; however, while in 
mortal cells its distribution is diffuse and cytoplasmic (pancytosolic), in immortal cells 
the protein is less diffuse and more perinuclear (Wadhwa et al., 1993b). Intriguingly, 
four such perinuclear distributions of mortalin exist in immortal human cells and these 
enigmatically correlate with immortality complementation group assignment (Wadhwa 
et al., 1995). Group A cells exhibit a granular juxtanuclear cap, group B cells a granular 
gradient from nuclear to cell membrane, group C cells a granular juxtanuclear arch, and 
group D cells a fibrous perinuclear distribution (Figure 3.2). In 17 of 18 cell lines tested 
that had been assigned to a single complementation group by somatic cell hybridisation, 
the mortalin distribution was perinuclear rather than pancytosolic and correlated with 
the original complementation group assignment. Although the molecular basis of this 
correlation remains unknown, staining for mortalin appears a theoretically simple way to 
both distinguish mortal from immortal cells and to assign a cell line to a particular 
complementation group.
To confirm that we too could detect the correlation of mortalin distribution with 
complementation group assignment, I used an antibody against mortalin to carry out
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indirect immunofluorescence on pre-senescent normal fibroblasts and on a cell line 
representative of each complementation group. The chosen representative of group A 
was the fibrosarcoma cell line HT1080, of group B the cervical tumour cell line HeLa, 
of group C the osteosarcoma cell line 143BTK, and of group D the immortal fibroblast 
cell line SUSM1. Confocal images of the stained cells are shown in Figure 3.3. In 
accordance with Wadhwa’s findings the protein appeared to be pancytosolic in 
fibroblasts, but perinuclear in each of the immortal cell lines. In the representatives of 
immortality complementation groups B and D the protein showed the predicted granular 
gradient and fibrous distribution respectively. The representatives of groups A and C 
also showed the predicted distribution, with a concentration of the protein on one side of 
the nucleus, but as had been suspected it was not possible to tell the difference between 
the two distributions. In each case over 60% of the cells analysed showed the 
appropriate distribution, while phase contrast microscopy of unstained cells indicated 
that the differential distributions were not simply a consequence of different cellular 
morphologies (data not shown). Thus it appeared that we could reliably use the 
distribution of mortalin to assign our cell lines of unknown complementation group to 
group B, group D or group A/C.
3.3.2 Cell lines of unknown senescence complementation group assignment
Immunofluorescence with the mortalin antibody was then carried out on the tumour cell 
lines that I had previously shown to be homozygous for chromosome 7q. Unfortunately, 
only the breast tumour cell line MDA-MB-231 and the ovarian tumour cell line 
OVCAR5 gave reliable, reproducible staining (and in the case of MDA-MB-231 it was 
necessary to carry out the experiment on plastic rather than glass slides to achieve a 
reasonable degree of cell adherence). Images of the stained cells are shown in Figure 
3.4. Both of these cell lines showed the highly distinctive fibrous, perinuclear 
distribution of mortalin which is associated with cells from immortality 
complementation group D. I also investigated the distribution of mortalin in the 
pancreatic tumour cell line SUIT2, which was not hemizygous for 7q (Table 3.1). 
Rather than showing the group D-associated localisation, the distribution of mortalin in 
this cell line resembled that of cells from complementation group B (Figure 3.5).
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3.4 The replicative lifespan of cell-cell hybrids
3.4.1 Generation of hybrids
As a definitive test of the immortality complementation group assignment of the 
OVCAR5 and MDA-MB-231 cell lines, somatic cell hybridisation studies were 
performed. Both cell lines were fused with SUSM1, a known representative of group D, 
and HeLa, a known representative of group B (Pereira-Smith & Smith, 1988). As a 
control, it was also necessary to fuse each of these cell lines to itself. The four cell lines 
were each transfected with a plasmid encoding resistance to hygromycin B and a 
plasmid encoding resistance to neomycin. At least eight transfectant clones of each type 
were expanded and pooled (thus minimising the risk of extrapolating results from a non­
representative sub-clone) to produce the parent cell populations. Each of these 
populations was then fused to each of the other parent cell populations, taking care to 
always fuse a hygromycin B-resistant parent to a neomycin-resistant parent. The 
subsequent use of dual hygro and neo selection permitted the expansion of hybrid 
colonies only. The morphology and colony size of hybrids was examined 
microscopically, and where possible several hybrids of each type were ring-cloned and 
expanded. Multiplex PCR-amplification of the two dominant drug resistance cassettes 
(ratio of HygR primers to NeoR primers 1:10) was then used to confirm that clones that 
survived dual selection and that proliferated to the extent that their DNA could be 
extracted, were true hybrids: 63 of the 64 clones analysed proved positive for both these 
markers (Figure 3.6 for representative gel images). The replicative potential of 
individual hybrid clones was then determined. Hybrids were maintained either until 
senescence, or until 50 population doublings had been achieved; cells that achieved 50 
population doublings were defined as being immortal.
3.4.2 Replicative lifespan of hybrids
Table 3.2 summarises the replicative potential of all hybrids generated. When either 
OVCAR5 or MDA-MB-231 were fused to SUSM1 (group D), all expanded hybrid 
clones achieved 50 population doublings; this indicates non-complementation of 
senescence genes, suggesting that the cell lines share a defect in the same senescence 
gene and belong to the same complementation group (Figure 3.7 shows images of these 
hybrids). In support, all expanded OVCAR5/MDA-MB-231 hybrids also achieved 50 
population doublings.
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Images of HeLa/SUSMl, HeLa/MDA-MB-231, and HeLa/0VCAR5 hybrids are 
shown in Figure 3.8. The majority of clones of each of these hybrid types had limited 
proliferative potential (Table 3.2), the point at which senescence occurred ranging from 
5 to 27 population doublings. A minority of hybrids of each type were immortal; this is 
presumably due to chromosomal segregation with the loss of critical growth regulatory 
genes. As mortal HeLa/SUSMl and HeLa/MD A-MB-231 hybrids approached the end 
of their replicative lifespan the cells enlarged and flattened, giving a morphology 
characteristic of senescent cells. Furthermore, these hybrids stained positive for 
expression of senescence-associated endogenous acidic P-galactosidase, while hybrids 
of all types that showed indefinite replicative potential (and maintained their youthful 
morphology) did not. While some growth arrested HeLa/OVCAR5 hybrids adopted the 
morphology characteristic of senescent cells and stained positive for acidic p- 
galactosidase expression, others appeared to undergo some form of cell death. These 
results are indicative of complementation of different senescence genes, and confirm 
that OVCAR5, MDA-MB-231 and SUSM1 do belong to a different complementation 
group from HeLa.
As a further control, each cell line was also fused to itself, to ensure that loss of 
proliferative potential was not a general, non-specific feature of hybridisation. Nearly 
all homotypic hybrids proliferated well and reached 50 population doublings (Table 
3.2). Some evidence of senescence was observed in HeLa/HeLa hybrids, but to a much 
smaller extent than that observed in HeLa/SUSMl, HeLa/MD A-MB-231 and 
HeLa/OVCAR5 hybrids.
I had intended to use the bladder cell line A1698 as the known representative of 
immortality complementation group D, rather than SUSM1. When A1698 was fused to 
HeLa, however, all of eight hybrids that were ring-cloned proliferated through to the 
cut-off point of 50 population doublings (data not shown). This result is not in 
accordance with those of Pereira Smith and Smith (1988).
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Figure 3.1 
Representative examples of tumour cell line microsatellite 
marker analysis
Autoradiographs from radiolabelled PCR products of three chromosome 7 
microsatellite markers, amplified from cell line DNA. All cell lines except 
A1698 are homozygous for each of the three markers.
A92/Hytkl: MMCT donor. COL0357, TMSG: pancreatic carcinoma. 
OVCAR5: ovarian carcinoma. MDA-MB-231: breast carcinoma.
A1698: bladder carcinoma.
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Table 3.1 
Summary of tumour cell line microsatellite marker analysis
Summary of analysis of microsatellite markers mapping to chromosome 7. 
Markers are given in order of chromosomal location.
Horn: homozygous. Het: heterozygous.
SUIT2, C0L0357, TMSG: pancreatic carcinoma.
MDA-MB-453, MCF7, MDA-MB-231, ZRF75: breast carcinoma.
OVIP, OVCAR3, OVCAR4, OVCAR5, CHI: ovarian carcinoma.
Summary of tumour cell line
arm
arm
microsatellite marker analysis
MARKER SUTJ2 0CLCG5/ 1M3G \TA-453 M3F7 TA-231’ ZR75 CMP CX/CATCO/CARI o/CAre CHI
D7S1819 Hat Hat
P34087 Hat Han
P19270 Hat Hat
P28070 Hat
D7S1831 Hat
D7S1797 Han Han Han Han
D7S820 Han Han Han Han
D7S821 Hat Han Han hfcm
D7S1841 Han Han Han Han
D7S501 Han Han Han Han
D7S796 Han Han Han Han
D7S818 Han Han Han Han
D7S1799 Han Han Han Han
D7S692 Han Han Han Han
D7S525 Han Han Han Han
D7S471 Han Han Han
D7S523. Han Han Han Han
D7S687 Han Han Hat Han Hat Han Hat Hat Hat Hat Han Han
D7S816 Han Han Han Han
D7S1811 Han Han Han Han
D7S486 Han Han Han He* Hat Han hfcm Hat Han Han Han Han
D7S522 Horn hfcm Han Hal Han Han Hat Hat Han Hat Han Han
D7S2460 Han Han Han Han
727CA htet Han Han Hat Hat Han Han Hat Hat Han hfcm He*
778CA Ust Han Han Hat Han Han Hat Han Hat Han htet
724CA Hst Han Han Hat Han Horn Hat Hat Hat Hat Han Hst
740CA hfcm Han Han Hat Han Han Hat Hat Hat Han Han htet
D7S633 htet Han Han Hat Hat Hat Han Hat Hat Hat hfcm htet
D7S677 Han Han hfcm Han
17TA-5/17B-FE3 Hel Han Han Hat Han Hat hfcm Horn hfcm htet
786CA htet Han Han Hat Hat hfcm Han Hat Hat hfcm htet
AFMA073ZB9 Han Han Han Hat Hat Han Hat Han Hat Han htet
D7S643 Han Han Han hfcm
D7S650 Han H an Han Han
D7S685 Han Han Han Han
D7S18O0 Han Han Han Han
D7S1801 Han Han hfcm hfcm
D7S1822 Han Han hfcm Han
D7S220G Han Han Han Han
D7S2197 Han hfcm Han
D7S649 Han Han hfcm hfcm
* MDA-MB-453/MDA-MB-231
Table 3.1
Figure 3.2
Figure 3.2 
Correlation of the cellular distribution of mortalin with 
immortality complementation group assignment
Schematic representation of the intracellular distribution of mortalin 
in mortal and immortal human cells. The four types of perinuclear 
distribution found in immortal cells correlate with immortality 
complementation group assignment. Wadhwa et al., 1995.
Correlation of the cellular distribution of mortalin with 
immortality complementation group assignment
Mortal 
( eg normal fibroblast)
Complementation
group A B C D
Wadhwa et al., 1995
Figure 3.2
F ig u r e  3 .3
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Figure 3.3 
The cellular distribution of mortalin in cell lines representative 
of immortality complementation groups A-D
Confocal immunofluorescence micrographs of normal fibroblasts (a) 
and representatives of each complementation group (b-e) stained for 
mortalin. The intracellular distribution of the protein in mortal and 
immortal cells assigned to complementation groups A-D is as described 
by Wadhwa et al. (1995). Scale bars represent 25 pm.
Normal fibroblasts, early passage. HT1080: fibrosarcoma.
HeLa: cervical carcinoma. 143BTK: osteosarcoma.
SUSM1: fibroblast (immortalised, non-tumourigenic).
The cellular distribution of mortalin in cell lines 
representative of immortality complementation groups A-D
a.
Normal fibroblasts
c.
HT1080 HeLa
Group A
■
Group B
*  r v * * y  * - v  >
e.
,  -V
i  T V  * ;  % - > t
r •, ..-^n i.
143BTK 
Group C
SUSM1 
Group D
Figure 3.3
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Figure 3.4 
The cellular distribution of mortalin in tumour cell lines 
homozygous for 7q
Confocal immunofluorescence micrographs of cells stained for 
mortalin. SUSM1 (a) is known to belong to complementation 
group D, and OVCAR5 and MDA-MB-231 (b & c) are 
homozygous for 7q. All three cells show the perinuclear, 
fibrous distribution of mortalin associated with cells of 
complementation group D (Wadha et al., 1995).
Scale bars represent 25 p,m.
SUSM1: fibroblast (immortalised, non-tumourigenic). 
OVCAR5: ovarian carcinoma.
MDA-MB-231: breast carcinoma.
The cellular distribution of mortalin in
tumour cell lines homozygous for 7q
SUSM1: Group D
OVCAR5
MDA-MB-231
Figure 3.4
Figure 3.5
Figure 3.5 
The cellular distribution of mortalin in a tumour cell line 
heterozygous for 7q
Confocal immunofluorescence micrographs of cells stained for mortalin. 
HeLa (a) is known to belong to complementation group B. SUIT2 (b) 
has not previously been assigned to an immortality complementation 
group and is heterozygous for 7q. Cells of each type show the granular 
gradient of mortalin from nuclear to cell membrane associated with 
cells of complementation group B (Wadhwa et al., 1995).
Scale bars represent 25 pm.
HeLa: cervical carcinoma. SUIT2: pancreatic carcinoma.
The cellular distribution of mortalin in a
tumour cell line heterozygous for 7q
i (
HeLa: Group B
c
t  * L-
SUIT2
Figure 3.5
Figure 3.6
Figure 3.6 
PCR analysis of cell-cell hybrids
Products of multiplex PCR reactions, using primers to amplify 
a portion of the hygromycin B resistance cassette (209 bp) and 
the neomycin resistance cassette (156 bp) from DNA extracted 
from cell-cell hybrid clones and their parental cell populations. 
PCR products were resolved on 3% (w/v) agarose gels and 
stained with ethidium bromide before visualisation on a UV 
transilluminator.
M: (J)X174 RF DNA/Hae III fragments.
Template DNA:
a: hygromycin B resistant parent, b: neomycin resistant parent. 
1-10: cell-cell hybrid clones, 
w: water blank.
PCR analysis of cell-cell hybrids
M D A -M B -2 3 1 ( H y g R) /O V C A R 5(N e oR)
bp M  a b 1 2  3 4 5  6 7 8 9 10 w
2 3 4
194
118
O V C A R 5 ( H y g R) / S U S M l ( N e o R)
M D A - M B - 2 3 1 (H y g R)/S U S M 1 (NeoR) 
I! |
M a b 1 2 3 4 5 6 7 8 9  10 a b 1 2 3 4 5 6 w
HeLa( H y g R) /M D A - M B - 2 3 1 (N e oR)
H eL a (H y g R) /O V C A R 5 ( N e o R)
H e L a ( H y g R) /S U S M l( N e o R)
1 r 1 rM '  a b 1 2 3 4 a b 1 2 3 a b 1 2 3 w
Figure 3.6
Table 3.2
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CHAPTER 4
RESULTS
Introduction of human chromosome 7 
into tumour cell lines and the analysis of
immortal hybrids
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4. Results 
Introduction of human chromosome 7 into tumour cell lines and the analysis 
of immortal hybrids
4.1 Purpose
Transfer of an intact copy of chromosome 7 into immortal fibroblast cell lines that 
belong to immortality complementation group D induces senescence (Ogata et al., 
1993). The cell lines used in this study, SUSM1 and KMST6, were immortalised by in 
vitro mutagenesis (Namba et al., 1988; Namba et al., 1985); however, the cells do not 
form colonies in soft agar or tumours in nude mice. We wished to determine whether a 
normal copy of chromosome 7 could induce senescence even in group D cells with a 
greater variety of genetic defects. The only reported incidence of chromosome 7- 
induced senescence in a tumourigenic cell line was for the human hepatoma cell line 
HepG2 (Ogata et al., 1995). We decided to perform similar experiments using the 
breast tumour cell line MDA-MB-231 and the ovarian tumour cell line OVCAR5, both 
of which we had mapped to immortality complementation group D (Chapter 3).
It was hoped that this study could also be used to map the senescence gene to a 
specific sub-chromosomal region. In Ogata’s experiments a proportion of chromosome 
7-containing hybrids escaped replicative senescence and could be passaged indefinitely: 
they appeared to retain, or revert to, their immortal phenotype (1993; 1995). This 
evasion of senescence was most likely caused by inactivation of the senescence gene on 
the donor chromosome. If such inactivation resulted from deletion or mitotic 
recombination then it should have been possible to map these events by determining the 
pattern of retention of informative SSR markers on the donor chromosome. We planned 
to pursue this mapping strategy for any immortal MDA-MB-231/Chromosome 7 and 
OVCAR5/Chromosome 7 hybrids that we obtained.
Based upon the probable role of replicative senescence in tumour suppression, 
and the finding that SUSM1 and KMST6 both display loss of genetic material from the 
7q31 region (Ogata, 1993), it is possible that the group D senescence gene is the target 
of the 7q31 LOH observed in tumours. However, the deletion mapping strategy 
outlined above potentially offers several advantages over LOH mapping: one, the 
unequivocal nature of the data (there is no DNA from normal stromal cells to 
complicate interpretation of banding patterns); two, the allele loss can be associated
9 0
with an observable phenotypic effect; and three, since the end product is an immortal 
cell line, there is an indefinite source of nucleic acid and proteins for further analysis.
4.2 Induction of senescence
4.2.1 In MDA-MB-231 and OVCAR5 cells
Microcell mediated monochromosome transfer was used to introduce intact copies of 
human chromosome 7—and, as a control, human chromosome 15—into MDA-MB-231 
and OVCAR5 cells. The donor chromosomes were tagged with a selectable fusion 
gene, Hytk; this is derived from both the hygromycin phosphotransferase gene Hph, 
conferring hygromycin resistance and allowing positive selection of transfected cells, 
and the herpes simplex virus thymidine kinase gene tk, allowing negative selection 
(Cuthbert et al., 1995). After two weeks under hygromycin B selection, the fusion 
plates were examined microscopically for both proliferating and growth-arrested 
colonies. The progress of individual colonies was then monitored periodically.
A summary of the effects of the chromosomes on the growth potential of hybrids 
is given in Table 4.1. Approximately 30% of MDA-MB-231/Chromosome 7 and 
OVCAR5/Chromosome 7 hybrids underwent growth arrest. This arrest occurred after 
between five and eight population doublings, resulting in colonies of around 30 to 250 
cells; despite weekly re-feeding, in most cases no increase in cell number was 
subsequently observed. No growth arrest was observed after introduction of 
chromosome 15, indicating that the chromosome 7-induced growth arrest was not a 
general, non-specific effect initiated by an excess of chromosomal material. 
Furthermore, introduction of chromosome 7 into the pancreatic tumour cell line SUIT2, 
which is heterozygous for 7q and does not show the fibrous mortalin distribution 
associated with complementation group D cells, also failed to induce growth-arrest 
(Table 4.1).
The cells of the growth-arrested hybrids were enlarged and flattened, a 
morphology characteristic of senescent cells (Figure 4.1 shows an 
OVCAR5/Chromosome 7 hybrid). To confirm the nature of the growth-arrest the 
hybrids were stained for senescence-associated endogenous |3-galactosidase activity. 
Growth-arrested hybrids of both recipient cell types showed positive blue staining 
(Figure 4.2 shows a stained MDA-MB-231/Chromosome 7 hybrid), detectable after 
hybrids had been maintained in culture for around seven weeks; immortal hybrids of the 
same age did not stain positive. Interestingly, growth-arrested OVCAR5/Chromosome
91
7 hybrids often underwent some form of cell death, and could often not be maintained in 
culture long enough to detect staining. This cell death is reminiscent of that observed in 
OVCAR5/HeLa cell-cell hybrids (Section 3.4.2).
Some growth-arrested hybrids were subjected to immunofluorescence using an 
antibody against mortalin. In addition to varying with complementation group 
assignment, the distribution of mortalin varies according to whether a cell is mortal or 
immortal (Section 3.3.1). Growth-arrested hybrids of both recipient cell types showed 
reversion of mortalin from its immortal (perinuclear) to its mortal (pancytosolic) 
distribution (Figure 4.3 shows MDA-MB-231/Chromosome 7 hybrid cells). 
Significantly, within a single growth-arrested OVCAR5/Chromosome 7 colony that 
spontaneously immortalised (presumably following the appearance of a variant 
immortal cell), the enlarged, growth-arrested cells showed reversion of mortalin to the 
mortal distribution while the smaller, proliferating cells did not (data not shown).
4.2.2 In HeLa cells
I introduced chromosome 7 into HeLa cells (complementation group B) as a potential 
control. Published reports indicate that the senescence-inducing effect of chromosome 7 
is specific to recipients that belong to complementation group D (Ogata et al., 1993), 
and that that of chromosome 4 is specific to recipients that belong to group B (Ning et 
al., 1991). Unexpectedly, all six HeLa/Chromosome 7 hybrids generated underwent 
growth arrest after between seven and twenty one population doublings, and stained 
strongly positive for senescence-associated endogenous p-galactosidase activity (Figure 
4.4).
We suspected this growth arrest to be a result of expression of the CAVEOLIN-1 
gene, which maps to chromosome 7 (Hurlstone et al., 1999). CAVEOLIN-1 is expressed 
at very low levels in HeLa cells (Figure 4.5), and previous work in the institute had 
shown that it induces a senescence-like growth arrest in this cell line when expressed 
under the control of a heterologous promoter (Ken Parkinson, personal communication). 
I therefore carried out immunoperoxidase staining with an antibody against Caveolin-1 
on growth-arrested HeLa/Chromosome 7 hybrids and on normal HeLa cells. Much 
greater levels of staining were observed in the growth-arrested hybrids than in the 
normal HeLa cells (Figure 4.6). This indicated that the CAVEOLIN-1 gene on the donor 
chromosome was being expressed and could therefore be responsible for the growth 
arrest.
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As the normal level of Caveolin-1 expression in OVCAR5 and MDA-MB-231 
cells is much greater than that in HeLa cells (Figure 4.5), we considered it unlikely that 
expression of this protein was the cause of the chromosome 7-induced growth arrest in 
these cell lines. Caveolin-1 expression clearly shows no correlation with immortality' 
complementation group assignment or 7q LOH, arguing against it being, the group D 
senescence gene. It is interesting that chromosome 7 had no growth-inhibitory effects 
when introduced into the SUIT2 cell line, which, like HeLa, expresses very low levels 
of Caveolin-1 (Figure 4.5). It may be that Caveolin-1-induced senescence is something 
of an oddity specific to HeLa cells. However, it is clear that the existence of genes such 
as CAVEOLIN-1 complicates both interpretation of monochromosome transfer 
experiments and the senescence complementation group picture in general.
4.3 Microsatellite deletion analysis of immortal hybrids
In all, 45 immortal OVCAR5/Chromosome 7 hybrids and 34 immortal MDA-MB- 
231/Chromosome 7 hybrids were generated. Many SSR markers mapping to 7q were 
assayed to determine whether alleles were informative, namely whether the allele size 
differed between the donor and endogenous chromosome. 34 of the markers assayed 
were clearly informative for OVCAR5/Chromosome 7 hybrids, and 17 for MDA-MB- 
231/Chromosome 7 hybrids. These markers were then PCR-amplified from DNA 
extracted from the immortal hybrids and run out under denaturing conditions on a 
polyacrylamide gel. The products were visualised by autoradiography and scored for 
loss or retention of the donor allele.
Representative examples of the deletion analysis are shown in Figure 4.7 and the 
results are summarised in Tables 4.2 and 4.3. Figure 4.8 shows an ideogram of the long 
arm of chromosome 7 with the approximate positions of markers. The presence of 
donor alleles in the majority of the DNA samples confirmed that the immortal colonies 
did indeed contain an additional chromosome 7. Overall, more than half the immortal 
hybrids of both cell types had lost one or more marker from the long arm of the donor 
chromosome, consistent with the hypothesis that the immortality of these hybrids was a 
result of loss or inactivation of the senescence gene on the introduced chromosome. 
However, it is very apparent that this mode of analysis is hampered by noise, with losses 
not restricted to one particular region of the chromosome.
62% (28/45) of immortal OVCAR5/Chromosome 7 hybrid samples had lost or 
partially lost at least one marker from the long arm. 11% (5/45) of hybrids—for
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example hybrids 17 and 24— appeared unequivocally to have lost the entire long arm, 
the hygromycin resistance marker having presumably integrated elsewhere in the 
genome. Several hybrids—for example hybrids 14 and 29—instead displayed multiple 
interstitial losses of the q arm; not including loss of the most telomeric markers, 27% 
(12/45) of hybrids displayed this pattern of loss. The most frequently lost q arm marker 
was the tetranucleotide repeat D7S818 (114 cM from 7pter; 7q22), which was lost or 
showed reduced intensity in 42% (19/45) of hybrid samples.
56% (19/34) of MDA-MB-231/Chromosome 7 hybrids had lost one or more 
markers from the long arm. None had lost every marker assayed, but 9% (3/34) had lost 
all but two. Multiple interstitial losses of the q arm, not including loss of the most 
telomeric markers, were displayed by 21% (7/34) of hybrids (for example hybrids 8 and 
11). The most frequently lost q arm markers were the dinucleotide repeat 
AFMA073ZB9, the tetranucleotide repeat D7S2847 (both approximately 125 cM from 
7pter; 7q31), and the telomeric tetranucleotide repeat D7S1807; these were each lost in 
35% (12/34) of hybrids.
A possible allele-loss ‘hot-spot’ in immortal OVCAR5/Chromosome 7 hybrids 
spans the markers 17TA-5/17B-RE3 to D7S650 (7q31; Table 4.2). A possible hot-spot 
in immortal MDA-MB-231/Chromosome 7 hybrids, spanning AFMA073ZB9 and 
D7S2847, lies within this region (Table 4.3). Moreover, the 17TA-5/17B-RE3 to 
D7S650 region largely lies within the minimum region of loss defined by six separate 
LOH studies (Takahashi et al., 1995; Achille et al., 1996; Koike et al., 1997; Shridhar et 
al., 1997; Edelson et al., 1997; Zenklusen et al., 1994). The hot-spots, however, do not 
stand out very distinctly, and in OVCAR5/Chromosome 7 hybrids there is a further 
possible hot-spot spanning the markers D7S1797 to D7S818.
For OVCAR5/Chromosome 7 hybrids the analysis was extended to the p arm of 
the donor chromosome, to determine whether losses were specific to the q arm. Again, 
over half the immortal hybrids (56%; 25/45) were found to have lost at least one of the 
two informative markers analysed from this arm (Table 4.2), raising doubts as to the 
significance of losses found on the q arm. Indeed, the frequency of loss (53%; 24/45) of 
the p arm marker GATAP19270 was greater than that of any long-arm marker analysed. 
In addition, a limited number of q arm markers were analysed from hybrids generated 
from the control SUIT2 line (Table 4.4). Again, a high frequency of apparently random 
losses was found: 37% of hybrids (7/19) had lost at least one of the four markers
9 4
assayed. These results call into question the significance of the allele-loss hot-spot 
identified on the long arm.
In summary, it difficult to draw conclusions from this analysis as to the sub- 
chromosomal location of the chromosome 7 senescence gene. For the combinations of 
donor chromosome and recipient cell lines used here, this mapping strategy appears 
inappropriate (see Discussion).
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Table 4.1
Table 4.1 
The proliferative capacity of tumour cell line clones after 
introduction of human chromosomes 7 and 15
The percentage of OVCAR5, MDA-MDA-231 and SUIT 2 clones 
that undergo growth arrest after introduction of chromosomes 7 
and 15 by MMCT.
OVCAR5: ovarian carcinoma. MDA-MB-231: breast carcinoma. 
SUIT2: pancreatic carcinoma.
The proliferative capacity of tumour cell line clones 
after introduction of human chromosomes 7 and 15
Chromosome 7 Chromosome 15
Total no. Percentage of Total no. Percentage of
of colonies hybrids that of colonies hybrids that
undergo growth undergo growth
arrest arrest
MDA-MB-231 * 30 20 0
OVCAR5 * 30 9 0
SUIT2 20 0 - -
* >50 colonies
Table 4.1
F ig u r e  4 .1
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Figure 4.1 
OVCAR5/Chromosome 7 hybrids
Phase-contrast photomicrographs of proliferating (a) and 
growth-arrested (b) OVCAR5/Chromosome 7 hybrid colonies 
at approximately 4 weeks after introduction of the chromosome 
Cells in the growth-arrested colony are enlarged and flattened 
compared to those in the proliferating colony. Both images are 
at the same magnification.
OVCAR5/Chromosome 7 hybrids
Proliferating OVCAR5/Chr7 colony
Growth-arrested OVCAR5/Chr7 colony
Figure 4.1
F ig u r e  4 .2
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Figure 4.2 
MDA-MB-231/Chromosome 7 hybrids
Phase-contrast photomicrographs of proliferating (a) and 
growth-arrested (b & c) MDA-MB-231/Chromosome 7 hybrid 
colonies. Cells in the growth-arrested colonies are enlarged and 
flattened compared to those in the proliferating colony, and stain 
positive for expression of senescence-associated endogenous 
P-galactosidase. The (3-gal staining was performed approximately 
9 weeks after introduction of the chromosome. All images are at 
the same magnification.
MDA-MB-231/Chromosome 7 hybrids
1
;■ :  '> ;■  i - -
X l u w *  \  rJ ? r   ______________
Proliferating MDA-MB-231/Chr7 colony
Growth arrested MDA-MB-231/Chr7 colony
c.
Growth-arrested MDA-MB-231/Chr7 colony 
p-gal stained
Figure 4.2
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Figure 4.3 
The cellular distribution of mortalin in growth arrested 
MDA-MB-231/Chromosome 7 hybrid cells
Confocal immunofluorescence micrographs of an MDA-MDA-231 
cell (a) and growth-arrested MDA-MB-231/Chromosome 7 hybrid 
cells (b & c) stained for mortalin. The intracellular distribution of 
the protein in growth-arrested cells has reverted from the fibrous, 
perinuclear distribution characteristic of immortal cells belonging to 
complementation group D to the pancytosolic distribution 
characteristic of mortal cells (Wadhwa et al., 1995).
Scale bars represent 50 pm.
The cellular distribution of mortalin in growth arrested
MDA-MB-231/Chromosome 7 hybrid cells
a.
M DA-M B-231
Growth-arrested MDA-MB-231/Chr7 cells 
Figure 4.3
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Figure 4.4 
HeLa/Chromosome 7 hybrid
Phase-contrast photomicrographs of HeLa cells (a) and a 
growth-arrested HeLa/Chromosome 7 hybrid colony (b). The 
cells in the growth-arrested colony are enlarged and flattened 
compared to normal HeLa cells, and stain positive for expression 
of senescence-associated endogenous |3-galactosidase. The colony 
was stained approximately 10 weeks after introduction of the 
chromosome. Both images are at the same magnification.
HeLa/Chromosome 7 hybrid
HeLa
Growth-arrested HeLa/Chr7 colony 
(3-gal stained
Figure 4.4
Figure 4.5
Figure 4.5 
Caveolin-1 expression in tumour cell lines
RT-PCR analysis (a) and western blot analysis (b) of CAVEOLIN-1 
expression in tumour cell lines. HeLa cells express very low levels of 
both transcript and protein. Primers that amplify a region of G3PDH 
cDNA were included in the RT-PCR reactions as an internal control for 
amplification efficiency, a  and (3 refer to the two protein isoforms of 
Caveolin-1.
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Figure 4.6 
Caveolin-1 expression in HeLa/Chromosome 7 hybrid cells
Phase-contrast photomicrographs of HeLa cells (a) and a growth-arrested 
HeLa/Chromosome 7 hybrid colony (b), immunoperoxidase stained for 
Caveolin-1. Cells of the growth-arrested colony express greater levels of 
Caveolin-1 than normal HeLa cells. The colony was stained approximately 
7 weeks after introduction of the chromosome. Both images are at the 
same magnification.
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Figure 4.7 
Representative examples of allele loss analysis in 
immortal tumour cell line/Chromosome 7 hybrids
Autoradiographs from radiolabelled PCR products of the 
chromosome 7 microsatellite markers D7S692, D7S1807, 
D7S1809 and D7S821, amplified from the DNA of immortal 
OVCAR5/Chromosome 7 hybrids (a) and 
MDA-MB-231/Chromosome 7 hybrids (b).
A92/Hytkl\ MMCT donor. EA: endogenous allele.
DA: donor allele. IB: invariant band (PCR artefact).
Representative examples of allele loss analysis in 
immortal tumour cell line/Chromosome 7 hybrids
a.
OVC AR5/Chromosome 7 immortal hybrids
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Figure 4.8 
Ideogram of the long arm of chromosome 7
The long arm of chromosome 7 is depicted as an ideogram 
showing cytogenetic banding. Alongside are shown the polymorphic 
SSR (and RFLP) markers used to perform allele loss analysis. Those 
in blue represent Genethon markers, in red CHLC markers, in green 
CA.GT markers identified by A. Hurlstone (BICR, unpublished data), 
and in black an RFLP (GH220/324) within the c-MET locus and a 
microsatellite marker (17TA-5/17B-RE3) in intron 17b of the CFTR 
locus. See Table A1 for more details of these markers.
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CHAPTER 5
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Analysis of the tumour suppressive 
effects of human chromosome 7
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5. Results 
Analysis of the tumour suppressive effects of human chromosome 7
5.1 Purpose
As detailed in the introduction, high frequencies of LOH are observed at 7q31 in a 
variety of human tumours (Reviewed in Zenklusen & Conti, 1996). This indicates the 
existence of a tumour suppressor gene in this region. Introduction of human 
chromosome 7 by MMCT was found to reduce the tumour-forming ability of a murine 
squamous cell carcinoma cell line, giving functional evidence for this gene (Zenklusen 
et al., 1994b). Significantly, one of the two hybrid clones that retained the 
tumourigenicity of the parent cell line had a deletion at 7q31.1-7q31.2. The observation 
that introduction of human chromosome 7 induces replicative senescence in two 
immortal, non-tumourigenic cell lines that have 7q31 defects (Ogata et al., 1993) also 
suggests the existence of a gene in this region with a role in replicative senescence. 
Given the probable role of replicative senescence in tumour suppression, it is tempting 
to speculate that the 7q31 tumour suppressor and replicative senescence gene are one 
and the same.
We chose to test this hypothesis, by investigating whether the senescence- 
inducing effect of chromosome 7 is separable from its tumour suppressive effect. To do 
this, we analysed the tumourigenicity of some of the immortal chromosome 7- 
containing hybrid clones already generated (Chapter 4). As these clones have 
presumably deleted or otherwise inactivated the senescence gene on the donor 
chromosome, any reduction in their tumourigenicity compared to the parent cell line 
would suggest the existence of an additional chromosome 7 tumour suppressor gene. 
Specifically, we used immortal hybrids for which no SSR losses on the donor 
chromosome had been found, as in such hybrids disruption to genes other than the 
senescence gene will have been minimised. To gain an in vitro measure of the 
tumourigenic potential of these clones we analysed their anchorage independent growth 
in soft agar, while as a more definitive test we determined their ability to form tumours 
in nude mice.
Should evidence be found for the existence of a separate tumour suppressor 
gene, we anticipated that the strategy we had pursued would facilitate relatively rapid 
gene mapping. SSR deletion analysis of DNA extracted from revertant soft agar
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colonies or tumours, and cDNA or DNA subtractions between tumourigenic and non- 
tumourigenic hybrid clones, would be two obvious mapping approaches.
5.2 Immortal OVCAR5/Chromosome 7 hybrids: their growth in soft agar
Pilot experiments confirmed that the OVCAR5 parent cell line was capable of 
anchorage independent growth in soft agar, with approximately 80 colonies forming per 
5000 cells plated. The colony-forming efficiency in agar of the MDA-MB-231 parent 
cell line, however, was rather lower, and the colonies that did form were irregular in 
terms of shape and size (data not shown).
We therefore proceeded with immortal hybrids generated from the OVCAR5 
parent cell line. First, the growth in soft agar of hybrids 3, 20 and 40, none of which 
showed any SRS losses on the donor chromosome (Table 4.2), was compared to that of 
OVCAR5. Two of the hybrids, hybrids 20 and 40, displayed a very marked (20-fold) 
reduction in colony-formation compared to the parent cell line, while the remaining 
hybrid, hybrid 3, exhibited a slight reduction (Figure 5.1a). These results could not be 
explained simply by variations in surface growth rates: while the doubling time of all 
three hybrids was slightly lower than that of the parent cell line (perhaps because they 
contained an additional chromosome), the hybrid with the fastest doubling time, hybrid 
40 (Figure 5.2), was one of the two hybrids with very low colony-forming ability in 
agar.
Further studies were then performed to determine whether the low colony- 
forming efficiency of hybrids 20 and 40 was within that of the normal clonal variation 
of the parent cell line. The growth in soft agar of six individual OVCAR5/p-babe Hygro 
transfectant clones (hyg 1-6), and of two OVCAR5/Chromosome 7 immortal hybrids 
that had lost every SSR marker analysed from the donor chromosome (hybrids 22 and 
41; Table 4.2), was measured. Two additional OVCAR5/Chromosome 7 immortal 
hybrids were included in this assay: these were hybrids 6 and 7, which from the SSR 
analysis appeared to have lost mutually exclusive regions of the donor chromosome 
(Table 4.2).
The results are summarised in Figure 5.1b. One of the p-babe Hygro transfected 
clones, hyg 3, and one of the immortal hybrids that had lost all markers from the donor 
chromosome, hybrid 22, showed an even greater reduction in anchorage-independent 
growth compared to the parent cell line than hybrids 20 and 40. Four p-babe Hygro 
transfected clones, hyg 1, 2, 4 and 5, showed a slighter (three to five-fold) reduction in
110
colony-formation, while one, hyg 6, exhibited a 3-fold increase (subsequent experiments 
suggested that this increase may be closer to 10-fold—data not shown). The other 
OVCAR5/Chromosome 7 hybrid that appeared to have lost all donor chromosome SSR 
markers, hybrid 41, displayed a level of anchorage independent growth comparable to 
that of the parent cell line.
From these results it is apparent that there is a huge amount of clonal variation 
within this cell line in the ability to form colonies in soft agar; again, this variation does 
not appear to correlate with differences in surface growth rates (data not shown). 
Indeed, the 20-fold reduction in colony forming ability of hybrids 20 and 40 (compared 
to the parent cell population as a whole) lies within the normal clonal variation of the 
cell line. However, in the absence of knowledge of the colony-forming efficiency of the 
specific OVCAR5 cells from which hybrids 20 and 40 were generated, it cannot be 
concluded that chromosome 7 has no tumour suppressive effect in OVCAR5. The fact 
that two out of three of the test hybrids showed a very marked reduction in anchorage 
independent growth, compared to just two out of eight of the control cell lines, perhaps 
argues in favour of a tumour suppressive effect. As further circumstantial support one 
of the two hybrids that appeared to have retained mutually exclusive regions of the 
donor chromosome exhibited a marked reduction in colony-forming ability (hybrid 7), 
while the other (hybrid 6) did not (Figure 5.1c).
5.3 Immortal OVCAR5/Chromosome 7 hybrids: their growth in nude mice
To help determine whether the donor chromosome 7 really was exerting a tumour 
suppressive effect in hybrids 20 and 40, the growth of these hybrids in athymic nude 
mice was analysed. The aim was both to ascertain whether tumour-forming ability 
correlated with colony growth in soft agar, and to extract and analyse DNA from any 
tumours that formed. If the donor chromosome did have tumour suppressive properties, 
there would be selection pressure for tumour cells to lose all or part of it—and such loss 
may be detectable by SRS deletion analysis.
Accordingly, 500 000 cells of the parent cell line and of each of hybrids 3, 20 
and 40 (the ‘test hybrids’) were injected subcutaneously into nude mice. In a subsequent 
experiment, the tumour-forming ability of the p-babe Hygro transfected clones hyg 2 
and hyg 3, and of the immortal hybrids 22, 41, 6 and 7, was also analysed. The results 
of both studies, in terms of the length of time it took for tumours to form, are 
summarised in Table 5.1. Perhaps unexpectedly, it is apparent that the tumour-forming
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ability of these hybrids and clones does not correlate particularly well with their ability 
to form colonies in soft agar. While hybrid 20 was very suppressed for growth in soft 
agar, it formed tumours in nude mice more rapidly than any of the other hybrids and 
clones tested (with the exception of the parent cell line). Hybrid 41 formed colonies in 
agar as readily as the parent cell line, but 3 of the 5 mice injected with it still showed no 
signs of tumours after 23 weeks. Similarly, of the two hybrids retaining mutually 
exclusive regions of the donor chromosome, hybrid 7 exhibited little growth in soft agar 
but formed tumours reasonably rapidly, while hybrid 6 displayed reasonable growth in 
soft agar yet took several months to form tumours. In agreement with the soft agar 
experiments, however, the tumour studies clearly demonstrate much clonal variation 
within the OVCAR5 parent cell line. The studies also show that the time taken for 
hybrids 20 and 40 to form tumours, although greater than that for the parent cell 
population as a whole, lies within that clonal variation.
DNA was then extracted from all five tumours formed by each of the three test 
hybrids, and the loss or retention of informative SSR markers on the donor chromosome 
was investigated. One microsatellite marker mapping to the p arm, and nine markers 
mapping to the q arm, were analysed; Figure 5.3 shows a representative autoradiograph. 
Hybrid 40 tumour 2 had lost every marker analysed. This, however, was the only one of 
the 15 tumour samples analysed that displayed any losses at all (Table 5.2a; see Figure 
4.8 for an ideogram of 7q giving approximate positions of markers.) This argues against 
there being selection pressure for tumours to lose the chromosome. DNA was also 
extracted from a limited number of cell clones expanded from agar colonies of the three 
test hybrids. This DNA was also subjected to microsatellite marker deletion analysis. 
Interestingly, both the clones expanded from colonies of hybrid 20 had lost all the 
markers analysed (Table 5.2b). While this is perhaps a random event there may be some 
selection pressure in soft agar, but not in tumours, for hybrids to lose the donor 
chromosome.
5.4 Immortal OVCAR5/Chromosome 7 hybrids derived from a single 
OVCAR5 cell clone: their growth in soft agar and nude mice
We had therefore found no conclusive evidence for the existence of a gene on 
chromosome 7, separate to the senescence gene, that suppresses the tumourigenicity of 
the OVCAR5 cell line. However, as a final test we investigated the soft agar growth 
and tumourigenicity of a panel of OVCAR5/Chromosome 7 hybrids that were all
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derived from the same single OVCAR5 cell clone. This approach eliminated the 
difficulty in interpretation of results caused by the large clonal variation in the OVCAR5 
cell line.
A single OVCAR5 colony was extracted from soft agar and expanded. 
Chromosomes 7 and 15 were then introduced into this clone by MMCT, and six hybrids 
of each type were expanded. The growth of these 12 hybrid clones in soft agar was 
compared to that of the parent cell clone and of the OVCAR5 cell line. Interestingly, 
five of the six chromosome 7-containing hybrids showed a marked reduction in colony 
formation compared to the parent cell clone (Figure 5.4); the sixth clone showed slightly 
greater growth than the parent cell clone. No differences in the surface growth rates of 
the parental clone and the six hybrids were noticed. Of the six chromosome 15- 
containing hybrids, five showed much greater colony formation in agar than the parent 
cell clone (Figure 5.5): this suggests that there may be a gene or genes on chromosome 
15 with anchorage independent growth promoting activity. The sixth displayed the 
same level of colony formation as the parent cell clone.
Overall, these results suggest that there is a gene or genes on chromosome 7, 
independent of the senescence gene, that suppresses the anchorage independent growth 
of the OVCAR5 cell line. The single chromosome 7-containing hybrid that is not 
suppressed for anchorage independent growth in soft agar (Chr 7/6) may have lost the 
region of the donor chromosome that contains this gene(s). Two million cells of the 
parent clone and of four of the chromosome 7-containing hybrids (Chr7/1, Chr7/3, 
Chr7/4 and Chr7/6) were then injected subcutaneously into nude mice, to determine 
whether those clones suppressed for anchorage independent growth in soft agar were 
also suppressed for tumour formation. The results are summarised in Table 5.3. Two of 
the hybrids suppressed for growth in soft agar, Chr7/3 and Chr7/4, were also suppressed 
for tumourigenicity: after eight weeks none of the mice injected with these hybrids had 
developed a tumour, while every mouse injected with the parent cell clone had. This 
suggests that there is indeed a gene on chromosome 7, separate to the senescence gene, 
that suppresses the tumourigenicity of the OVCAR5 cell line. Hybrid Chr7/6, which 
was not suppressed for growth in soft agar, was similarly unsuppressed for tumour 
growth in nude mice: every mouse injected with this hybrid had developed a tumour 
within eight weeks, the average time of tumour formation being only a week greater 
than for the parent cell clone. This supports the hypothesis that in this hybrid the region 
of the donor chromosome that contains the suppressor gene has been lost. Hybrid
1 1 3
Chr7/1, on the other hand, was suppressed for growth in soft agar but not for 
tumourigenicity, the average time of tumour formation being even less than that of the 
parent cell clone. Possible reasons for this anomaly are given in the Discussion.
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Table 5.1 
Tumour growth of immortal OVCAR5/Chromosome 7 
hybrids and of OVCAR5 single cell clones
Summary of tumour formation in athymic nude mice of the OVCAR5 cell 
line, immortal OVCAR5/Chromosome 7 hybrids and hygromycin B 
-resistant OVCAR5 single cell clones. 0.5 million cells were subcutaneously 
injected above the renal capsule (one injection site per animal). 5 animals 
were used for each of OVCAR5 and hybrids 3, 20 and 40; 4 animals were 
used for all other cell hybrids/clones. The times stated represent the average 
number of weeks taken for tumours to first appear.
Tumour growth of immortal OVCAR5/Chromosome 7 
hybrids and of OVCAR5 single cell clones
Cell line/Clone Average time 
for tumours to 
form 
(weeks)
OVCAR5 (parent cell line) - 3.0
Hybrid 3 7.2
Hybrid 20 5.6
Hybrid 40 11.4
Hyg 2 9.4
Hyg 3 9.0
Hybrid 22 23.0+ *
Hybrid 41 19.0+ *
Hybrid 6 00 o + ♦
Hybrid 7 6.6
* No tumours after 23 weeks in 4/4 mice
* No tumours after 23 weeks in 3/4 mice
* No tumours after 23 weeks in 2/4 mice
Table 5.1
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Figure 5.3 
Representative example of tumour allele loss analysis
Autoradiographs from radiolabelled PCR products of the chromosome 7 
microsatellite marker D7S1805, amplified from the DNA of tumours 
formed by immortal OVCAR5/Chromosome 7 hybrids. Loss of the 
donor allele is visible in only one tumour (hybrid 40 tumour 2). 
A92/Hytkl: MMCT donor. DA, donor allele;
IB, invariant band (PCR artefact); EA, endogenous allele.
Representative example of tumour allele loss analysis
Hybrid 3 Hybrid 20 Hybrid 40
Tumours T umours Tumours
D 7S1805
Figure 5.3
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Table 5.3 
Tumour growth of an OVCAR5 single cell clone after 
introduction of chromosome 7
Summary of tumour formation in athymic nude mice of an OVCAR5 
single cell clone and of four immortal OVCAR5/Chromosome 7 hybrids 
generated from this clone (Chr7/1, Chr7/3, Chr7/4 and Chr7/6). 2 million 
cells were subcutaneously injected above the renal capsule (one injection- 
site per animal). 4 animals were used for Chr7/3; 5 animals were used for 
all others. The times stated represent the average number of weeks taken 
for tumours to first appear.
Tumour growth of an OVCAR5 single cell clone 
after introduction of chromosome 7
Cell clone Average time for tumours to form 
(weeks)
OVCAR5 single cell clone 5.0
Chr 7/1 4.2
Chr7/3 8.0+*
Chr7/4 8.0+*
Chr7/6 6.2
No tumours after 8 weeks in 4/4 mice 
No tumours after 8 weeks in 5/5 mice
Table 5.3
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6. Discussion
Microcell mediated transfer of chromosome 7 into the immortal, non-tumourigenic 
fibroblast cell lines SUSM1 and KMST6, and into the hepatoma cell line HepG2, 
induces senescence in a proportion of hybrids (Ogata et al., 1993; Ogata et al., 1995). 
These findings provided the first functional evidence for the existence of a chromosome 
7 senescence gene that is capable of reversing the immortal phenotype of human cells. 
In my own studies, chromosome 7 induced growth arrest with features of senescence in 
a proportion of hybrids of both the ovarian tumour cell line OVCAR5 and the breast 
tumour cell line MDA-MB-231. Introduction of chromosome 15 into these cell lines, 
and of chromosome 7 into the control pancreatic cell line SUIT2, had no effect. These 
results provide further support for the existence of a chromosome 7 senescence gene. 
Although the forced expression of a variety of genes can result in a non-specific, 
senescence-like growth arrest, genes introduced by MMCT are under the control of their 
normal endogenous promoter. This, coupled with my observation that mortalin reverts 
to its mortal distribution and that the chromosome has no effect in a control cell line, 
makes it unlikely that the chromosome 7-induced growth arrest is simply a consequence 
of increased expression of a gene that normally has no role in senescence. However, 
because of the sheer number of genes introduced during the procedure—chromosome 7 
is 150 MB and represents 5% of the genome—non-specific gene dosage effects cannot 
be entirely ruled out. Ultimately, it will be necessary to show that specific chromosome 
7-derived sequences—for example BAC or PAC clones of a particular 7q region—can 
also induce the senescence phenotype.
My observations of chromosome 7-induced senescence differ from those 
published in two main aspects: the percentage of hybrids that senesce, and the speed 
with which they senesce. Approximately 60% of chromosome 7-containing SUSM1 
and KMST6 hybrids underwent senescence (Ogata et al., 1993), compared to 
approximately 30% of MDA-MB-231 and OVCAR5 hybrids. (The precise proportion 
was difficult to quantify, particularly for the OVCAR5 cell line, because of rapid 
seeding of new colonies by the immortal hybrids). This difference may reflect the 
greater variety of genetic defects in tumourigenic as opposed to non-tumourigenic 
recipients: the growth-inhibitory effect of the senescence gene may be partially 
swamped by the growth-promoting effects of a multitude of oncogenic loci. This does 
not provide the complete answer, however, since chromosome 7 also induced 
senescence in approximately 60% of hybrids generated from the tumourigenic cell line
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HepG2 (Ogata et al., 1995). It is possible that small alterations to the experimental 
procedure can increase or decrease the extent of chromosome breakage/recombination 
that occurs, and hence alter the proportion of hybrids that delete the senescence gene on 
the donor chromosome. The position of the senescence gene relative to the integration 
site of the drug resistance marker would also affect the yield of clones with limited 
division potential. The activity itself of the senescence gene may also vary, particularly 
given that the donor chromosome used in my study is of different origin to that used in 
Ogata's experiments. In one published study the efficiency with which chromosome 7- 
derived radiation hybrids induced senescence was increased by treating the donor cells 
with azacytidine (Nakabayashi et al., 1997); the extent of methylation of the donor 
senescence gene may thus be at least partly responsible for variations in the percentage 
of hybrids that senesce. Differences in the proportion of donor cells that contain an 
intact donor chromosome may also provide a partial explanation.
The OVCAR5/Chromosome 7 and MDA-MB-231/Chromosome 7 hybrids that 
underwent growth-arrest did so just 5-8 population doublings after introduction of the 
chromosome. This compares to 10-30 population doublings for SUSM1 and KMST6 
hybrids and 10-24 doublings for HepG2 hybrids (Ogata et al., 1993; Ogata et al., 1995). 
I have not determined whether telomere shortening is associated with chromosome 7- 
induced senescence of OVCAR5 and MDA-MB-231. However, the appropriate 
experiments have been performed for hybrids generated from SUSM1, demonstrating 
that telomere shortening does indeed take place (Nakabayashi et al., 1997). It is 
possible, therefore, that the difference in the timing of the growth arrest is a result of 
differences in the length of the recipients’ telomeres. SUSM1 cells have extremely long 
telomeres (Bryan et al., 1995) which, after introduction of the chromosome, may take a 
greater number of population doublings to shorten to the critical length at which 
senescence is triggered. It is also possible that the critical telomere length itself is cell- 
type specific.
It is interesting that a proportion of growth-arrested OVCAR5/Chromosome 7 
hybrids appeared to undergo some form of cell death, particularly given that senescent 
cells can be very resistant to apoptosis (Wang, 1995). A similar phenomenon occurs 
following introduction of chromosome 4— which is also believed to carry a senescence 
gene (Ning et al., 1991)—into HeLa cells: although cells in the growth-arrested hybrids 
stain positive for expression of senescence-associated |3-galactosidase, TUNEL assays 
demonstrate a four-fold increase in apoptosis compared to HeLa cells alone (Steven
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Bryce and Hazel Ireland, BICR, personal communication). It is possible that the 
chromosome 4 gene and the chromosome 7 gene both restore crisis (M2) rather than 
true senescence (Ml). (This is consistent with evidence that the complementation group 
B and D gene products act in the same biochemical pathway (Loughran et al., 1997).) 
The fact that the telomeres of SUSM1 shorten following introduction of chromosome 7 
indicates that the senescence gene product suppresses telomere maintenance—and is 
thus involved in M2. It is significant that expression of the endogenous p-galactosidase 
gene is not specific to cells in Ml: SV40-infected human fibroblasts undergoing crisis 
(M2) also stain positive for its expression (Dimri et al., 1995).
The chromosome 7 senescence gene is believed to represent the immortality 
complementation group D gene, its inactivation giving rise to immortal cell lines 
belonging to this group. Pereira Smith and Smith (1998) identified four 
complementation groups, A-D, by interfusing 30 immortal cell lines and observing 
whether or not the resulting hybrids senesced. The groups do not correlate with the 
activity of known immortality suppressor genes, giving support for the existence of at 
least four more senescence genes or critical steps in the pathway to immortalisation. 
However, some controversy still surrounds the existence of the complementation 
groups. My own cell-cell fusion studies, while not intended to be a comprehensive test 
of Pereira-Smith and Smith’s results, indicate that HeLa (which they assigned to group 
B) and SUSM1 (which they assigned to group D) do indeed belong to different 
immortality complementation groups. Further supporting the theory that immortal cell 
lines belong specifically to one of the four groups, the cell lines OVCAR5 and MDA- 
MB-231 formed mortal hybrids when fused to HeLa, but immortal hybrids when fused 
to SUSM1 and to each other. (However, without knowing the status of, for example, 
pRB and p53 in OVCAR5 and MDA-MB-231, complementation of genes known to be 
involved in senescence cannot be ruled out as an explanation of the mortality of 
OVCAR5/HeLa and MDA-MB-231/HeLa hybrids.) Also as expected, the proportion of 
cell-cell hybrids that underwent growth arrest was higher than that of microcell hybrids 
(the generation of which causes damage to the donor chromosome). However, when I 
fused HeLa to the bladder cell line A1698, mapped by Pereira Smith and Smith to group 
D, no signs of senescence were observed in the hybrids: although the cells in some 
hybrid colonies underwent a fairly rapid form of cell death, all the eight colonies that 
were ring-cloned and expanded were successfully propagated through to fifty population 
doublings. Segregation and loss of chromosomes is a common feature of cell-cell
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hybrids but, although I haven’t tested this, it seems unlikely that all eight hybrids would 
have ejected the relevant chromosome 4 or 7 (the chromosomes carrying functional 
copies of the group B and group D gene respectively).
It is perhaps significant that other investigators have also failed to reproduce 
some of the findings of Pereira-Smith and Smith. One group reported that 38 of 39 
hybrids generated from the fusion of immortal cell lines that were reported to 
complement each other failed to senesce (Ryan, Maher & McCormick, 1994). To 
explain this discrepancy, the authors suggest that the ‘senescence’ observed in Pereira- 
Smith and Smith’s experiments resulted from the long-term use of drug selection, rather 
than from genetic complementation. However, this seems unlikely, as all Pereira-Smith 
and Smith’s homotypic hybrids (those generated by fusing a cell line to itself) 
proliferated indefinitely, despite presumably being kept under the same drug selection 
conditions as the heterotypic hybrids. Furthermore in my own studies, where drug 
selection was discontinued after initial selection for hybrid colonies, senescence of 
HeLa/SUSMl, HeLa/OVCAR5 and HeLa/MDA-MB-231 hybrids was still observed. It 
is difficult, however, to disregard the fact that so many of Ryan et al.’s hybrids failed to 
senesce. A further study assigns two human epidermal squamous cell carcinoma cell 
lines to more than one senescence complementation group: almost without exception, 
hybrids generated from fusing these cell lines to known representatives of three of the 
four complementation groups proliferated indefinitely (Berry, Burns & Parkinson, 
1994). As the authors suggest, it is possible that the two cell lines have inactivated all 
three of the complementation group genes involved. Similarly, it is feasible that the 
A1698 cell line used in my study had undergone further genetic changes in culture, 
inactivating the group B gene in addition to the group D gene. However, this 
explanation is inconsistent with evidence that the complementation group gene products 
act in a linear pathway: in this scenario, inactivation of a second, third or fourth 
complementation group gene would not be expected to confer any further selective 
advantage.
The senescence-inducing effect of chromosome 7 is reportedly restricted to cell 
lines that belong to complementation group D. Indeed, such specificity was the basis for 
assigning the group D gene to this chromosome. Ogata et al. (1993) claim that 
chromosome 7 has no effect when introduced into the cell lines HT1080, HeLa, and 
TE85, representative of complementation groups A-C respectively. However, I noticed 
a strong growth-inhibitory effect of chromosome 7 in HeLa cells. Moreover, the
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growth-arrested hybrids exhibited features of senescence. Chromosome 4 has also been 
observed to induce features of senescence in a non-complementation group-dependent 
manner (Nick Forsyth, BICR, personal communication): of fifteen hybrids generated 
from the group A osteosarcoma cell line HT1080, half proliferated significantly more 
slowly than the parent cell line and one ceased to proliferate completely, staining 
positive for expression of senescence-associated endogenous p-galactosidase. Again, 
the chromosome is reported to have no effect in non-group B cell lines (Ning et al., 
1991). Although the genes responsible for this non-complementation group-specific 
growth arrest may be entirely different from the complementation group genes 
themselves (as suspected for the case of chromosome 7-induced growth arrest in 
HeLa—see Chapter 4), these findings do call into question the clear-cut results of 
Pereira-Smith and Smith. Any gene that can induce features of senescence in a non­
complementation group-dependent manner would be predicted to complicate the results, 
and interpretation, of cell-cell fusion analysis.
One phenomenon that supports the findings of Pereira-Smith and Smith 
is the correlation of the distribution of mortalin with complementation group assignment 
(Wadhwa et al., 1995). In Wadhwa’s study, 17 of 18 cell lines tested that had been 
assigned to a single complementation group by cell-cell fusion experiments exhibited 
this correlation. In my limited analysis, four cell lines (one representative of each 
complementation group) showed the predicted distribution; moreover, the two cell lines 
that I assigned to group D by cell-cell fusion, MDA-MB-231 and OVCAR5, also 
exhibited the group D distribution. The molecular basis of this correlation remains 
unknown, but the mortalin distributions may reflect a complementation group gene 
product pathway. If the complementation group gene products in some way support a 
system of mortalin transport, loss of a particular complementation group gene would 
disrupt this; the four different perinuclear distributions may each reflect disruption at a 
different point in the transport pathway. In conclusion, the existence of four different 
complementation groups for senescence has been neither satisfactorily confirmed nor 
refuted. What for the sake of my project is more important (and less contentious) is that 
a gene exists on chromosome 7 that can induce senescence in certain immortal cell 
lines.
My attempt to map this gene by SSR deletion analysis of immortal hybrids has 
proved unsuccessful. This is perhaps not suprising: to my knowledge, SURF1 is the 
only gene so far cloned by the microcell hybrid deletion mapping strategy (Zhu et al.,
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1998). In my immortal hybrids a great variety of losses were found scattered throughout 
the donor chromosomes, with several chromosomes exhibiting multiple interstitial 
losses. It is probable that chromosome breakage occurs during the actual preparation of 
microcells, resulting in random deletions that confer no proliferative advantage to the 
hybrid. For certain markers and in certain hybrids, loss of the endogenous allele, rather 
than the donor allele, was detected. This implies that, after fusion with microcells, 
mitotic recombination may also act to induce losses in the donor chromosome. Such 
random losses, and indeed losses resulting from selective pressures other than the 
evasion of replicative senescence, would mask the regions of loss that contain the 
senescence gene. A further complication is that the frequency of ‘random’ losses is not 
uniform along the chromosome. The frequency of loss of a particular region depends 
upon its position relative to the integration site of the selectable marker: if the selectable 
marker is situated near the centromere then the frequency of loss of either telomeric 
region will be inflated, and if near a telomere the frequency of loss of the other telomere 
will be inflated. It would be easy to interpret frequencies of loss exaggerated in such 
manner as meaningful. To avoid this, and to eliminate other ‘random’ regions of loss 
from the analysis, it is necessary to analyse a control cell line. In such cell lines there 
should be no evidence for endogenous inactivation of the gene of interest and hence 
little selective pressure to inactivate the gene on the donor chromosome. The true 
region, that containing the gene of interest, should thus be lost at a higher frequency in 
hybrids of the test cell line than in the control cell line, while other regions should be 
lost at equal frequency. This type of analysis, however, can require a very large number 
of hybrids, and the technique is still limited by the density of informative markers. In 
my own hybrids, the pattern of loss was so complex that the utility of the control line 
SUIT2 was limited.
While several hybrids complicated the analysis by containing multiple interstitial 
deletions, the opposite situation also proved problematic. A large percentage of the 
hybrids I generated were entirely uninformative for mapping, with every marker 
analysed either being lost (the hygromycin B resistance marker presumably integrating 
elsewhere in the genome) or retained. In the latter hybrids, where the donor 
chromosome does not undergo extensive breakage or recombination, the gene is 
presumably inactivated by microdeletions, mutations, or epigenetic mechanisms such as 
promoter silencing by methylation—none of which are likely to be detected by SSR 
analysis. When the inactivation of known growth suppressor genes in immortal
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microcell hybrids is analysed, many losses found are very small; after chromosome 9 
was introduced into mouse cells, for example, many deletions were found to encompass 
just a single exon of p l6 INK4a (England et al., 1996). In my own hybrids, it may be 
worth returning to those for which no microsatellite losses were found, and to try to 
detect microdeletions using alternative techniques such as RDA.
It is possible that the success of an SSR deletion mapping strategy depends at 
least partly on the particular chromosome used. Certainly, similar studies performed in 
this institute with chromosome 6 have not generated such a complex pattern of loss 
(Sara Fitzsimmons, personal communication). Chromosome 7 is known to contain both 
an aphidicolin-inducible fragile site and a recombination hot-spot (discovered in the 
hunt for CFTR, when it was noticed that some markers underwent recombination more 
often than expected), which may or may not be related to each other (Huang et al., 1998; 
Kerem et al., 1989). These features may make chromosome 7 particularly predisposed 
to breakage and recombination, complicating this type of analysis. Alternatively, it is 
possible that recipient cell type-specific differences may affect the frequency of losses 
incurred post-fusion.
The fact that high frequency of deletion of known growth suppressor genes is 
detected in the appropriate hybrids suggests that the strategy is sound in principle 
(England et al., 1996). However, to be used successfully when no prior positional 
information is available, some modification to the procedure may be required. One 
approach would be to initially introduce smaller chromosome segments, for example 
fragments contained within radiation hybrids, and thus eliminate large regions of the 
chromosome that do not induce the required phenotype. Having identified the smallest 
fragment capable of inducing senescence, deletion analysis could then be performed on 
immortal hybrids generated with it.
There is independent evidence for the existence on chromosome 7 of a tumour 
suppressor gene; this may or may not be the same as the chromosome 7 senescence 
gene. As discussed in the introduction, high frequencies of LOH centring on 7q31 are 
found in a wide range of human cancers, including breast, ovarian, head and neck, 
colon, gastric and prostate tumours (Reviewed in Zenklusen & Conti, 1996). Work 
carried out in our laboratory supports these findings: Adam Hurlstone found 40% 7q 
LOH in a panel of breast tumour samples centring on the 7q31 marker 17TA-5/17B- 
RE3, and Vincent O’Neill found high frequencies of LOH on chromosome 6 in murine 
skin carcinomas centring on a region syntenic to 7q31 (unpublished data). However, the
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significance of LOH data is not always easy to judge. A wide spectrum of LOH 
frequency at 7q31has been reported, ranging from less than 10% to 80% at a single 
marker and within a single tumour type (Kerangueven et al., 1995; Zenklusen et al., 
1994a). It is difficult to fully account for this variation in terms of factors such as 
tumour stage, sample processing and data analysis, and such studies do raise some 
doubts about the 7q LOH data. The recombination hot-spots and aphidicolin-inducible 
fragile site found at 7q31 pose additional complications. It is possible that in cancer 
cells such inherently unstable regions undergo deletions and rearrangements without 
actually contributing to the disease process itself, and are simply co-selected with other 
mutations that do confer a selective growth advantage. However, the fact that LOH at 
7q31 is not observed in all tumour types (for example bladder, cervix and glioma), and 
that LOH of 7q31 and 4q32-34 are not observed in the same tumour samples (Loughran 
et al., 1997), both suggest that LOH at 7q31 is directly selected for during tumour 
development.
It is also encouraging that functional evidence for the existence of a tumour 
suppressor gene at 7q31 has been obtained. Introduction of chromosome 7 into a 
murine squamous cell carcinoma cell line was found to reduce the tumour-forming 
ability of five of the seven hybrids generated (Zenklusen et al., 1994b). Furthermore, 
one of the non-suppressed hybrids was found to have a deletion in the donor 
chromosome at 7q31. My own observation, that introduction of chromosome 7 
suppresses the anchorage-independent growth and tumourigenicity of an OVCAR5 
single cell clone, provides additional functional evidence for the existence of a tumour 
suppressor gene on this chromosome. Five of the six hybrids generated in this study 
exhibited significantly reduced colony formation in agar compared to the parent cell 
clone. This proportion of suppression is very similar to that (five out of seven) observed 
in Zenklusen’s tumour experiments. The single hybrid whose anchorage independent 
growth was not suppressed had presumably deleted or otherwise inactivated the putative 
tumour suppressor gene on the donor chromosome. Introduction of chromosome 15 
into the same parent cell clone did not suppress anchorage independent growth, 
indicating that the effect of chromosome 7 was due to DNA sequences specific to that 
chromosome. Of three suppressed chromosome 7 hybrids that I tested for tumour 
formation in nude mice, two proved less tumourigenic than the parent cell line. To my 
knowledge, this is the first demonstration of chromosome 7-induced suppression of 
tumourigenicity in a human ovarian tumour cell line.
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It is perhaps odd that one of the three clones was suppressed for anchorage 
independent growth in soft agar but not for tumour growth in nude mice. In my 
previous studies hybrids 20 and 7 were also largely incapable of growth in soft agar yet 
able to form tumours in nude mice (Chapter 5). A group employing a similar strategy to 
investigate a putative colorectal tumour suppressor gene on chromosome 8 also 
generated a hybrid with these properties (Gustafson et al., 1996). Although some 
investigators have demonstrated a perfect correlation between anchorage independent 
growth and tumourigenicity (Newbold et al., 1982), studies of non-tumourigenic 
HeLa/fibroblast hybrids and of tumourigenic segregants derived from them indicate that 
the two phenotypes are separable in certain cell systems (Stanbridge & Wilkinson, 
1980). Gustafson et al. suggest that anchorage independence is associated with 
metastatic ability, not tumourigenicity per se. However, this does not explain why 
introduction of chromosome 7 should suppress both the anchorage independent growth 
and tumourigenicity of two hybrids, but the anchorage independent growth only of one 
(Chr7/1). Introduction of chromosome 8 in Gustafson et al.’s experiments resulted in 
similarly differentially suppressed hybrids (1996). They suggest that the pattern of 
endogenous mutations present in the parental cell line may determine the precise 
response to the suppressor gene. Although my hybrids were all generated from the same 
single cell clone, this explanation could still apply if any relevant mutations occurred 
after the clone’s isolation. Alternatively, two different genes on chromosome 7 could be 
involved, one with the capacity to suppress anchorage independent growth and one with 
that to suppress tumourigenicity per se. The latter gene may have been lost from the 
donor chromosome of the clone that was not suppressed for tumour formation.
Given the evidence for a gene(s) on chromosome 7 that suppresses the 
transformed phenotype of OVCAR5 cells, why did there appear to be no selection 
pressure in vivo for tumours of hybrids 20 and 40 to lose all or part of the donor 
chromosome? It is feasible that these hybrids were not suppressed by chromosome 7 to 
begin with: the colony-forming ability in agar of the parental clones from which these 
hybrids were generated is unknown, and, given the high level of clonal variation 
observed within the cell line, it is possible that these clones were not themselves capable 
of appreciable levels of anchorage-independent growth. Alternatively the gene could, as 
described above, have acted in these hybrids in such a way as to suppress anchorage 
independent growth but not tumourigenicity. In this instance there would have been 
selection pressure for agar colonies, but not for tumours, to lose the gene; the fact that
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both hybrid 20 agar colonies analysed had lost the donor chromosome supports this 
explanation. A scenario where two different genes are responsible for suppression of 
anchorage independence and tumourigenicity, with hybrid 20 retaining only the former, 
would also explain these findings. It is possible too that the putative tumour suppressor 
gene had been lost from the donor chromosome of these hybrids, but in such a way as to 
be undetectable by SSR deletion analysis; inactivation of tumour suppressor genes in 
this type of study by no means always occurs by way of large chromosomal deletions 
(Gustafson et al., 1996). A more reliable way to test for loss of a tumour suppressor 
gene is to re-inject cells derived from the relevant tumour; if the suppressor gene has 
been deleted or otherwise inactivated, cells derived from the tumour should form a new 
tumour at the same speed as the parent cell line.
There are no published studies addressing the issue of whether the group D 
senescence gene and the tumour suppressor gene defined by LOH studies and 
Zenklusen’s mouse experiments are one and the same. Certainly the genomic 
abnormalities of SUSM1 and KMST6, the region of LOH in tumours and the deletion in 
Zenklusen’s non-suppressed hybrid clone all involve 7q31. In my own studies, at least 
two of the cell lines homozygous for chromosome 7 also belonged to complementation 
group D. But although these findings are consistent with the hypothesis that the two 
genes are one and the same, they do not prove it. The fact that certain bladder cell lines 
have been assigned to complementation group D, but that LOH at 7q31 is not seen in 
bladder tumours, perhaps argues against the senescence gene being the target of tumour 
LOH. My agar studies showing suppression of anchorage independent growth and 
tumourigenicity in immortal, chromosome 7-containing hybrids of an OVCAR5 single 
cell clone suggest that there is a gene on chromosome 7, separate to the senescence 
gene, that can suppress the transformed phenotype. However, this interpretation relies 
on the assumption that the chromosome 7-containing hybrids have indeed deleted or 
inactivated the group D senescence gene. It is formally possible that the immortal 
hybrids had instead inactivated a different, endogenous complementation group gene, 
and that the group D gene on the donor chromosome was intact and responsible for 
suppressing the transformed phenotype of the hybrids. However, for this to have 
occurred in all five hybrids suppressed for anchorage independent growth seems 
unlikely. Perhaps a more serious argument against the existence of two separate genes 
is that, despite the use of a control cell line and chromosome in the MMCT experiments, 
the chromosome 7 senescence gene was not responsible for the growth arrest observed
1 3 2
in OVCAR5. In this scenario there would be no selection pressure for the hybrids to 
lose this gene. However, although it is easy to envisage how a gene involved in 
replicative senescence could be a target of LOH in tumours, it is less easy to imagine 
that a senescence gene could act to suppress anchorage independent growth in soft agar 
or tumour growth in nude mice without actually inducing senescence. On balance, the 
simplest interpretation of my data is that there is indeed a gene on chromosome 7, 
separate to the senescence gene, that suppresses the transformed phenotype of 
OVCAR5. It is not yet possible to say whether this gene maps to the minimum region 
of LOH in tumours. It could be that both genes—the chromosome 7 senescence gene 
and the separate tumour suppressor gene—are targets for LOH in tumours. This would 
perhaps explain the particularly high frequencies of loss found on chromosome 7 in 
tumours, and the fact that some 7q LOH studies have defined non-overlapping minimal 
regions (Kerr et al., 1996; Hilary Russell, Queen’s University Belfast, personal 
communication).
Cloning and characterisation of the chromosome 7 senescence and tumour 
suppressor genes would give further insight into the mechanisms of cellular 
immortalisation and tumourigenesis. Several experiments might facilitate the cloning of 
these genes. Efforts to identify the senescence gene should probably focus on the 
immortal microcell hybrids that do not show any microsatellite losses: it may be 
possible to isolate DNA (or cDNA derived from it) mapping within microdeletions on 
the donor chromosome. To do so, RDA could be performed between genomic DNA 
extracted from immortal OVCAR5/Hytkl hybrids that show no microsatellite losses 
mixed with A92 mouse genomic DNA, and that extracted from OVCAR5 mixed with 
A92/Hytkl DNA. Success would, however, depend upon there being a sufficient 
number of RFLPs that discriminate between endogenous and exogenous copies of the 
chromosome. Alternatively, MMCT could be used to transfer the donor chromosome of 
immortal OVCARS/Hytkl hybrids that have no obvious losses into rodent A92 cells. 
After checking that the transferred chromosome had not undergone further deletions, 
RDA could be performed between DNA extracted from the new hybrid cells and that 
extracted from normal A92/Hytkl donor cells. Any material obtained would be 
screened for candidate genes. It may additionally be possible to carry out subtractive 
hybridisation between cDNA PCR-amplified from senescent OVCAR5/Hytkl hybrid 
cells and that amplified from a comparable number of immortal OVCAR5/Hytkl cells; 
the technology to perform RT-PCR cDNA subtraction on a very small number of cells
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already exists (Weaver et al., 1999). Any cDNA expressed in senescent but not in 
immortal hybrids that mapped to chromosome 7 would then be a candidate for the 
senescence gene. An alternative approach, which assumes that the protein is 
upregulated during senescence, would be to carry out subtractive hybridisation between 
cDNA derived from pre-senescent fibroblasts and that derived from senescent 
fibroblasts. Again, any cDNA mapping to chromosome 7 would be a candidate.
It would be necessary to screen any candidates for the ability to induce 
senescence in cell lines that belong to immortality complementation group D. Ultimate 
proof would depend on the demonstration of inactivating mutations (or gene silencing 
mechanisms) in complementation group D cell lines and immortal microcell hybrids: 
RNA blots prepared from such cell lines could be screened for aberrant transcripts or 
loss of expression; Southern blot analysis could be used to screen candidate genes for 
microdeletions and methylation differences; and SSCP could be used to carry out 
mutational analysis of cDNA and exonic regions of genomic DNA. Once the 
senescence gene had been identified, its ability to suppress anchorage independent 
growth and tumourigenicity in target cell lines could be tested; this would help resolve 
the issue of whether or not there really is a separate tumour suppressor gene.
The chromosome 7-containing hybrids generated from the single cell clone of 
OVCAR5 may prove a useful resource in the mapping of the tumour suppressor gene. 
The hybrid that was not suppressed for either anchorage independent growth in soft agar 
or tumour formation in nude mice has presumably deleted or otherwise inactivated the 
gene on the donor chromosome. Although, based on my previous experience, there is 
little reason to suppose that SSR deletion analysis would help delineate a specific 
region, such an approach would show whether or not the donor chromosome is largely 
intact. If it is intact, RDA could be performed between genomic DNA prepared from 
this hybrid and from one of the five suppressed hybrids. Again, should the technique 
fail to discriminate between endogenous and exogenous copies of chromosome 7, the 
donor chromosome of the non-suppressed hybrid could be transferred into A92 cells. 
RDA would then be performed between DNA extracted from this new hybrid and from 
the normal A92/Hytkl donor. Alternatively, subtractive hybridisation could be 
performed between cDNA derived from suppressed and non-suppressed hybrids. Any 
cDNAs obtained that map to chromosome 7 would again be candidates. Microsatellite 
deletion analysis could help delineate regions of loss in revertant agar colonies or 
tumours formed by suppressed hybrids; as the generation of these revertants from the
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parent hybrids did not involve any microcell preparation, the number of ‘random’ losses 
on the donor chromosome should be minimal. For those hybrids which do not show any 
SSR losses, RDA or a cDNA subtraction could be performed between genomic DNA 
(or cDNA) extracted from the revertant and from the parent hybrid. As a 
complementary approach to cloning this gene, candidates could be identified from the 
minimum common region of LOH found in tumours (our lab already has a contig 
spanning the region of LOH found in our panel of breast tumour samples). YAC clone 
DNA or interAlu PCR products generated from YAC clones could be used to perform 
direct cDNA selection, using pooled cDNA from various libraries as the starting 
material. In addition, as much of the interval has been sequenced, probes designed from 
sequences that either have significant homology to known genes or ESTs or have 
features of putative exons could be used to probe and extract the full length candidate 
from cDNA libraries. Candidate genes identified by any of the above methods would 
then be tested to determine whether they fulfil the properties expected of a tumour 
suppressor gene. The gene should be expressed in the tissues from which tumours 
showing 7q LOH are derived, testable by northern blot analysis of multi-tissue RNA 
preparations. Introduction of the gene into cell lines, for example the OVCAR5 single 
cell clone used previously, should suppress anchorage independent growth and 
tumourigenicity in the same way as did the whole chromosome. Detection of mutations 
or any alterations of expression of the gene in tumours could then be carried out as 
above.
When either gene has been identified further experiments will be necessary to 
elucidate its function. Any homology with known genes may give an initial indication. 
It would be important to ascertain the cellular distribution of the gene product, either by 
generating antibodies against it or by expressing the protein as an epitope-tagged 
molecule. In the case of the senescence gene, it would be interesting to determine 
whether it is actually upregulated in senescence, and whether any such upregulation is 
sustained or transient. Any effect of overexpression of the gene on telomerase activity 
or expression (in immortal cell lines) could also be analysed. For either gene product, 
the nature of its interactions would need to be investigated. Binding partners could be 
identified in a number of ways, including immunoaffinity chromatography, 
immunoprecipitation and two hybrid screening in yeast, insect or mammalian cells. It 
could then be determined whether any interacting proteins were also targets for mutation 
during tumourigenesis or immortalisation. The issue of whether the senescence gene
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product is involved in transducing signals from shortened telomeres could also be 
addressed, by seeing whether mutant and wild-type cells differ in their ability to undergo 
senescence after deletion of their telomeres by homologous recombination. It would 
also be interesting to see whether mutant cells have an altered response to DNA damage. 
Assuming that mouse homologues of the senescence and tumour suppressor genes exist, 
knock-out mice could eventually be generated. These would allow investigation of the 
role of the genes in development and differentiation and assessment of the effect of gene 
disruption on tumour susceptibility and the replicative potential of mutant cells. 
However, because of the differences in the regulation of senescence in mice and human 
cells it is possible that the biological role of the chromosome 7 senescence gene is not 
identical in these species.
Immortality gives cells the opportunity to acquire the often multiple mutations 
needed for metastasis, therapeutic resistance and recurrence; it may thus ultimately be 
responsible for cancer lethality. Cloning of the chromosome 7 senescence gene would 
doubtless enhance understanding of the mechanisms that curb the proliferative potential 
of normal cells. It may also provide novel pathways to manipulate in cancer therapy. 
Identifying and characterising an additional chromosome 7 tumour suppressor gene 
might similarly provide new therapeutic targets, and would further increase our 
understanding of the multi-step process of tumourigenesis.
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